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Summary 
One of the most common craniofacial congenital deficiencies is cleft palate with an 
incidence of 1.7:1000 live births. The clinical management of cleft palate involves 
multiple surgical interventions and gives rise to post-operative complications. Recently, 
tissue-engineering approaches have been developed to treat cleft palate using 
osteoprogenitor (bone forming) cells seeded on biodegradable electrospun mat scaffolds 
to repair the defects. 
Animal sera are frequently employed as a regular supplement in vitro for osteoprogenitor 
cell proliferation and differentiation in culture conditions. However, serious drawbacks 
have been recorded, such as contamination, poorly defined components, and disease 
transmission. To overcome these obstacles, xeno-free media have recently been 
developed. This project aims to test a set of commercially available xeno-free media or 
supplements in which human-derived cells (hBMSCs and HJPs) can be grown to create a 
bone-like matrix suitable for craniofacial tissue engineering. 
The investigation showed that a commercially available medium containing 2% (v/v) 
human serum is best able to support human Bone Marrow Stem Cells (hBMSC) growth 
and differentiation among the media tested. However, there was noticeable donor 
variability in cell growth rates and osteogenic potential in the different media studied. 
Although 10% (v/v) foetal bovine serum is frequently employed for the proliferation of 
cells supporting in vitro growth, it was shown to poorly to support osteogenic 
differentiation compared to human-derived culture media. 
Polycaprolactone scaffolds were fabricated by electrospinning and these were shown 
support osteogenesis and bone-like matrix formation in selected xeno-free media with 
differential effects on secretion of angiogenic growth factor (VEGF). A tri-layer PCL mat 
scaffold could support and separate three different cell types (Fibroblasts, Keratinocytes, 
and hBMSCs) to allow osteogenic differentiation on one side and create an oral mucosa 
on the other side indicating this would be a promising scaffold to incorporate the cell 
types needed for cleft palate repair. 
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CHAPTER ONE: LITERATURE REVIEW 
1.1 Introduction 
Cleft palate and cleft lip pose a highly significant birth problem or defect with a global 
incidence of approximately 1.7 per 1000 live births (Mossey et al., 2009). 
The causes of the defects include both genetic and environmental factors, the latter 
including maternal ailments, alcohol abuse or side effects from prescription medication 
involving anti-convulsants or retinoic acid based medications. 
All these factors can influence initial embryonic development during the first trimester 
especially between the fourth to tenth weeks of pregnancy (Stanier and Moore, 2004). 
Cleft palate is a morphological abnormality that commonly affects the maxillofacial 
region (i.e. jaw and teeth) with effects on speaking, feeding, hearing, and social 
relationships. Recently, multidisciplinary teams, including, oral and maxillofacial 
surgeons, plastic surgeons, paediatric surgeons and dentists have managed the 
treatments of cleft palate. These teams can play a crucial role in supporting and providing 
some surgical operations to achieve the final result (from childhood to adulthood) 
(Moreau et al., 2007). 
Conventional surgical operations for bone regeneration often use bone grafts that are an 
autograft, isograft, allograft, xenograft, prosthetic material and/or combination grafts. 
The autologous graft is the gold standard to achieve bone regeneration, but it has a 
limited use. Autologous graft causes morbidity; threatening the donor site, creating bone 
resorption, disturbance of gait, and prolonged numbness and/or paraesthesia of the leg, 
especially when taken from the lateral aspect of the femoral bone (Elsalanty and Genecov, 
2009). (Bergland et al., (1986) and Samee et al., (2008) review and present the limitations 
of harvesting autologous bone for grafting. Allograft and xenograft have the limitations of 
processing steps which affect the bone’s mechanical properties and risk of disease 
transmission. A substitute bone source for bone regeneration should be further 
investigated to enhance cleft palate repair. 
In the past decade, tissue engineering systems have been trialled to correct 
malformations during facial growth (Smahel et al., 2009). The approach showed promise 
for reconstruction of the alveolar ridge which reinforces teeth during the management of 
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cleft palate. However, the presence of a connective and/or scar tissue between the grafted 
tissue engineered bone and the cleft palate resulted in impaired facial growth and 
development warranting further investigations (Ophof et al., 2008; Smahel et al., 2009). 
This project aims to develop a bone tissue engineering methodology which is appropriate 
for eventual clinical by using xeno-free (free of non-animal derived ingredients) media 
for reconstruction of bony defects in the oral cavity, especially in the treatment of cleft 
palate. The long-term purpose is to develop approaches to culture stem cells in xeno-free 
conditions as a pre-culture for clinical applications in cleft palate repair by investigating: 
1) primary human mesenchymal stem cells, 2) electrospun 3D scaffolds, 3) appropriate 
media and supplements for extracellular matrix formation by the bone-like cells. The 
following literature review will focus on the fundamental principles of bone biology, cleft 
palate development, advance treatment of cleft palate, and current clinical strategies for 
bone tissue engineering. 
1.2 Bone structure 
1.2.1 Function and anatomy bone 
Bones are a rigid part of our body and have blood vessels which preserve living cells and 
promote them to grow. They provide several functions such as movement, support of 
body structures, internal organ protection, and mineral homoeostasis. They store crucial 
elements which are essential for bone development such as growth factors, and 
cytokines; the red bone marrow houses blood-creating cells. A newborn human has 
around 300 bones while the human adult typically has 206 bones. Bone structure is 
comprised of two fundamental parts: cortical (compact) bone and trabecular (cancellous) 
bone.  Cortical bone is a dense part of the skeleton with less than 5% porosity (Clarke, 
2008), and is comprises 80% of healthy adult bone. In contrast, the trabecular bone is 
mainly porous with around 50-400 µm of strut thickness (Seeley et al., 2008) and 
corresponds to around 20% of healthy adult bone (Roger, 2011). Trabecular bone is the 
internal tissue of the bone filled with bone marrow. 
1.2.2 Macroscopic anatomy 
Bones are classified according to their function into four different shapes- long, short, flat, 
and irregular. The first includes the femur of the leg and humerus of the arm while the 
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second contains bones of the ankles and wrists. Flat bones include the craniofacial bones 
and ribs (Figure 1.2.2). The vertebra, coccyx and sacrum bones are irregular bones. The 
long bones are organised into three main parts: the diaphysis is a hollow part of the 
central region and is composed of cortical bone, the metaphysis is flared with a cone 
shape, and the epiphysis is an expanded portion which is located at each end of the long 
bones, and coated with articular cartilage. Flat bones have a significantly large surface to 
improve protection and muscular attachment specifically, craniofacial bones. 
The outer surface of bones is firmly coated with a periosteal membrane which is essential 
for bone apposition on the exterior surface of the bone. The endosteal layer contacts the 
bone marrow with covers the interior surface of compact and cancellous bones. 
Furthermore, the endosteal sheet is essential for bone formation and resorption on the 
interior surface (Figure 1.2.2). 
                                                                                 
 
Figure 1.2.2: (A) The diagram reveals a flat bone which comprises of compact and 
cancellous bone layer, (B) layer of spongy bone between the compact bone layers, (C) a 
major structure of a long bone consists of diaphysis and epiphysis. Reprinted from Seeley et 
al., (2008) with kind permission of McGRAW-HILL 
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1.2.3 Microscopic anatomy 
Bone is categorised into two types depending on the microscopic level, lamellar and 
woven bone (fibrous bone). Collagen type I is the main protein present in the bone matrix. 
Woven bone is distinguished by a random collagen fibre organisation which is 
mechanically weak, it is an immature bone and forms quickly. It is formed when 
osteoblasts construct osteoid rapidly and is considered to be the initial bone produced 
after fracture, more flexible than lamellar bone (Clarke, 2008). Lamellar bone is 
secondary bone formed after woven bone remodelling which has a regular dense well-
aligned collagen and is mechanically robust. After one month of birth, human lamellar 
bone starts remodelling and a majority of the bone structure converts into lamellar bone 
by 4 years of age. The concise arrangement of individual lamella leads to the production 
of osteons surrounding a central canal which houses blood, lymph vessels, and nerves at 
the core to form a secondary osteon or Haversian system. A Volkmann’s canal is a small 
canal located in the bone which transmits the blood vessels to the bone and 
communicates with each Haversian canal. Lacunae are the spaces which house the 
mature bone cells, termed osteocytes, located between lamellae. Osteocytes 
communicate with other osteocytes through long, thin channels known as canaliculi, 
through which nutrients can also pass. Haversian system and osteons represent a major 
structural component of the bone and line up parallel up to the long axis of the bone to 
enhance the mechanical strength. Cortical bone is produced from several osteons, which 
unite with circumferential (beneath periosteum and endosteum) and interstitial lamellae 
(between osteon) (Doll, 2005). Osteons are the essential structure of compact and 
cancellous bones (Clarke, 2008). There are no blood vessels at the centre of trabecular 
bone’s osteon (Figure. 1.2.3) (Seeley et al., 2008). 
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Figure 1.2.3: A transverse region of the trabecular bone illustrating an osteon. Reprinted 
from Seeley et al., (2008) with kind permission of McGRAW-HILL 
1.2.4. The bone extracellular matrix composition 
The substantial components of the extracellular matrix (ECM) of bone are the inorganic 
constituents (about 60%) and the organic matrix (up to 40%) together with trace 
quantities of lipids and water. The inorganic component is predominantly hydroxyapatite 
with a trace amount of carbon and magnesium which contributes to the mechanical 
compressive strength of bone. The organic matrix consists of non-collagenous proteins 
and collagen. Bone proteins are divided into about 90% collagenous which are mainly 
collagen type I and a minimal amount of Type III and V, collagen type I contributes to the 
tensile strength of bone. The remaining bone proteins are non-collagenous proteins 
which represent 10% of the total organic matrix and are composed of cytokines, matrix 
proteins, proteoglycans, and growth factors. Proteoglycans are ubiquitous molecules that 
consist of a core protein, covalently linked to either one or several glycosaminoglycan 
(repeating sugar unit) chains. The main functions of bone matrix are to provide structural 
support and to regulate the activity of bone cells, bone mineral deposition and bone 
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resorption.  Furthermore, growth factors and cytokines are presented in a bone matrix 
such as bone morphogenetic proteins (BMP), transforming growth factor (TGF) and 
vascular endothelial growth factor (VEGF). These growth factors regulate bone cell 
proliferation, differentiation, angiogenesis and bone remodelling (Clarke, 2008; 
Lamoureux et al., 2007; Salbach et al., 2012). 
1.3 Bone cell biology  
Bone is a dynamic organ that contains many active different cells for processing of 
formation and resorption to maintain the stability throughout life such as 
osteoprogenitor cells, osteoblast cells (which form bone matrix), osteocyte cells (which 
support bone matrix), and osteoclast cells (which resorb bone matrix) (Martin et al., 
1988). 
1.3.1 Osteoprogenitor cells 
Osteoprogenitor cells are a population of undifferentiated, mesenchymal stem cells, 
characterised by a fibroblast-like fusiform shape in vitro (Figure 1.3.1). They are derived 
from primitive mesenchymal stem cells which give rise to the more specialised bone-
producing cells to form a new bone matrix. Bone marrow stroma contains mesenchymal 
stem cells that can differentiate into a variety of lineages such as bone, cartilage, or 
fibrous connective tissue depending on the supplementation (James and Anderson 2015). 
Mesenchymal stem cells are useful for bone tissue engineering because of their ability to 
osteogenic differentiation. 
1.3.2 Osteoblasts 
Osteoblast cells are large cuboidal cells which are located along bony surfaces covering 
4-6% of the whole bone and are derived from mesenchymal stem cells. They 
communicate with bone cells, and bone matrix through specific receptors for activation 
of signalling pathways such as growth factors, hormones, and cytokines to encourage the 
cell function (Florencio-Silva et al., 2015). In vivo; osteoblasts can produce 0.5-1.5 µm of 
osteoid per day which is a non-mineralised organic portion of the bone matrix 
(Sommerfeldt and Rubin 2001). An early sign that a cell is becoming a preosteoblast is 
activity of the enzyme alkaline phosphatase. Eventually, the osteoblasts become trapped 
in the calcified matrix and transform their phenotypes to form osteocytes (Sommerfeldt 
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and Rubin, 2001; Florencio-Silva et al., 2015). 
1.3.3 Osteocytes 
Osteocytes are the most abundant of bone cells which comprise about 90-95% of total 
bone cells and represent the osteoblasts differentiation terminally. They are smaller than 
osteoblasts and have abundant cytoplasmic extensions number. Osteocytes are located 
within lacunae in the calcified bone matrix. Once the maturation of osteocytes occurs, 
several osteoblast markers are downregulated. The osteocyte’s functions are to enhance 
intercellular communication and to regulate the mineral exchange within lacunae. 
Osteocytes can interconnect with adjacent cells by their cytoplasmic extensions and can 
survive in the lacunae for up to 25 years. In aged bone, an empty space in lacunae can be 
observed due to the cell apoptosis or cellular interaction disturbance (Franz-Odendaal et 
al., 2006; Verborgt et al., 2000). 
1.3.4 Osteoclasts  
Osteoclast cells originate from mononuclear hematopoietic stem cells (derived from 
blood cells) which are found within either periosteal or endosteal surfaces. Osteoclast 
cells are large, multinucleate (containing approximately 6-12 nuclei) and have ruffled 
borders. The main function of osteoclasts is remodelling of the bone through bone 
resorption. Osteoclasts secret acid to dissolve the inorganic component of the 
mineralised bone matrix, and its lysosome enzyme digests the organic component. An 
activated osteoclast can resorb a bone volume of 200,000µm3/day (Jeon et al., 2012; 
Sommerfeldt and Rubin, 2001). 
 
Figure 1.3.2: transverse section of trabecular bone displaying the three typical bone cells 
osteoblasts, osteocytes and osteoclasts. Reprinted from Seeley et al., (2008) with kind 
permission of McGRAW-HILL. 
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1.4 Morphogenesis of bone 
In the first few weeks of prenatal development, the bony structure is formed and 
continues to grow into adulthood. There are two methods for ossification of bone; 
intramembranous and endochondral. 
1.4.1 Intramembranous ossification 
This type of ossification begins during embryonic development and occurs in flat bones. 
In intramembranous ossification, mesenchymal stem cells directly differentiate into 
osteoblasts. These osteoblasts can form and mineralise a bone matrix. The remaining 
osteoblasts are trapped in bone matrix to become osteocytes. Consequently, small 
trabecula is generated (Figure 1.4.1 A), which integrates to develop a network of 
trabecular bone. At the surrounding surface of trabeculae, some osteoblasts increase the 
thickness of trabeculae (Figure 1.4.1 B). Eventually, the remodelling process replaces the 
woven bone to mature lamellar bone (blue stain in Figure 1.4.1 C) that is more organised 
than woven bone. The cells inside the trabecular bone spaces form red bone marrow, 
while the osteoblasts in the periosteum develop a bone matrix and create compact bone 
(Seely et al., 2008) 
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Figure 1.4.1: Intramembranous ossification in a 12-week old foetus, (A) Osteoblasts at the 
outer surface create bone matrix and differentiate into osteocytes when they embed in the 
bone matrix. (B) Interconnection of many trabeculae forms cancellous bone. (C) The 
trabecular bone (blue colour) is in the centre and the spaces contain red bone marrow. 
Under the periosteum is developing compact bone. Reprint from Seeley et al., (2008) with 
kind permission of McGRAW-HILL. 
 
1.4.2 Endochondral ossification 
Endochondral ossification begins with the differentiation of mesenchymal stem cells into 
chondroblasts (cartilage cells). Overtime the chondrocytes undergo apoptosis due to lack 
of nutrition, then vasculature develops at the centre of the cartilaginous template. The 
perichondrium is a membrane cover the external surface of the cartilage which is 
replaced by periosteum and progenitor cells that eventually differentiate to the 
osteoblasts. The bone collar is a layer of osteoblasts that produce bone which covers the 
outer part of diaphysis (Figure 1.412 A). Blood vessels are attracted into the medullary 
cavity and osteoblasts are recruited form these blood vessels creating the primary 
ossification centre. Osteoblasts start to establish the bone matrix at the centre of primary 
ossification (Figure 1.412 B). At the epiphysis regions, the secondary ossification centres 
form. The cartilaginous structure on both sides of the ossification centres become woven 
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bone, and through the remodelling process are replaced by lamellar bone (Figure 1.4.2 
C). As a result of endochondral ossification, the centre of the long bone forms via two 
directions of growth either lengthening or widening, by adulthood only the articular 
cartilage is left at the joint ends (Figure 1.4.2 D). This ossification is a critical process in 
long bone formation and also occurs during natural healing of fractured bone (Yaszemski 
et al., 1996). 
 
Figure 1.4.2: Process of the endochondral ossification. (A) The cartilage was produced by 
chondroblasts. It has bone a collar at the diaphysis area. (B) The penetration of blood vessels 
become a primary ossification centre and bring osteoblasts to this area. (C) Secondary 
ossification centre occurs at the proximal of long bone. (D) The bone is fully developed, the 
cancellous and compact bones are mature, articular cartilage is the only cartilage present. 
Reprint from Seeley et al., (2008) with kind permission of McGRAW-HILL. 
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1.5 Bone healing and remodelling 
Bone healing is a proliferative physiological approach to repair fractured bone. There are 
three essential stages for bone healing the inflammatory stage, repairing stage, and finally 
the remodelling process. The inflammatory stage begins in the first few hours of injury 
and lasts for several days during which a heamatoma is created from white blood cells 
and fibroblasts, producing granulation tissue, initiating vascular ingrowth and promoting 
mesenchymal stem cell migration. 
In the repair stage, the cells in the heamatoma create a callus which contains different cell 
and tissue types such as fibrous tissue, cartilage and immature bone. At the initiation of 
this stage, the fibrocartilage formation predominates, which is followed by 
mineralisation.  
In the remodelling stage of bone repair, the chondrocytes differentiate and eventually 
become apoptotic. Cartilaginous calcification occurs, new blood vessels penetrate at the 
junction between the new bone formation and chondrocyte regions. New bone is 
generated by the co-ordinated activity of the osteoblasts and osteoclasts. 
The bone remodelling cycle consists of three consecutive phases: resorption, reversal, 
and formation (Kini and Nandeesh, 2012). 
The bone resorption starts with the activation and recruitments precursors of the 
mononuclear monocytes-macrophage osteoclasts to produce preosteoclasts (Roodman, 
1999). Integrin receptors interact with RGD (arginine, glycine and asparagine) to 
facilitate the preosteoclast attachment to the bone matrix. Osteoclast creates extensively 
specialised folds called the “ruffled border”, which is surrounded by annular zones called 
“sealing zone”. Osteoclast-mediated bone resorption is regulated by secretion of the 
lysosome enzyme and breakdown of the bone matrix proteins. After the process, the 
apoptosis of osteoclasts takes place. The remodelling process has distinct sequential 
aspects that changeover from bone formation to resorption and vice versa. In the creation 
of bone, osteoblasts produce a new proteinaceous matrix that contained predominately 
collagen type I and minerals, controlling the mineralisation of bone matrix (Anderson, 
2003; Clarke, 2008). They store a range of growth factors including platelet-derived 
growth factor (PDGF), insulin-like growth factor (IGF), transforming growth factor-beta 
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(TGF-β), basic fibroblast growth factor (bFGF), and bone morphogenetic proteins (BMP). 
Osteoblasts regulate these growth factors by two mechanisms, autocrine and paracrine 
process. After new bone formation, nearly 50 to 70% of osteoblasts become apoptotic 
(Clarke, 2008; Jilka et al., 1998). 
Bone remodelling is regulated by the Receptor activator of nuclear kappa-B ligand 
(RANKL) /RANK and osteoprotegerin (OPG). Remodelling can be activated by change in 
fundamental circumstances in the bone, such as fracture, bone diseases, calcium 
deficiency, and poverty. RANKL is a protein expressed by osteoblast that can be 
membrane bound or soluble, when it binds to the receptor of RANK locates on the surface 
of osteoclast precursors and mature osteoclast this activates an intercellular signal 
pathway inside the osteoclasts, driving differentiation and osteoclastogenesis. OPG 
protein is secreted by osteoblast cells and is a mimic of RANK that can bind to RANKL 
thereby blocking its ability to activate RANK and inhibiting osteoclastogenesis. The ratio 
between RANKL: OPG regulates the amount of bone resorption a given bone remodelling 
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Figure 1.5: The RANKL, RANK and OPG axis during bone remodelling (Owen and Reilly, 
2018, creative commons liscence). 
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1.6 Introduction to cleft palate 
1.6.1 Development of the palate 
The human face begins to develop four weeks after  conception and this is followed by 
palatal shelf development (Stanier and Moore, 2004). Embryologically, palatal 
development begins at around the sixth-week post conception with the formation of 
three main structures; the lateral palatal shelves, median palatal processes, and the nasal 
septum. The median palatal processes represent the main segment of the intermaxillary 
region which is known as the anterior or primary palate and also forms the central 
segment of the lip, while the posterior or secondary palate forms from migration fusion 
of two lateral palatal shelves which arise from maxillary processes (Figure 1.6.1 A and B) 
(Yoon et al., 2000; Zuk, 2008). 
  




Figure 1.6.1: Embryonic formation and anatomical development of human palate. (A) 
Development of human palate (1). (B) Human anatomy of the maxilla (anterior and medial 
view) (2). 
 
16 | P a g e  
 
1.6.2 Incidence and aetiology of cleft palate 
Cleft palate is the most common craniofacial congenital abnormalities in new-borns. A 
permanent opening occurs in the roof of the oral cavity because of a failure of the palatal 
shelves to fuse correctly during the early stage of embryonic development. This leads to 
communication between the nasal and the oral cavity. The frequency of cleft lip with or 
without cleft palate is between 1 in 300 and 1 in 2500 per new-born, while the cleft palate 
defect only has an incidence of 1 in 1500 per new-born. Several factors play a crucial role 
in increasing the prevalence of these defects such as geographical area, ethnicity and 
socio-economic situation (Lidral and Murray, 2004). The causes of cleft anomalies have 
been elucidated and include (Sabbagh et al., 2015): 1) environmental factors, for example, 
maternal ailments, exposure to chemicals/smoking especially through the first trimester, 
alcohol abuse, drug use including anti-convulsant and retinoic acid based drugs, 2) 
genetic factors which are passed down from either one or both parents, 3) infection such 
as rubella “German measles” and 4) consanguinity. Although the pathogenesis of cleft 
palate is unknown so far, some suggested causes are teratogenic exposure and/or genetic 
effects via the combination effect of environmental causes with allele genes during 
embryonic face development. these can give rise to variant form of phenotypes (Wu et al., 
2014). For example, in an animal study, retinoic acid medication of the treated group 
induced morphological changes such as excessive growth inhibition, orofacial 
deformities, failure of palatal shelves fusion, and Meckel’s cartilage hypoplasia 
(Padmanabhan and Ahmed, 1997). 
All these factors can influence initial embryonic development during the first trimester 
especially between the fourth and tenth weeks of pregnancy (Stanier and Moore, 2004). 
It is not life threatening but may commonly affect speaking, feeding, hearing and social 
relationships. The orofacial clefts are classified into syndromic and nonsyndromic types. 
In a syndromic orofacial cleft, the infant has mental and physical impairments which 
occur in about 30 percent of cleft defect patients. However, the remaining 70 percent of 
infants have nonsyndromic orofacial anomalies and do not have any mental and physical 
disturbances, as reviewed in the thesis of a colleague at University of Sheffield (Puwanun, 
2014). 
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1.6.3 Treatments of cleft palate 
The UK gold standard for treatment of cleft palate and/or lip (National Health Service, 
2013) begins with case management, which includes examination and diagnosis of cleft 
lip and palate, hearing tests, and feeding control. A cleft lip is closed approximately in the 
third month of a child’s life while the closure of cleft palate is usually achieved between 
6-12 months of child’s life using a soft tissue to close the defect.  The objectives of this 
management are to enable speech acquisition and allow for the encouragement of 
maxillary bone growth (R J Rohrich et al., 1996) (Table 1.6.3). 
Complications may occur after the operation including problems at the suture joint, 
which is the fibrous tissue joint between skull bones (Cohen, 1993) with morphological 
changes during growth and orthodontic treatment (Hahn et al., 2009) and ossification of 
the maxilla. The remaining bony defect in the cleft site leads to maxilla narrowing and 
distortion, shallow palate with shorting vault and may cause speech problems (Figure 
1.6.3). The soft tissue may fill the cleft in the hard palate and develop scar formation 
which affects facial development (Smahel et al., 2009). If defects include the alveolar 
process, surgical intervention is performed to support teeth during eruption so that the 
bone graft frequently takes place between the ages of 8-11 years (Wolford and Stevao, 
2002)
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Table 1.6.3: Timeline of care of a patient with cleft palate/lip defects, indicating the key times during a child’s growth (months/years) 
during which interventions would take place. Treatment is performed by multidisciplinary teams, including oral and maxillofacial 
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Figure 1.6.3: Post-operative complications after cleft palate correction surgery. (A) 
Shallow Palate (4). (B) Short Palate with narrow maxilla (5
A B 
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Conventional surgical operations for bone regeneration utilise bone grafts which can be 
an autograft, isograft, allograft, xenograft, prosthetic materials and/or combination 
grafts. The autologous graft is the gold standard to achieve bone regeneration. However, 
bone graft has limited use because of high morbidity and complications at the donor site 
such as bone resorption, disturbance of gait, impermanent numbness and/or 
paraesthesia of the leg, especially when taken from the lateral aspect of femoral bone 
(Elsalanty et al., 2009). Ross (1987) mentioned that 73 per cent of patients suffering from 
unilateral cleft lip and palate needed orthodontic treatment for the arrangement of teeth 
while the remaining per cent (27) required orthognathic surgery (surgical correction of 
the jaw). The management of cleft palate usually takes an extended period. 
1.6.4 Arguments about the timing of cleft palate repair 
Cleft palate management protocols still create controversy, in which the perfect time of 
surgical intervention for the closing of the cleft palate is not fully established. The surgical 
intervention depends on a number of factors including the kinds of cleft anomaly (cleft 
lip, cleft palate, cleft lip and cleft palate, unilateral and/or bilateral: Figure 1.6.4) 
(Shkoukani et al., 2014), patient-specific factors and the medical team’s opinion. Cleft 
palate in children usually causes a delay in speech onset because of the opening between 
the oral and nasal cavity (Peterson-Falzone et al., 2001). 
Berkowitz et al., (2005) reported that an appropriate age for repairing a cleft lip is around 
the age of 3 months, following by cleft palate correction between 6-18 months. Although 
this time is essential to improve the phonetics, maxillary growth may be affected. The 
study of Ysunza et al., (2010) claimed that an early repair of the cleft palate at around 4-
6 months of infant`s age could improve speech development, and can be followed by 
orthodontic treatment to enhance the normal maxillary expansion and growth. 
Nevertheless, specific studies found scar formation in the anteroposterior direction 
which leads to retrusion of the midface (Puwanun, 2014; Ross, 1987b). 
Many procedures can be undertaken for the reconstruction of cleft palate (Moreau et al., 
2007; Shkoukani et al., 2014). The autologous graft is the gold standard to achieve bone 
regeneration at the alveolar ridge because it contains factors that improve the 
osteogenesis. The reconstruction of alveolar cleft depended on the fresh autologous bone 
graft that can be harvested from different sources such as iliac, tibia, rib, cranial bone, and 
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mandibular symphysis. These provide a corticocancellous bone block that can be 
reshaped depending on the defect shape and then transplanted to the alveolar cleft space 
(Rawashdeh and Telfah, 2008; Scalzone et al., 2019). 
In bilateral cleft palate and lip, which is a more complicated case and more challenging to 
treat, maxillary arch development was shallower and narrower than in the unilateral cleft 
case. Furthermore, there was a slight enhancement of the maxillary arch provided by 
orthodontic treatment (Smahel et al., 2009). The reviews of Schweckendiek and Doz, 
(1978) and Prydso et al., (1974) claimed that the soft palate defect could be corrected in 
the first year of a child’s age which led to improved speech development and diminished 
speech difficulty with age. The hard palate defect is repaired at around 12-14 years of 
patient’s age due to the completed maxillary growth, which leads to minimising the 
maxillary disturbance. On the other hand, Rohrich et al., (1996) observed that there was 
no significant difference in maxillary growth disturbance in patients whose hard palate 
was closed early (10.8 months of age) compared with delayed (40.8 months of age). 
However, greater speech difficulties are noticed in the delayed treatment group that can 
cause hearing loss, and there was a higher incidence of palatal fistula compared to the 
early closure group. They proposed a protocol in which intact cleft palate correction 
should occur before two years of the child’s age to facilitate the healthy development of 
phonetics and also eliminate the risk of deafness (Rohrich and Gosman, 2004). 
Recently, tissue engineering has been considered a promising technique for 
reconstruction of the alveolar ridge area which reinforces tooth eruption and also can 
integrate with a tissue in the palate region (Martin-de-Campo et al., 2019). 
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Figure 1.6.4: Veau cleft lip and palate classification. (A) Class I_ cleft in soft palate. (B) class 
II_ Cleft in both hard and soft palate. (C) Class III_ complete unilateral cleft. (D) Class IV_ 
Complete bilateral cleft. Printed from Shkoukani et al., (2014) with kind permission of Birth 
defects research. 
 
1.7 Use of tissue engineering to repair cleft palate 
A new technique for the regeneration of missing bone tissue is known as tissue 
engineering.  This technique would reduce problems noted during conventional 
treatments such as immune rejection, donor site morbidity, bone resorption, disturbance 
of gait, impermanent numbness and/or paraesthesia of the leg, and pathogen cross-
contamination. The ideal standard for bone tissue engineering is to collect cells from a 
patient’s tissue and isolate the relevant cell population, usually adult stem cells, then 
culture the cells to allow proliferation and seed them into a scaffold for tissue 
development before re-implantation into a patient (Figure 1.7) 
  




Figure 1.7: Strategies of craniofacial bone tissue engineering, Kumar and Kandalam 
(2017) with kind permission of British Journal of Oral & Maxillofacial Surgery 
In a clinical study, Moy et al., (1993) reported that the quantity of bone formation in the 
craniofacial after implantation of a combination of autologous corticocancellous bone 
chips and hydroxyapatite granules was significantly more than when hydroxyapatite was 
implanted alone. Using cells in tissue engineering may be a reliable alternative to 
standard autologous grafting approaches to achieve clinically successful bone 
regeneration for craniofacial reconstruction. The cells used for bone tissue engineering 
should be able to incorporate into the adjacent tissue and be capable of osteogenic 
differentiation. 
Scaffolds are either mechanically fabricated or natural biomaterials which can act as a 
carrier for specific biological elements such as cells, hormones, growth factors, and drugs. 
The scaffold requirements for bone tissue engineering are biocompatibility, adequate 
mechanical strength and stability, bioresorbability, ease of manipulation, and 
interconnected porosity (Tevlin et al., 2014). Hibi et al., (2006) described the use of a 
combination of autologous mesenchymal stem cells harvested from the bone marrow of 
patient’s iliac crest, platelet-rich plasma (PRP), and a gel matrix to fill the alveolar cleft 
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defect in a 9-year-old patient. Consequently, the bone volume augmented about 79% 
when assessed nine months postoperative follow up. Moreover, the maxillary lateral 
incisor and canine teeth erupted after two-years post-operation at the location 
surrounding the defect. These results indicate that tissue engineering can support cleft 
palate repair. However, there are many crucial factors that affect the result of tissue 
engineering repair include donors’ variation such as gender, age, habit, physiological 
status and anatomy. 
The methods and sources of stem cell collection and isolation affect the outcome of any 
tissue engineering strategy as these will affect the quality of the cell and its proliferation, 
and differentiation in vitro. Finally, the bone defect in the maxillofacial region will have a 
variety of vascularisation and loading functions. Current research in tissue engineering is 
working to control these variables and minimise the subsequent healing time before 
implantation (Phinney et al., 1999). 
1.8 Stem cells 
Stem cells have the capability to self-renew and to differentiate into two or more cell 
types. Totipotent cells can differentiate into any cell type of an embryo including the 
placenta whereas pluripotent cells can differentiate into any cell of the body. 
There are two significant sources of stem cell which have been used in medical sciences; 
embryonic sources called “embryonic stem cells”, which are found in the inner cell mass 
of the early stage of the embryonic blastocyst and adult stem cells, which are already 
present in the adult tissue. Embryonic stem cells are pluripotent which means they are 
capable of being differentiated into all types of body cell; they also have an unlimited 
capacity of self-renewal. On the other hand, adult stem cells are considered multipotent 
as they have a more limited number of cell types that they can differentiate into. During 
the growth process, embryonic stem cells undergo significant proliferation which may be 
considered advantageous, as they provide an inexhaustible source of cells for tissue 
regeneration. Nevertheless, although embryonic stem cells can regenerate missing tissue, 
they can also form teratoma (Ben-David and Benvenisty, 2011). In addition, there is 
ethical resistance to using embryonic stem cells in the clinic. From another view, adult 
stem cells do not display the same ethical issues, although questions could be raised 
during therapeutic uses involving possible risk of cancer (Chandaet al., 2010). In general, 
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they are assumed to be safe as they are derived from adult tissue (Obokata and Vacanti, 
2014). 
A proportion of stromal cells found in bone marrow, are considered to be a source of 
mesenchymal stem cells. The bone marrow stromal cells were previously considered to 
be purely a supporting structure for hematopoiesis. Many studies have demonstrated 
that these stromal cells can be differentiated into many mesenchymal cell lineages, such 
as bone, muscle, fat, cartilage (Chamberlain et al., 2007). 
Friedenstein and colleagues (1966) first isolated MSCs from bone marrow (Mafi et al, 
(2011). MSCs exhibit adherence to tissue culture plastic and are spindle-shaped. The 
expansion of mesenchymal stem cells has been undertaken from cells of many sources, 
for example; muscles (Dodson et al., 2010), fat tissue, dental pulp, umbilical cord, 
amniotic fluid, embryonic stem cells (Lian et al., 2007; Phinney and Prockop, 2007), 
periosteum (Choi et al., 2008), synovial membrane (Bari et al., 2001), skin (Belicchi et al., 
2004), peripheral blood (Shi et al., 2009), primary teeth (Miura et al., 2003) and 
periodontal ligament (Seo et al., 2004). There are, however, difficulties in cell isolation 
which include the small numbers of isolated cells that can be obtained from a tissue 
biopsy or blood/marrow aspirate, and there also issues associated with segregating cell 
populations within tissues. For these reasons, stem cells derived from adults need be able 
to be expanded in vitro and undergo advanced manipulation before use in preclinical or 
clinical trials, and this leads to safety and efficiency issues (Obokata and Vacanti, 2014). 
There has recently been a significant focus on the application of mesenchymal stem cells 
for several varieties of ailments (Wappler et al., 2013). Researchers have investigated the 
beneficial effects of mesenchymal stem cells for paracrine support and modulation of 
immunity (Horwitz and Rph, 2009; Meirelles et al., 2009; Patel et al., 2008). 
Human mesenchymal stem cells are characterised by secretion of a range of growth 
factors (including basic fibroblast growth factor, epidermal growth factor, hepatocyte 
growth factor, platelet-derived growth factor, stromal-derived growth factor 1 α, 
transforming growth factor β, vascular endothelial growth factor) and cytokines 
(interleukin 1 β, interleukin-6, interleukin-8, tumor necrosis factor α) (A I Caplan, 2009; 
Führmann et al., 2010). They represent a small amount (1-2%) of whole bone marrow 
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cells, and hence, expansion to high cell numbers is important (Fibbe and Noort, 2003; 
Pittenger et al., 1999). 
 
1.8.1 Mesenchymal stem cells 
Mesenchymal stem cells can undergo differentiation and proliferation under the control 
of some critical factors which involve: growth factors, cytokines, hormones, and 
transcription agents (Alexander et al., 2014). Although bone marrow is an essential 
source of mesenchymal stem cells and is easy to access, there are still drawbacks to its 
use, which are: the morbidity and pain at the donor site and low cell numbers compared 
to the defect to be filled (Baksh et al., 2004; Campagnoli et al., 2015; Gregoryet al, 2005; 
Tuan et al., 2003). 
The rate of proliferation, multipotency, tissue origin, donor gender and age, ailment stage, 
potential capability for differentiation, and ease of access are considered crucial factors 
which determine the usefulness of mesenchymal stem cells (Alexander et al., 2014). 
Biochemical signals are used to modify stem cell behaviour for example; the cytokines 
and growth factors discussed above (Delaine-Smith and Reilly, 2011). Environmental 
agents such as; surface chemical components and topography, also seem to influence 
stem cell fate (Dalby et al., 2007; Reilly and Engler, 2010), as do mechanical forces for 
instance; tension, fluid shear, and hydrostatic pressure (Delaine-Smith and Reilly, 2011). 
Mesenchymal stem cells are commonly grown in vitro after selection by plastic adherence 
(Nombela-Arrieta et al., 2011). They are considered to be a heterogeneous population, 
and to date, no specific cell-surface marker identification for mesenchymal stem cells has 
been presented (Schauwer et al., 2012). Therefore, specific common guidelines are used 
for the identification of mesenchymal stem cells. As well as adherence to plastic tissue 
culture they should show positive expression of surface antigen markers including CD73, 
CD 90, and CD 105; and negative to CD11b, CD 19 or CD 34, CD 45, CD 79 α, and HLA-DR 
(Dominici et al., 2006; Alexander et al., 2014).  
Mesenchymal stem cells are typically harvested from bone marrow aspirates collected 
from either the anterior or posterior iliac crest. MSCs hold great promise therapeutically 
and offer benefits either by direct tissue repair through differentiation into specific tissue 
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damage or indirect wound regeneration by releasing specific bioactive proteins such as 
growth factors, chemokines, and anti-apoptotic agents (Rehman et al., 2004). These 
proteins play crucial significant roles in angiogenesis and cell recruitment which is also 
very important for regeneration of damaged tissues (Meirelles et al., 2009). Mesenchymal 
stem cells also can create immunosuppression by acting together with T and B 
lymphocyte, monocytes, and Natural Killer Cells (Sioud, Mobergslien, Boudabous, and 
Fløisand, 2011) therefore could become a competent resource for allogeneic cell sources 
(Koç et al., 2002). 
1.8.2 Mesenchymal stem cells differentiation in vitro 
The differentiation of MSCs can be controlled in vitro through the preparation of specific 
culture conditions and tested using some phenotypic markers related to that tissue type. 
Growing cells are typically observed in an optimised medium which is prepared by 
adding specific supplements or growth factors. To determine if the cells have 
differentiated, expression of markers specific to differentiation pathways and the 
extracellular matrix (ECM) structure are observed (Delaine-Smith and Reilly, 2011). 
These conditions and markers are described in the following sections 
1.8.3 Human periosteum cells as promising cells for osteogenicity 
The periosteum has been considered to be a promising origin of immature osteogenic 
progenitor cells and also has a tri-layer membrane which envelops the whole outer 
surface of bone except the joint (Kawase et al., 2014; Olbrich et al., 2012). Its purpose is 
to enable growth, remodelling, and bone healing. The internal layer of the periosteal 
membrane contains mesenchymal stem cells which can differentiate into many different 
cells such as osteoblasts and chondroblasts; these are similar to mesenchymal stem cells 
that are harvested from bone marrow (Puwanun, 2014). Periosteal cells from older 
donors are still able to exhibit osteogenic properties; in contrast, this property is reduced 
in bone marrow mesenchymal stem cells (Stolzing et al., 2008). 
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Figure 1.8.3: Facial development by intramembranous ossification and endochondral 
ossification. pink colour and green colour “chondrocranium” - endochondral ossification 
forms the base of skull. Light blue “membranous” - intramembranous ossification forms 
superior-anterior of skull and face (.) 
There are arguments about what is the best harvesting area of mesenchymal stem cells 
for the regeneration of facial bone deformities. During development, the facial skeleton 
emerges from the cranial neural crest. Periosteal tissue from two different regions could 
differ in bone formation and healing (Puwanun, 2014). Fuji et al., (2006) and Choi et al., 
(2002) used animals to compare bone formation from periosteum harvested from the 
tibia and facial regions with implanted into suprahyoid muscle. The results showed that 
intramembranous ossification (Figure 1.8.3) was induced by the harvested periosteum 
from the facial bone. While the periosteum from the tibia initiated endochondral 
ossification (Figure 1.8.3). In alveolar bone augmentation, D’Addona and Nowzari (2001) 
reported that the graft bone harvested intraorally induced bone augmentation without 
cartilage formation. These previous studies indicated that human periosteum cells might 
be considered as an alternative source for the engineering of bone tissue and that Jaw 
periosteum might be more relevant to induce intramembranous ossification.  
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1.8.4 Osteogenesis 
Two types of markers are commonly used to test the osteogenic differentiation of 
mesenchymal stem cells. The initial or early markers include: mesenchymal stem cells 
morphology switching from fibroblast, fusiform to a more cuboidal shape, and expression 
of mRNA for Runt-related transcription factor-2 (RUNX-2), alkaline phosphatase enzyme 
(ALP), bone morphogenetic protein 2 (BMP-2), osteonectin matrix protein (ON), 
transforming growth factor-β1 (TGF-β1), and the abundant matrix protein collagen type 
I (COLΙ). The late markers of osteogenic differentiation include the proteins osteocalcin 
(OC), osteopontin (OPN), continuing expression and deposition of COL Ι and finally bone 
mineral formation. The mineral present in the bone is a type of calcium phosphate in the 
form of carbonated hydroxyapatite. Studies have identified the presence of a calcium 
group via alizarin red staining or a phosphate group via Von Kossa staining (Delaine-
Smith and Reilly, 2011). 
VEGF comprises the secreted glycoproteins that play essential roles in the regulation of 
vasculogenesis (controlling of the sprouting of new blood vessels). Later VEGF studies 
discovered a family of VEGF, which are designed of seven secreted types; family 
comprises seven secreted glycoproteins that are designated VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, placental growth factor (PlGF) and VEGF-F (Ferrara et al., 2003). VEGF-
A (is also alluded to VEGF) mostly exerts its biological influence through secretion of 
vasculogenetic protein and initiates the proliferation of endothelial cells, bone sprouting 
and new blood vessels. The human gene of VEGF comprises of four different mature 
isoforms (VEGF121, VEGF165, VEGF189 and VEGF206) (Tischer et al., 1991). VEGF189 
and VEGF206 are wholly sequestered in the ECM that is indispensable for vascularisation 
of epiphyseal region in endochondral bone construction. While the significant isoform of 
VEGF165 is slightly diffused but is mainly attached to ECM that takes the essential effects 
of angiogenesis in the ossification of primary centre. VEGF directly interacts with three 
central receptors (VEGFR1, 2 and co-receptor neuropilin-1). VEGF and its receptors are 
indicated to human osteoblast cells and expressed the significant level in the late stage of 
osteogenesis, which contributed to osteoblast differentiation and bone regeneration via 
directly and indirectly effects of vascularisation promotion. Clinical investigation 
indicated that the highest expression of VEGF could lead to figuring out a variety of 
diseases such as rheumatoid arthritis, diabetic retinopathy and cancer (Risau, 1997). The 
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secretion of VEGF regulates by among factors such as hypoxic environments, 
prostaglandin, vitamin D, BMPs, transforming growth factor-beta (TGF-β), insulin-like 
growth factor 1 (IGF1), platelet-derived growth factor (PDGF) and fibroblast growth 
factor 2 (FGF-2). Whereas the glucocorticoid is diminished the secretion of VEGF (Maes 
and Carmeliet, 2008). 
Ascorbic acid (AA), beta-glycerophosphate (βGP), and dexamethasone (Dex) are typically 
used during the preparation of osteogenic medium. These components are usually 
applied from one to several weeks. Ascorbic acid is essential for the stabilisation of 
collagen production, and it is essential for the formation of bone matrix proteins. It also 
plays a significant co-factor role for proline residue hydroxylation in collagen fibres 
(Kielty et al., 1993). βGP supplies inorganic phosphate for the production of bone-like 
mineral via the cells (Chang et al., 2000). Dexamethasone is considered as a steroidal anti-
inflammatory agent, glucocorticoid, and is required for multi-differentiation media such 
as chondrogenic, adipogenic, and osteogenic media. Osteogenesis is inhibited if there is a 
lack of one or more of osteogenic inducers especially in 2D static culture (Porter et al, 
2003). Although it stimulates early differentiation Dex has the general ability to inhibit 
collagen synthesis and high levels (≥100 nM) has been observed to facilitate adipogenesis 
(Beresford et al., 1992). BMP, transforming growth factor-β1, growth factors, and also 
vitamins D3 (VD3) all play crucial roles in the enhancement of osteogenesis when added 
to the supplements mentioned above (Seong et al., 2010; Vater et al., 2011). 
BMPs are considered to be one of the superfamilies of transforming growth factors. They 
can be used for the stimulation of osteogenic differentiation in both in vivo and in vitro, 
but in vitro, the effect may be dependent on species  (Diefenderfer et al., 2003). For 
example, to activate human mesenchymal stem cells during osteogenesis in vitro, 
specifically defined media, such as serum-free, are required when using BMP-2 (Osyczka 
and Leboy, 2005). 
1.9 Soft tissue-engineering 
1.9.1 Human normal oral fibroblasts  
The oral epithelium contains basal cells that use the hemidesmosome contacts to 
adherence to the connective tissue of the basement membrane. They split and apically 
transfer into the suprabasal spinous layer, with express constant modifications in gene 
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morphology and expression, which consequently differentiate into cells that produce the 
specific layer called “granular layer”. Finally, this layer represents the primary 
permeability of the epithelium barrier. The cells of oral mucosa undergo further 
differentiation into either a highly keratinised layer that locates in the hard palate or non-
keratinized layer that underlies the buccal mucosa and lingual regions. The basal cells 
express keratin; whereas, the suprabasal cells express keratin in the skin (Jennings et al., 
2016). The paracrine interactions between the NOFs and NOKs are indispensable for the 
differentiation and growth of the keratinocytes to create a multilayer, stratified 
squamous epithelium (Costea et al., 2003). 
1.9.2 Tissue-engineered oral mucosal models 
The first time using of primary keratinocytes cultivation was by Rheinwald and Green in 
1975.  They employed mouse mature fibroblast cells cultured in Green’s media to create 
a feeder layer for keratinocytes and attained an appropriate epidermal cells proliferation 
(Kriegebaum et al., 2012).  In the early 1980s, tissue-engineered oral mucosa (TEOM) has 
been introduced in vitro and in vivo (Tayebi and Moharamzadeh, 2017).  The researchers 
cultured the epithelial sheets that took from different parts of the body to treat some 
injuries such as burns and oral mucosa defect (Madden et al., 1986; Lauer et al., 1991).  
Recently, investigators have focussed on the development of 3D multilayers of human 
oral mucosal. TEOM is increasingly being used to model drug delivery, toxicity and oral 
diseases (Jennings et al., 2016). Currently, TEOM mainly consists of co-culture of primary 
normal oral keratinocytes (NOKs) on top of an oral fibroblasts-containing matrix 
(Dongari-Bagtzoglou and Kashleva, 2006; Moharamzadeh et al., 2012) which, when 
cultured at an air-to-liquid interface, form a stratified epithelium and display histological 
features similar to their in vivo counterparts. Therefore, they are an excellent alternative 
for native tissue (Lee et al., 2004).  However, a limited commercial supply of NOK 
challenges widespread application of these mucosal models. Furthermore, NOKs are 
restricted due to poor longevity and also donor-to-donor variability. NOKs have been 
immortalised by overexpression of hTERT using stable transfection (Dongari-Bagtzoglou 
and Kashleva, 2006). Consequently, this prevents telomere shortening, thereby 
incrementing the life-span with associated improvement of cell proliferation capacity 
while preserving their phenotype (Lee et al., 2004). Therefore, the creation of TEOM 
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based on commercial immortalised oral keratinocytes (FNB6) may provide wider access 
to NOK-based TEOM (Jennings et al., 2016). 
1.10   Introduction of serum and serum-free media 
The most common culture cell media used in vitro cell expansion is a base media, typically 
Dulbecco’s Modified Eagle’s Medium (DMEM) or alpha Minimum Essential Medium 
(αMEM) supplemented with foetal bovine serum (FBS).  
The basal supplementation of culture media with different sera of animal origin is 
essential for cell growth metabolic activity, metabolism and for stimulating proliferation 
(Brunner et al., 2010). However, although various cell lines are cultured in medium 
supplemented with serum, in many cases cultures could be cultured and proliferated in 
serum-free media (Freshney, 2010). 
FBS is a collection of numerous factors which are very important in cell attachment, 
growth and proliferation, and for these reasons are usually used as a growth supplements 
for many types of human and animal cell (Brunner et al., 2010). FBS is used in the most 
common media formulations utilized for isolation and expansion of human mesenchymal 
stem cells (hMSCs). These interact with the other basic conditions of temperature, pH, 
osmolarity and oxygen supply, (Davis, 1994) which are essential to control successful 
growth, cell survival, maintenance and differentiation of human and animal cells in vitro 
(Figure 1.10). 
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Figure 1.10: Parameters controlling growth, proliferation and expression of differentiated 
functions of cultured cell in vitro. Printed from Brunner et al., (2010) with kind permission 
of Altex. 
Serum is a complex mixture of different molecular weight biomolecules that creates a 
balance between growth-promoting and growth-inhibiting actions (Werner and Grose, 
2003; Freshney, 2010). The critical ingredients of serum and their major functions are 
shown in (Table 1.10 A). 
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The roles of serum in cell culture media include provision of many different types of 
growth factors, hormones and proteins for binding and transport. As well as, enzymes 
such as protease inhibitors and amino acids, vitamins and trace elements. Moreover, the 
serum provides detoxification and controls osmotic pressure (Brunner et al., 2010). 
The advantages of serum in media are as follows (Brunner et al., 2010): 
i. The natural coagulated serum is highly productive of cell proliferation by 
secretion of specific polypeptides from activated platelets during the clotting 
cascade (Balk et al., 1981; Gospodarowicz  and Ill, 1980). 
ii. FBS has been considered as a standard supplement for cell culturing because of its 
content high growth factors and low ϒ-globulin. 
iii. FBS has a mixture of essential factors which are very important during cell 
proliferation and maintenance. 
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iv. Reduction the time and effort involved in preparing a media with all the factors 
needed for cell growth. 
However, the use of animal serum in cell culture has many disadvantages and 
potential risks which include (Mannello and Tonti, 2007; Berger et al., 2006): 
i. The risk that contamination could be transmitted to cell culture such as viruses, 
mycoplasma, bacteria and/or identification of zoonotic agent. 
ii. In a clinical context, xenogeneic proteins could induce an immunological reaction 
in patients, especially during cell culture therapeutics. 
iii. Batch-to-batch variability can lead to inconsistencies between experiments. 
iv. The content of growth inhibitors, cytotoxic elements and serum could also contain 
some ingredients that can inhibit the growth of specific cell types. As well as this, 
serum is toxic for most cell type if it uses in too high concentration (Barnes and 
Sato, 1980). 
v. A set of voracious quality requirement controls are needed to reduce 
contamination risk (Barnes and Sato, 1980). 
vi. The serum can interfere with unidentified factors which affect hormones, growth 
factors and other additives (Barnes and Sato, 1980). 
vii. Availability limitations (Barnes and Sato, 1980). 
viii. Ethical concerns and animal welfare issues (Jochems et al, 2002.; Tekkatte et al., 
2011). 
1.10.1 Foetal bovine serum alternatives 
Recently, due to the disadvantages and problems raised for serum used in cell 
propagation and maintenance, the reduction of FBS in culture media with alternatives of 
animal serum substitutions have been recommended (Culture & Gstraunthaler, 2003). 
The substitutions are extracted from other animal species such as horse, pig, goat, 
pituitary, chicken embryo or ocular fluid (Filipic et al., 2002), bovine milk fractions or 
bovine colostrum (Belford et al., 1995; Pakkanen and Neutra, 1994) or plants are used 
for extraction of protein fractions called vegetal serum (Pazos et al., 2004). Alternatively, 
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human platelet lysates could be extracted from donor red blood cells (Rauch et al., 2008), 
autologous serum has been described to induce faster proliferation of bone marrow stem 
cells (BMSCs) and reduce differentiation (Dahl et al., 2008; Shahdadfar et al., 2005) 
however, it still has problems of limited availability (Lindroos et al., 2009). 
There are many methods for reduction of FBS including: 
i. Existing culture media optimisation (Brunner et al., 2010; Jung et al., 2012). 
ii. Serum media reduction (Brunner et al., 2010). 
iii. Defined serum-free media (Gstraunthaler, 2003; Zimmerman et al., 2000) or 
serum deprived media (Solmesky et al., 2010).  
iv. Allogeneic human serum (HS), xeno-free (XF) media formulations (Kocaoemer et 
al., 2007; Mannello and Tonti, 2007). 
1.10.2 Serum-free media 
Recently, the availability of commercial serum-free media has increased significantly. 
Most types of cells; both primary cultures and cell lines can be grown in growth media or 
“application media”. Growth media could be considered as a primary media which can 
maintain the cells and enable proliferation; they are termed in the literature replacement 
media or basal media. Application media describes a media designed for specific 
functions of metabolism, for example, a simple washing solution, the medium of transport 
(Brunner et al., 2010). 
There are plenty of factors which can be altered that affect cell maintenance, growth and 
characteristics. Furthermore, the attachment of anchorage-dependent cells such as 
hMSCs will be affected by the specific components of any serum-free media. Additionally, 
since hMSCs are obtained from adult human donors, the responses to the components of 
the media may be donor-specific. For these reasons, the processing of a defined serum-
free medium especially for specific cell type is a complex task (Jung et al., 2012). 
A number of methods for developing of serum-free medium either for specific cell line or 
initial culture have been described (Freshney, 2010; Jung et al., 2012). 
The first approach is called Ham’s approach which is partly reducing or eliminating 
serum amount in a medium. The essential concept of Ham’s approach is minimising 
serum to a level that confines growth and then adding serum ingredients and observing 
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any changes in the medium or culture conditions that will create growth improvement 
(Jung et al., 2012). Using this approach, Ham and colleagues assorted the growth-
promoting functions of serum into two basic classes, “replaceable” and “non-replaceable” 
(Jung et al., 2012; Ham and Mckeehan, 1978). 
The second method is called Sato’s approach; it is different from Ham’s approach as it 
used an artificial method for serum replacement in culture media. It based on what 
functions serum plays for cell growth and maintenance in the culture media and then 
supplementation of the existing basal medium formulation with essential hormones and 
growth factors, stimulating the growth stimulation function of whole serum (Barnes and 
Sato, 1980). Jung and colleagues mentioned that Sato’s group distinguished different 
essential chief supplements, hormones, binding proteins, lipids and trace elements for 
medium basal addition. In particular, insulin, transferrin, and selenium were required for 
essential growth of most cells but some cell types additionally required hydrocortisone 
and epidermal growth factor (Jung et al., 2012). 
The final methods are called a top-down and bottom-up approach, which could be 
effectively applied to cell growth by new serum-free medium formulation development 
(Jung et al., 2012). 
The top-down approach uses existing medium formulations for a similar cell type, and 
the stimulatory ingredients are identified in serum present during target cell growth. This 
process is based mainly on the gradual reduction of serum concentration but when this 
approach is used the user should be careful as any cytotoxic or growth inhibitory 
elements in the medium may have a stronger effect with reduced serum (Jung et al., 
2012). 
The bottom-up approach uses an appropriate basal medium (cell type growth is used) 
and observation of different selected exogenous factors for their growth-stimulatory 
effect. Just the active elements necessary for growth cell are added to the medium (Jung 
et al., 2012; 2010). 
Nutrients are chemical materials that are transferred to the cells and used as substrates 
in energy metabolism or biosynthesis, catalysts or structural elements of cellular 
organelles. In general, they are classified as organic nutrients, inorganic salts, and trace 
components. The organic nutrients are subclassified into amino acids, carbohydrates, 
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vitamins, lipids and other (Jung et al., 2012). Typically, the nutrients are a significant part 
or “defined” portion of culture media as they play essential roles for functional regulation 
(Ham and Mckeehan, 1978). 
Among the organic nutrients are amino acids which are essential critical compounds of 
media as building blocks for the synthesis protein. Some amino acids, especially in serum-
free conditions, have crucial roles in the multiplication of cells in culture, for example, 
glutamine shows an essential purpose in many metabolic pathways (Parker et al., 2007). 
Carbohydrates are important for cell growth in culture and a vital source of energy for 
cells in culture, such as glucose. Although glucose can be harmful if used at high 
concentrations. Nevertheless, specific recent research appears to show that a high 
glucose concentration (~25mM) could lead to faster animal and human MSC growth (Li 
et al., 2007; Nauman and Deorosan, 2011; Weil et al., 2009). 
Specific lipids that stimulate mammalian cell growth such as cholesterol and free linoleic 
acid are not involved in the defining part of cell culture media. Therefore, external lipids 
are supplemented in specific serum-free culture (Jung et al., 2010; Parker et al., 2007). 
There are 12 vitamins which are divided into four fat-soluble vitamins (A, D, E and K) and 
eight members of the B complex, all these vitamins are required for mammals. Vitamins 
B act as enzyme cofactors and are required for the diploid cell (cell division). For this 
reason, all B vitamins are included in many cell culture media (Jung et al., 2012). Vitamin 
C (ascorbic acid) is essential for individual cell growth and its functions include playing a 
role as an oxygen acceptor in several mixed-function oxidase systems, and stabilising 
collagen fibrils factor (Rowe et al., 1977). Vitamin C was shown to be an essential element 
for increasing cell proliferation and stimulated the biosynthesis of extracellular matrix 
constructions in the primary or initial culture of human bone marrow cells under serum-
free conditions (Gronthos and Simmons, 1995; Harada et al., 1991). Vitamin C has also 
been demonstrated to support specifically hMSC growth (Jung et al., 2010; Kuznetsov et 
al., 1997) and osteogenesis (Jung et al., 2010). Vitamin C is generally being utilised as a 
supplement in specific MSC differentiation media, and has been shown to maximise 
osteoblastic marker expression in hMSCs grown under serum-free condition (Mimura et 
al., 2011). 
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There are many salts founded in the media which include Calcium ions (Ca2+), Chloride 
ions (Cl-), Sulphate ions (SO42-), Phosphate anions (PO43-), Sodium ions (Na+), Potassium 
ions (K+), Magnesium ions (Mg2+) and Bicarbonate ions (HCO3-), and these have many 
functions which are: firstly, maintaining the osmotic balance of the cells. Secondly, acting 
as divalent cation, especially Ca2+ for specific molecule cell adhesion. Thirdly, acting as an 
intermediate for signal transduction and regulation of membrane potential. Fourthly, the 
matrix and nutritional precursors of macromolecules need SO42-, PO43- and HCO3. Finally, 
HCO3- is considered as a buffer in media and the concentration of Carbon dioxide (CO2) in 
the gas phase determines the concentration of HCO3- (Jung et al., 2012). 
As well as the inorganic salts, other inorganic compounds found in serum play a role as 
enzyme cofactors and are required for survival and growth of cells, such as Copper (Cu2+), 
Manganese (Mn2+), Molybdenum (Mo6+), Zinc (Zn2+), Selenium (Se8+), Silicon (Si4+), Iron 
(Fe2+) and Nickel (Ni2+) (Jung et al., 2012). 
Mammalian cell growth requires additional factors as well as nutrient ingredients. These 
include growth factors and attachment proteins and hormones. These factors are not 
present in serum-free basal media and, therefore, supplementation is required. These 
growth-stimulating regulatory components have commonly been the priority in serum-
free media optimisation (Chase et al., 2010; Jung et al., 2010; Ng et al., 2008). It is crucial 
to note that TGF-β 1 alone appears to have a growth-inhibitory effect on hMSCs while 
showing as considerable synergistic effect with bFGF (Jung et al., 2010). The influence of 
PDGF on hMSCs is debatable. Some research suggested that PDGF increases MSC 
proliferation (Lennon et al., 1995; Ng et al., 2008). Furthermore, plasma containing a high 
level of PDGF or platelet lysate has been demonstrated to enhance anchorage and hMSCs 
expansion; but their effect is often masked in the presence of other potent factors (Jung 
et al., 2010). 
Binding proteins such as albumin and transferrin are commonly supplemented with 
serum-free media. The absence of albumin in serum-free formulations has reduced hMSC 
growth (Parker et al., 2007). Conversely, many other reports also show the growth-
promoting effects of these proteins in many cell types (Freshney, 2010). The hormone 
hydrocortisone is considered to be a key ingredient in serum-free media for hBMSCs 
growth, and furthermore displays a significant positive effect on cell metabolism when 
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combined with fetuin. Fetuin is an essential plasma glycoprotein which is synthesised in 
the liver by hepatocytes and has the ability to regulate bone metabolism clinically and 
has also been shown to be an essential requirement for serum-free primary cultures of 
hMSCs and other cell types such as mouse fibroblast and epithelial cells (Jung et al., 2010; 
Wang and Haslam, S, 1994). 
Heparin, a glycosaminoglycan anticoagulant factor has been shown to have both 
proliferative and anti-proliferation effects (Jung et al., 2012). It was shown to reduce the 
growth of hMSCs from adipose tissue and bone marrow (Jung et al., 2010; Kocaoemer et 
al., 2007). In contrast, Mimura et al. reported the growth-enhancing effect of heparin on 
a genetically modified hMSCs line (Mimura et al., 2011). 
1.11 Human platelet-rich blood products  
The life cycle of platelets begins with hematopoietic differentiation of stem cells in the 
surface endosteal layer of bone, megakaryocyte progenitors then migrate to the blood 
vessels in the bone marrow (Malhotra et al., 2013). Platelets have an essential role in 
wound healing where they attach to exposed surface promoting blood clotting and the 
inflammatory molecules and cytokines are attracted to the region (Figure 1.11 A). 
 
Figure 1.11 A: The consequence of platelet activation during wound healing. Printed from 
Burnouf et al., (2016) with kind permission of Biomaterials. 
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Platelets are small (2 µm in diameter), anuclear cells with a 7 to 10-day lifespan. They 
have many pseudopodia extensions, and the morphology is often described to be similar 
to the natural sea sponge (Marx and Garg, 2005). 
Platelets contain three essential kinds of granules: dense, lysosomes and alpha granules 
(Blair and Flaumenhaft, 2009; Marx and Garg, 2005). The essential function of the 
lysosome is to serve as the storehouses for digestive enzymes (Malhotra et al., 2013; Marx 
and Garg, 2005). While the dense granules play a crucial role in storing and releasing 
adenosine diphosphate (ADP) which is responsible for the activation of other platelets. 
They also secrete calcium ions (Whiteheart, 2011). Therefore, the α-granule storehouse 
is considered to be a key source of growth factors. After degranulation, a considerable 
number of proteins are delivered either into the extracellular matrix or fused with the 
cell membrane. These proteins are collected from a cluster of chemotactic and mitogenic 
growth agents or factors, haemostatic agents, adhesion molecules and different cytokines 
(Blair and Flaumenhaft, 2009). Finally, the secretion of specific and nonspecific growth 
factors can initially control the platelets for tissue repair (Malhotra et al., 2013). The 
growth factors contained in platelets are platelet-derived growth factors (PDGFaa, 
PDGFbb, and PDGFab), transferring growth factors beta (TGFβ1, TGF β2), vascular 
endothelial growth factor (VEGF) and epithelial growth factor (EGF) (Marx and Garg, 
2005) (Figure 1.11 B). As a consequence of platelet activation, the contents of granules 
are released and distributed to enhance wound healing (Burnouf et al., 2016). 
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Figure 1.11 B: The cargo of platelet granules. Three essential granules store an abundance 
of substances, there are lysosomes, dense granules and α-granules. Printed from Burnouf et 
al., (2016) with kind permission of Biomaterials. 
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1.11.1 Human blood serum  
Human blood serum is a complex body fluid that derives from human plasma in which 
blood cells are suspended and circulated around the body. With the removal of clotting 
factors plasma; serum contains various proteins ranging in concentration from 60 to 80 
mg of protein per mL in addition to different small molecules including salts, lipids, amino 
acids, and sugars. The primary protein ingredients of serum include albumin, 
immunoglobulins, transferrin, haptoglobin, and lipoproteins (Burtis et al., 2014). 
Furthermore, these significant components, serum has several additional other proteins 
that comes through the lysis method of the cells and tissues throughout the body. It is 
predicted that up to 10,000 proteins may be commonly found in serum (Adkins et al., 
2002). It is obviously that sera extracted from human and animal are routinely filtered at 
0.22 µm. however, in particular clinical applications, human serum is taken place either 
filtered at 0.2 mm (Behnia et al., 2009) or without filter. 
Human blood products are often applied in the clinical regenerative dentistry due to their 
easy preparation. For example, platelet-rich fibrin (PRF), can be separated by blood 
centrifugation without anticoagulation agents and applied clinically. It has been stated 
that the levels of growth factors are higher with high platelet concentrations (Huang et 
al., 2017; Kitamura et al., 2018), Figure 1.11.1. Although PRF is frequently identified as an 
advanced second-generation of PRP, it is differentiated from other PRP derivatives in 
terms of the removal of anticoagulant substances and coagulation elements (Dohan et al., 
2006). 
Previously, it was thought that PRF does not have a high quantity of growth factors 
(Gassling et al., 2009) however, this was contradicted recently (Masuki et al., 2016). Sera 
extracted from human and animals and used in the laboratory are routinely filtered at 
0.22 µm. however, in particular clinical applications, human serum is either filtered at 0.2 
mm (Behnia et al., 2009) or used without a filter for autologous uses.  
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Figure 1.11.1: mechanism of platelet-rich fibrin formation (Kitamura et al., 2018) 
1.11.2 Human plasma 
Plasma is prepared by centrifugation after mixing of an anticoagulant agent with blood. 
It has numerous growth factors and nutrients which are used for cell proliferation, 
expansion, and can support differentiation into different cell lineages (Mannello and 
Tonti, 2007). Although platelet-poor plasma can be used for the initial growth of colonies-
derived from bone marrow, the addition of platelet lysate is essential to enhance cell 
proliferation (Horn et al., 2010). 
Both plasma and serum are the essential ingredient of blood and have different functions. 
Because they are frequently applied in the medical field, it is important to know what the 
differences between them are (Table 1.11.2) (7). 
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Table 1.11.2: the important differences between the human serum and plasma (7) 
Aspects Serum Plasma 
Definition and Extraction 
Liquid obtained from blood 
after allowing the blood to 
clot and separated from the 
clot 
Intravascular liquid 
obtained by centrifuging 
blood and separating the 




Anti-coagulant agents are 
needed to separate it? 
No  Yes  
Has undergone 
coagulation process? 
Yes  No  
Contains fibrinogen? No  Yes  
Medical applications 
 Serological test 
 Investigation of 
blood groups 
 Test for cholesterol 
and proteins 
 Diagnosis for 
certain blood 





 Serological test 
 Investigation of 
blood groups 
 Test for cholesterol 
and proteins 
Diagnostic for certain 
blood diseases such as 
haemophilia and clotting 
disorder 
 
1.11.3 Human platelet concentrate  
Fractionated blood components have been used in the medical field for several decades. 
Extracted fibrin glue has also been used in intraoperative surgery as a topical haemostatic 
agent (Brennan, 1991). Platelets can be concentrated by three procedures using the 
anticoagulating agent in whole blood for clinical applications which include: 1) the buffy 
coat procedure (commonly used in Europe), 2) the PRP procedure (commonly used in 
Asia and USA), and 3) plateletpheresis methodology to create human platelet lysate 
(HPL) (globally used) (Figure 1.11.3) (Burnouf et al., 2016).
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Figure 1.11.3: the essential methodology for platelet concentrate preparation. Printed from Burnouf et al., (2016) with kind permission of 
Biomaterials. 
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Platelets concentration (PC) is a standard of blood production; it has ten times the 
number platelets than PRP and is approximately independent from donors’ gender and 
age. PC contains the growth factors in the cell-free supernatant which are secreted from 
the platelets after a freeze-thawing step (Krüger et al., 2012). It is clinically used for the 
management of different regenerative pathologies such as wounds and ulcerations 
(Dellera et al., 2014). In in vitro studies, PC was shown to enhance the wound healing 
processes (Backly et al., 2011). A further advantage of PC is that it can be stored frozen 
and can be analysed for growth factor content and other characteristics (Burnouf et al., 
2016). Additionally, an allogenic PC can be based on clinical blood collections as these 
have already established safety and absence of known pathogens (Strunk et al., 2018).  
Platelet-rich plasma (PRP) is a normal blood fluid consisting of a highly significant 
number of platelets and clotting factors. The concentration of platelets has been reported 
to be approximately ten million per micro-litre of plasma in 5 ml, and PRP contains a 3-
5-fold higher concentration of growth factor which is associated with enhancement of 
healing (Foster et al., 2009). It is free of any transmissible diseases and any 
hypersensitivity reaction due to it being derived from the patient’s own blood (Marx and 
Garg, 2005). It is prepared from whole venous blood combined with anticoagulants to 
avoid clotting (Middleton et al., 2012). Two methods of PRP production have been 
described, either a two-step centrifuge method which is the most common application or 
a one-step method (Malhotra et al., 2013). Marx et al., (1998) used PRP in the 
regeneration of mandibular bony defects and consequently reported positive results. 
This report led to more interest and research funding for the application of PRP in oral 
and maxillofacial surgery (Kassolis et al., 2000; Landesberg et al., 2000). 
Some proteins can be used to activate PRP to initiate the clotting mechanism and 
secretion of growth factors. These proteins are bovine thrombin (Fréchette et al., 2005), 
calcium chloride (Nagata et al., 2010), mixed bovine thrombin and calcium chloride (Fufa 
et al., 2008; Marx and Grag, 2005), type I collagen (Fufa et al., 2008), thrombin receptor 
agonist peptide (TRAP)(Landesberg et al., 2005), autologous thrombin (Everts et al., 
2006), freeze-thaw (Baik et al., 2014) and batroxobin activator (Middleton et al., 2012). 
While the methods used for activating growth factors and other bioactive substances 
from HPL can be categorised into four procedures either repeating freeze-thaw 
procedure (Baik et al., 2014; Schallmoser et al., 2007), sonication (Umeno et al., 1989), 
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solvent-detergent treatment (Shih and Burnouf, 2015), and those of proteins used for 
initiating PRP.  
The principal factor important for tissue engineering of bony defects is the combination 
of signalling molecules, cell and matrices (Langer and Vacanti, 2015). PC can provide the 
molecules and cell-supporting matrix signalling through the provision of growth factors, 
and fibrin matrix respectively (Malhotra et al., 2013). 
The clinical applications of PC have increased significantly and it is used in many areas, 
especially in dental surgical procedures such as sinus lifting augmentation (Schaaf et al., 
2008); ridge augmentation or atrophy (Schuckert et al., 2011); third molar socket (Kaul 
et al., 2012); periodontal defect treatment (Kitoh et al., 2007); preservation of alveolar 
ridge (Marx and Garg, 2005) and in dental implants (Polimeni et al., 2010). It has also 
been used in craniofacial surgery for example, in the: reconstruction of the alveolar ridge 
(Luaces-Rey et al., 2010); mandibular reconstruction, split-mouth; double-mask (Hanna 
et al., 2004); maxillary and midface reconstruction (Kuvat et al., 2009). 
1.11.3.1 Mechanisms of PC during regeneration of bony defects 
Bone loss or bone defects can arise as a result of surgery, different ailments or serious 
injuries. Bone can rebuild itself with complex processing (Ingham and Fisher, 2005; Stea 
et al., 2000). 
The principles of PC mechanisms through three phases of bone regeneration include the 
inflammatory cytokines phase with growth factors which are released during 
degranulation of α –granules, and angiogenesis (Zhang et al., 2013; Zimmerman et al., 
2002).  
1. PC in the function of inflammatory cytokines enhances bone regeneration 
Inflammatory mediators play an essential role in the early phase of both intrinsic and 
extrinsic clot formation. There are aggregation and secretion of cytokines and growth 
factors as well as haemostatic factors during bone deficiency healing (Glass et al., 2011; 
J. Zhang et al., 2012). Both histamine and serotonin are secreted from dense granules, 
and the primary function of them raises the capillary permeability which leads to 
accumulation of inflammatory cells on the wound site and stimulation of macrophages 
(McManus and Pinckard, 2000). 
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2. PC in the function of growth factors enhances bone regeneration 
The increase of growth factor concentration and the released bioactive proteins can lead 
to tissue regeneration where there is low potential for healing and regeneration (Zhang 
et al., 2013). 
Growth factors acts on the regulation of genes and control this through the feedback of 
normal wound healing. The relationship between growth factors and stages of 
endochondral healing and how the growth factors interact with main the cell types 










Figure 1.11.3.2: the relationship between growth factors and stages of endochondral 
healing how the growth factors interact with main cell types during bone healing. Printed 
from Malhotra et al., (2013) with kind permission of Archives of Orthopaedic and Trauma 
Surgery. 
 
3. The Influence of PC in angiogenesis factors enhances bone repairing 
A sufficient blood supply is needed for osteogenesis, in the last stage of endochondral 
ossification. The specific matrix metalloproteinase would break the cartilage and bone to 
lead to the new growth of blood vessels. There are two independent approaches to 
angiogenesis: the first one depends on VEGF, and the second depends on angiogenin. The 
renewal of vessel growth and a specific mitogen of endothelial cells are mainly affected 
by VEGF, while large vessels and formation of collateral circulation are mainly affected 
by angiogenin (Zhang et al., 2013). 
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1.12 Scaffolds for craniofacial bone tissue engineering 
A scaffold is structure which acts as a vehicle for growth factors; cells and drugs and also 
may partially imitate the native structure of extracellular matrix. The biomaterial scaffold 
plays a crucial role in reconstructive surgery by allowing an adequate microenvironment 
for regeneration of the required cells (Florencio-Silva et al., 2015; Tevlin et al., 2014). 
Tevlin et al., (2014) and Salgado et al., (2004) suggest that the properties of scaffolds for 
craniofacial bone tissue engineering must consider the: 
i. Biocompatibility: the scaffold should be able to integrate with the neighbouring 
tissue without unfavourable immunological reaction. 
ii. Bioresorbability or Biodegradability: the scaffold should be able to degrade with 
time and in a controlled manner. 
iii. Porosity: the scaffold should be interconnective to facilitate essential nutrient 
diffusion, cell attachment and growth, oxygen diffusion, and removal of metabolic 
waste to ensure cell survival. 
iv. Mechanical strength: the scaffold should have an adequate mechanical strength to 
overcome the implantation method and the mechanical forces which are generally 
applied to the scaffold-tissue construct after implantation, and also to preserve 
space for cell growth. 
v.  Pore size: the diameter of the pores plays a crucial role in cell penetration, 
production of bone matrix, and angiogenesis (blood vessel formation). 
vi. Surface properties: cell attachment and proliferation are influenced by the 
properties of the scaffold surface such as hydrophobicity and ability to bind to 
proteins. 
vii. Osteoinductivity: the scaffold should be able to encourage osteogenesis and bone 
matrix deposition. 
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1.12.1 Types of scaffolds 
Biomaterials using in craniofacial bone tissue engineering scaffolds can be classified into 
several basic material types (Tevlin et al., 2014): 
i. Polymers are commonly used for creating scaffolds because of controllable 
degradation, easy manipulation, and biocompatibility. The degradation of polymer 
scaffolds is usually achieved by hydrolysis, permitting the supporting tissue to 
recover functionality slowly. Biodegradable polymers can further be classified into 
two groups: firstly, natural materials such as polysaccharides (e.g., chitosan) and 
proteins (e.g., collagen) secondly, synthetic polymers such as poly (lactic acid) and 
polycaprolactone. Biodegradable polymers have some advantages especially in 
paediatric surgery, as they should be replaced by the patient’s bone to allow growth 
and perform the therapy; they may also have clinical advantages during radiography 
as computed tomography scans can see the resorbed bone formation, Table 1.12.1, 
shows specific widely used scaffold materials approved by the US Food and Drug 
Administration (FDA) for medical use, for example in craniofacial regeneration. 
Table 1.12.1: Characteristic features of synthetic and natural polymers utilised in bone 
tissue engineering  
Materials Origin Characteristics 
Collagen Natural Minimum immune activation. 
Cell adhesion is facilitated via cell adhesion 
molecules similarly to in the physiological 
environment (because collagen is the major ECM 
protein of human tissue).  
Assist with cell morphology, migration, 
modification, and differentiation. 
Poor mechanical properties (Kleinman et al., 
1981). 
Chitosan Natural Support to haemostatic processes. 
Increase osteoconductivity and wound healing 
(Pogorielov et al., 2017). 
Poly(hydroxybutyrate) Natural A natural resource. 
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Restricted usefulness because of brittleness 
(Chen and Wang, 2002). 
Poly(Ɛ-caprolactone) Synthetic The aliphatic family of polyester. 
Approved by U.S. FDA. 
Degradation by hydrolysis (Hutmacher et al., 
2001). 
Biocompatibility (Langer and Tirrell, 2004). 
Controllable degradation. 
No toxicity. 
Low cost (Yoshimoto et al., 2003). 
Adequate mechanical attributes (Delaine-smith 
et al., 2014). 
Polylactic acid (PLA) Synthetic Inadequate mechanical attributes. 
Controllable degradation. 
Degradation by hydrolysis method. 
Inflammation might be created in vivo (Cheung 
et al., 2007). 
Polyurethane (PU) Synthetic Biocompatibility. 
Degradable and nondegradable substances. 
A broad range of adjustable mechanical, 
biological, and degradable attributes. 
An essential problem is potential toxicity 
(Gunatillake et al., 2003). 
Hydrogel Synthetic Absorption of a considerable amount of water. 
Act as matrices for tissue engineering. 
Mimic of extracellular matrix topography. 
Transferring of bioactive factors (Lee and Shin, 
2007). 
 
ii. Metals are solid and rigid and robust; commonly used metals for clinical applications 
include gold, cobalt-chromium, stainless steel, and titanium. Titanium is especially 
important for craniofacial applications (Yusop et al., 2012). 
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iii. Bioactive glass and ceramic (Hoppe et al., 2011). 
iv. Composite scaffolds which are composed of two or more materials such as a scaffold 
constructed from both polymer and ceramic (Rezwan et al., 2006). 
There are drawbacks of these materials for example, metals are non-degradable, 
ceramics are very brittle and difficult to shape for thin defects, and composites are 
complicated to produce in a reproducible way. 
1.12.1.1 Poly (ɛ-caprolactone)  
A poly (Ɛ-caprolactone) (PCL) is produced from aliphatic polyester (Figure 1.12.1.1), and 
is considered to be a biocompatible and biodegradable material. PCL is broken down by 
hydrolysis into biocompatible products, many studies have employed PCL clinically and 
it is officially approved by the U.S. Federal Drug Administration (FDA) for human 
applications such as Monocryl® sutures (Hutmacher et al., 2001; Reed et al., 2009). PCL 
is suitable for bone regeneration as a tissue engineering scaffold because it has a slow 
degradation rate. Therefore, it has been implicated as an adequate material for replacing 
bone in load-bearing areas to support bone while it undergoes mature development and 
forms a functional tissue. Hutmacher et al., (2001) indicated that a PCL scaffold could 
preserve its mechanical attributes for 5-6 months and be completely metabolised in more 
than two years. Furthermore, several researchers have employed PCL as a material for in 
vitro research, for example, to support human osteoblast and fibroblast-like cells for 
attachment, proliferation, extracellular matrix formation, and tissue development 
(Delaine-Smith et al., 2014; Tuan and Hutmacher, 2005; Williams et al., 2005). Moreover, 
PCL is inexpensive and easy to produce large quantities. 
 
Figure 1.12.1.1: Chemical formula of polycaprolactone. 
 




Electrospinning is a versatile system for scaffold preparation in tissue engineering. It 
usually utilises an electric force to create polymer fibres of different diameters from 
micrometres down to nanometres; many types of polymer can be used in this technique. 
The advantages of electrospinning over other fabrication techniques are that it is 
controllable, specific orientations can be achieved, a high surface area and high porosity 
is created and it is an inexpensive approach. However, this technique has limitations such 
as slow rate of production, and difficulties of scale-up (Delaine-Smith et al., 2014; Rim et 
al., 2013). 
1.13.2 Spinning mechanism and theory 
The first discovery of the electrospinning was by Rayleigh in 1897, while the first 
description of the technique in details was by Zeleny in 1914 (Zeleny, 1914). The main 
idea of his work is created an electrostatic repulsion via applied a considerable voltage 
on a polymer solution. The repulsion effect is to frustrate the value of surface tension of 
the polymer solution. Consequently, it causes a small drop to flare up and becomes stretch 
to create a Taylor cone. Polymer solution jet is released when the solution charge resists 
the tension of the surface (Taylor, 1964). Polymer fluid emerged and polymerised on the 
collector. A continuous flow of liquid has two stages; firstly, it is a stable stage (alignment 
form), polymer steam releases from the tip of the needle as an extending uniformly in one 
direction line to form a woven mat of fibre. Secondly, it is unstable stage (non-alignment 
form), in which the polymer steam presents a non-aligned whipping orientation to 
fabricate a non-woven fibre mat of thin fibres onto a collector (Reneker et al., 2000). 
1.13.3 Electrospinning in tissue engineering 
The electrospun scaffold is employed for tissue engineering as an extracellular matrix to 
support cell growth and differentiation. Both synthetic and natural polymers have been 
investigated for use in tissue engineering applications (Burger et al., 2006). 
Electrospinning can be adjusted to produce different fibre sizes which are appropriate 
for a particular tissue and has been the basis for studies on many different tissues such 
as bone (Ma et al., 2005), skin (Blackwood et al., 2008), tendon (Yin et al., 2010), heart 
(Zong et al., 2005), and nerve (Daud et al., 2012). Electrospun scaffolds can also be used 
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as delivery vehicles for bioactive components such as proteins, drugs, and DNA if using 
degradable polymers (Luu et al., 2003). The amount of agent released depends on the 
technique of consolidation between the bioactive component and the scaffold (Liu et al., 
2010). 
1.13.4 Electrospinning rig set up 
 Four main components comprise electrospinning equipment (Katta et al., 2004):  
1) An electricity source with a controllable high voltage which charges the polymer 
solution. 
2) A syringe pump which determines the amount and rate of polymer solution dispensing. 
3) A syringe to hold the polymer solution and needle to charge the polymer solution. 
4) An earthed collector for fibre collection. 
Different kinds of collectors are designed to fit the objective such as a rotating drum or 
flat plate. An unevenly distributed mat may be created when using a flat plate. Therefore, 
a rotating drum collector was applied in our experiments (Table 1.13.4) (Figure. 1.13.4). 
 
Figure. 1.13.4: Schematic of electrospinning machine (8) illustrating the components 
described in section 1.13.4. 
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Table 1.13.4: shows the effect of parameters on the fibre structure of an electrospun 
scaffold. 





Breaking in the jet and bead formation 
No jet creation because of the dryness of droplets 





Wet beaded structure and fibres 
Bead morphology 
The flow rate of polymer 
⮚ Low flow rate 
⮚ High flow rate 
 
Reduced fibre diameter 
High fibre diameter and bead formation  
Voltage supply 
⮚ Low voltage 
⮚ High voltage  
 
High fibre diameter 
Low fibre diameter and beading morphology (Zuo 
et al., 2005). 
Humidity  
⮚ High humidity (>60%) 
 
Wet fibres and pore formation on the fibre surface 
called “breath figure”. The breath figure is 
produced from the air condensing on the fibre 
surface because of the jet cooling and evaporation 
(Casper et al., 2004). 
Temperature 
⮚ High temperature 
 
Reduced fibre diameter 
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1.14 Aims and objectives of the research project 
Hypothesis  
The primary hypothesis of this project is that xeno-free media will have the ability to 
support osteogenic differentiation of human mesenchymal stem cells and to support 
creation of a bone-like matrix suitable for craniofacial tissue engineering.  The long term 
goal is to create a co-culture construct of a human bone-like tissue layer and a human 
soft/fibrous-tissue layer. After clinical development such a strategy could be applied in 
the future to repair defects in the roof of the mouth for patients afflicted with cleft palate. 
Objectives 
The objectives of this PhD project were to characterise and evolve a novel methodology, 
which would be convenient for eventual clinical application for repair of bone defects in 
the oral cavity. Furthermore, to understand how commercial animal-free media may be 
used to engineer bone tissue for developing cleft palate repair in 2D and 3D. A tri-layer 
electrospun PCL scaffold was used to separate three different cell types; human normal 
oral fibroblast cells (NOFs), immortalised human normal oral keratinocytes (FNB6), and 
primary human mesenchymal stem cells derived from bone marrow (hBMSCs). This type 
of multi-layered tissue construct could permit normal development of facial bone and 
reduced the operational steps required to reconstruct the cleft palate.   
The tasks to be undertaken to carry out the projects aims are to: 
1. Evaluate animal-free component culture media on monolayer cultured primary 
human bone marrow mesenchymal stem cell and human jaw periosteal cells (HJPs). 
1.1 Assess whether there are differences in the ability of xeno-free media to support 
osteogenesis in relation to the typically used osteogenic supplements: ascorbic acid-
2-phosphate (AA) and β-glycerophosphate (βGP) using the indicators of osteogenic 
differentiation- Alkaline Phosphatase activity and calcium and collagen deposition. 
1.2 Asses the effects of xeno-free media on proliferation of hBMSCs using flow cytometry. 
2. Elucidate the ability of xeno-free media to support osteogenic differentiation of 
human cells on 3D poly (ɛ-caprolactone) electrospun scaffolds. 
58 | P a g e  
 
2.1 Evaluate cell metabolic activity on selected electrospun scaffolds (PCL) for hBMSCs 
and HJPs in a variety of xeno-free media. 
2.2 To compare osteogenic differentiation of hBMSCs and HJPs cultured in different xeno-
free basal culture media on PCL scaffolds. 
2.3 Assess whether there is variability between different donor’s cells when grown in 
xeno-free media. 
2.4 Elucidate using VEGF secretion, as a marker of angiogenic potential whether the 
different culture conditions under investigation would influence the ability of cells to 
initiate angiogenesis. 
 
3. Further, develop a tri-layer electrospun PCL scaffold to separate cell types on either 
side of a nano-fibre membrane. 
3.1 Optimise growth conditions using xeno-free media for human normal oral fibroblast 
cells (hNOFs) and immortalised human normal oral keratinocytes (FNB6).  
3.2 Visualise the osteogenic differentiation and oral mucosa development in the 3D tri-
layered PCL scaffolds. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 Materials 
1. 4‟-6-Diamidino-2-phenylindole(DAPI) (Sigma-Aldrich, Dorset, UK). 
2. Alizarin red (stain which binds to calcium-containing) (Sigma-Aldrich, Dorset, UK). 
3. Alkaline Phosphatase Yellow (pNPP) Liquid Substrate System ELISA (Sigma-Aldrich, 
Dorset, UK). 
4. CellCrown™ (made from polyethene terephthalate: PET) (Scaffdex®, Tampere, 
Finland). 
5. Click-iT™ EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit (Invitrogen; 
ThermoFisher, UK). 
6. Data analysis software: GraphPad Prism 7. 
7. Dichloromethane (Sigma-Aldrich, Dorset, UK) for solubility polymers for 
electrospinning. 
8. Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, Dorset, UK).  
9. Electrospinning apparatus contains a syringe pump (Genie™ Plus, Kent Science, USA), 
a high voltage electric source (Genvolt, UK), a rotating motor (Heidolph Instrument, 
Germany). 
10. Flow Cytometry, FACS Calibur, BD Biosciences. 
11. Formaldehyde (37% (v/v), grade 1) (Sigma-Aldrich, Dorset, UK). 
12. Hexamethyldisilazane (HMDS) (Sigma-Aldrich, Dorset, UK). 
13. Human bone marrow mononuclear cells (Lonza®, Bruxelles, Belgium). 
14. Human mesenchymal-XF expansion medium (XF2) (Millipore, UK). 
15. Human normal oral fibroblasts (NOF) were isolated from connective tissue from 
waste mucosa collected during routine dental surgeries at the Charles Clifford Dental 
Hospital, Sheffield, with written, informed consent with ethical approval granted from 
Sheffield Research Ethical Committee. 
16. Image processing software: Flowjo-win64-10.2  
17. Image processing software: image analysis and processing in Java-based (ImageJ) 
(developed by National Institutes of Health, USA). 
18. Immortalised human oral keratinocytes (FNB6), kindly donated by Professor Keith 
Hunter, University of Sheffield. 
19. Infinite F200 microplate fluorescence reader (PRO, TECAN, Labtech, UK).  
20. Insulin-transferrin-selenium (ITS -G) (ThermoFisher, UK). 
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21. Laboratory digital balance (Mettler Toledo, UK). 
22. Medical grade steel ring (2cm diameter, 1.2cm inner hole diameter) (produced by 
NHS medical workshop). 
23. Minimum Essential Medium Alpha Eagle (α-MEM) (Lonza®, UK).  
24. MSC NutriStem® XF medium with supplement mix solution (biological Industries BI, 
USA). 
25. PBS without calcium (Ca2+) and magnesium (Mg2+) (Sigma-Aldrich, Dorset UK). 
26. PeproGrow-1 serum-free cell culture supplement kit (Peprotech, London, UK).  
27. Phosphate buffered saline (PBS) (Dulbecco A) (OXOID Limited, Hamshire, England).  
28. Picric acid solution (Sigma-Aldrich, Dorset UK ). 
29. Sirius red stain (Sigma-Aldrich, Dorset UK). 
30. Poly(-caprolactone) (PCL), 80kDa (Sigma-Aldrich-Aldrich, Dorset, UK) to 
manufacture the electrospun scaffolds.  
31. Porcine gelatine (Sigma-Aldrich, Dorset, UK).  
32. Primary human jaw periosteal (HJPs) cells were derived from periosteum tissue 
which was collected during routine wisdom tooth extraction at the Charles Clifford 
Dental Hospital, Sheffield. 
33. Quantikine® ELISA Human VEGF Immunoassay Kit (RandD, USA). 
34. Quant-iT™ PicoGreen® dsDNA Reagent Assay Kits (Invitrogen™, Paisley, UK). 
35. Resazurin reduction assay (Sigma-Aldrich, Dorset, UK). 
36. Scanning electron microscope (SEM, Philips XL-20 SEM, Netherlands). 
37. Stem X VivoTM xeno-free human MSC expansion medium (RandD, USA). 
38. StemulateTM pooled human platelet lysate (HPL) (COOK, USA). 
39. Trypan blue (Sigma-Aldrich, Dorset, UK). 
40. Trypsin-EDTA (Sigma-Aldrich, Dorset, UK).  
41. Xylenol Orange tetrasodium salt (Sigma-Aldrich, Dorset, UK). 
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2.2  Methods 
2.2.1 Media preparation 
A range of media and supplements were tested during this thesis they will be referred to 
using the short-name or acronym as described below each was used with and without a 
range of supplements typically used in osteogenic media to identify interaction between 
the media type and the supplements: 
BCM: Basal media: This refers to the selected media under investigation supplemented 
with FBS where required (see table 2) and 1% (v/v) antibiotics (either Penicillin - 100 
units, Streptomycin – 100 µg/mL, L-Glutamine – 2 mM, or Penicillin and Streptomycin). 
10% (v/v) FBS: alpha MEM supplemented with 10% FBS. 
XF1: Stem X VivoTM xeno-free human MSC expansion medium. 
XF2: Human mesenchymal-XF expansion medium has 2% (v/v) human serum 
(the formulation for this product is confidential and therefore, can't be shared 
with our customers). 
5% (v/v) HPL: StemulateTM pooled human platelet lysate: alpha MEM 
supplemented with 5% HPL. 
2% (v/v) FBS+ITS: Insulin-transferrin-selenium: alpha MEM supplemented with 
2% FBS and ITS. 
MSC-NutriStem: MSC NutriStem® XF medium with supplement mix solution 
SR1: PeproGrow-1 serum-free cell culture supplement: PeproGrow-1 serum-free 
cell culture supplement kit, it contains two essential components: 1. Serum 
replacement solution containing a non-animal derived and chemically-defined 
salt. 2. Lipid mixture solution contains non-animal derived fatty acid and lipid, 
designed to improve cell growth in serum-free media. 
Green’s Medium: consists of Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco, Paisley, UK) and Ham’s F12 medium (Biosera, East Sussex, UK,) in a 3:1 
(v/v) ratio supplemented with 10% (v/v) FCS (Biosera), 0.1 mM cholera toxin, 10 
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ng/ml EGF, 0.4 mg/ml hydrocortisone, 0.18mM adenine, 5mg/ml insulin, 5mg/ml 
transferrin, 2mM glutamine, 0.2 nM triiodothyronine, 0.625mg/ml amphotericin 
B, 100 IU/ml penicillin, and 100mg/ml streptomycin. (All remaining products 
were obtained from Sigma-Aldrich Aldrich, Dorset, UK unless otherwise stated). 
NOCM: Non-osteogenic culture medium: basal media supplemented with 50µM AA-2-Ph 
and 10mM β-GP (Sigma-Aldrich, Dorset, UK) this contains supplements required for 
matrix mineralisation but without the osteogenic factor Dexamethasone (Dex), know to 
stimulate differentiation. 
OCM: Osteogenic culture medium: Dex containing osteogenic media; basal media 
supplemented with 50µM AA-2-Ph and 10mM β-GP, and either 10nM or 100nM Dex 
(Sigma-Aldrich, Dorset, UK), respectively. 
BCM+Dex: Supplemented with Dex medium; basal media supplemented with either 
10nM or 100nM of Dex. 
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Table 2.2.1: Media compositions investigated 
Media Compositions 
Basal Culture Medium (BCM) 
BCM supplemented with Dex 10 nM 
BCM supplemented with Dex 100 nM 
BCM supplemented with AA 50 µM and BGP 10 mM 
BCM supplemented with Dex 10 nM, AA 50 µM and BGP 
10 mM 
BCM supplemented with Dex 100 nM, AA 50 µM and 
BGP 10 mM 
 
 
General cell culture conditions 
Cell maintain ace and passaging 
Cells were routinely maintained in T-75 flasks in their respective culture media at 37°C 
in 5% CO2 in a humidified atmosphere. The medium was changed every 2-3 days. Cells 
were passaged when they reached 80% confluence.  
For passaging the medium was removed, and the cell monolayer washed twice with PBS. 
Three ml of trypsin-EDTA solution was added and incubated for five minutes to detach 
the cells enzymatically from the tissue culture plate. Cell detachment was monitored 
using a light microscope. Once all cells had detached, trypsin was neutralised by the 
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adding of fresh culture medium. The cell suspension was centrifuged at 112 g for 5 
minutes. The supernatant was aspirated and the cell pellet resuspended in a known 
volume of fresh media. To determine the cell number and the percentage of viable cells a 
trypan blue exclusion assay was performed. Twenty µl of trypan blue cell solution was 
mixed with twenty µl of the cell suspension, ten µl was then transferred to a 
hemocytometer and the number of cells counted under a light microscope. 1 X 105 cells 
were transferred to new culture flask or seeded into tissue culture treated plates for the 
experiments described below. 
Cryopreservation of cells 
Cells were removed from the tissue culture flask, centrifuged for 5 min at 112 g and 
suspended in FBS or XF2 culture medium containing 10% (v/v) final concentration DMSO 
as a cryo-protectant. 1 X 106 cells were transferred into a cryovial and stored at -80oC for 
24 hours before moving to a liquid nitrogen dewar (-196oC) for long-term storage. 
2.2.2 Isolation of human jaw periosteal cells (HJPs) 
The human jaw periosteum consists of two layers; the outer layer is called the “fibrous” 
layer which contains fibroblasts, collagen, nerves, and a microvascular network. This 
layer provides mechanical stability to the periosteum. The inner layer “cambium” 
comprises of high cellular content and presents with cells that encourage bone formation 
and repair (Allen et al., 2004; Lin et al., 2014). Periosteal tissues were collected by Mr. 
Robert Bolt during routine wisdom tooth extraction at the Charles Clifford Dental 
Hospital, Sheffield, with written, informed consent with ethical approval (number 
09/H1308/66) granted from Sheffield Research Ethical Committee. The periosteum 
tissue was processed by Dr Helen Colley and supplied for the project after extraction from 
tissue, briefly; tissues were stored in DMEM basal culture medium containing 1% (v/v) 
of 100 mg/ml P/S at 4oC for 4 hours before the cell isolation. Collagenase type II (0.25% 
(v/v) in serum-free medium) was added to the tissue and incubated at 37oC for 3 hours 
(Samee et al., 2008) before resuspending in basal culture medium and centrifuging at 447 
g for 5 minutes, the supernatant was removed and the cell pellet resuspended in basal 
culture medium and transferred to a T-25 culture flask. A 50% (v/v) medium change was 
performed after 72 hours and a complete medium change after seven days. These HJP 
cells were supplied for this project and used between passages 3 and 10.  
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2.2.3 Human mesenchymal stem cells derived from bone marrow (hBMSCs) 
Primary bone marrow mononuclear cell samples obtained from six different donors were 
purchased commercially (Lonza®) (Table 2.2.3). The purchased cells contain both 
haematopoietic cells and hMSCs. The isolation of hMSCs is dependent upon their ability 
to adhere to tissue culture plastic (Chao et al., 2012; Dominici et al., 2006). The cell 
solutions were transferred to 5 ml of pre-warmed basal culture media (10% (v/v) FBS, 
XF1 and XF2) to observe cell proliferation. 2 ml of fresh basal culture media was 
supplemented with samples every 2-3 days for seven days. Floating cells and non-
adherent cells were removed and fresh culture media was added. The cells were cultured 
until 80% confluence was reached and labelled passage 0. The cells were serially sub-
cultured at a density of 5 X 105 per T-75 flasks until passage four for experiments (Lee et 
al., 2013). Cells from donors numbered 1 to 4 were cultured in 2D monolayer 
experiments. Cells from donors numbered 4, 5, and 7 were cultured in 3D PCL scaffolds. 
Table 2.2.3: Information about human bone marrow mesenchymal stem cells acquired from six 
different donors. (Donor numbered 6 was used in the laboratory but not for any experiments 









1 081291B 05-Aug-2008 23 Male 
2 081286A 05-Aug-2008 30 Male 
3 081294A 06-Aug-2008 23 Male 
4 080007B 02-Jan-2008 22 Female 
5 0000497388 04-Aug-2015 32 Male 
7 080030A 07-Jan-2008 18 Male 
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2.2.4 A measure of cell metabolism using the resazurin reduction assay 
The resazurin reduction assay has been applied to investigate the cytotoxicity and 
metabolic activity of many different cells. The can be used to analyse continuous cell 
growth as it is a non-toxic stain. The blue non-fluorescent colour of the resazurin solution 
reduces to resorufin, a pink colour that is also fluorescent (Figure 2.2.4). The mechanism 
of reduction is currently unknown, but it is believed to be due to the intercellular activity 
of mitochondrial enzymes. The resazurin reduction product can be measured either by 
measuring absorbance or fluorescence in a spectrometer. However, the measurement of 
fluorescence is more sensitive than measuring the absorbance (O'Brien et al., 2000). 
A 1 mM stock solution of resazurin reduction salt dissolved in distal water was prepared 
and diluted to a working solution of 0.1 mM in α-MEM culture medium (MW=251.17 
g/mol). Media was removed from the cells (either in 2D monolayer or on 3D electrospun 
PCL scaffolds), and 2 ml working solution was added. Working solution was also added 
to an empty cell culture well to provide a blank, background reading. The samples were 
wrapped in aluminium foil and incubated for 4 hours at 37°C. 200 μl of production of pink 
resorufin was transferred to a 96-well plate (triplicate from each well) and assessed using 
a spectrofluorometer was setting 540 nm and 590 nm of an excitation wavelength, and 
an emission wavelength respectively. 
 
Figure 2.2.4: A chemical structure of blue non-fluorescent resazurin and pink resorufin 
product. Printed from O'Brien et al., (2000) with kind permission of Wiley. 
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2.2.5 DNA quantification as a measure of cell number using PicoGreen® 
The fluorescent dye (PicoGreen®) was used to detect double-stranded DNA (dsDNA) for 
DNA quantification. The dye exclusively binds to dsDNA, and the fluorescence indicates 
the amount of dsDNA. The medium was removed from the cells and washed twice with 
PBS. The cell digestion buffer was added to the monolayer (200 µl) or to submerge the 
scaffold (500 µl) to extract cellular DNA. The cells were incubated at 37°C for 30 minutes 
before the lysates were transferred to microcentrifuge tubes. For 2D monolayer, the well 
was scraped using a pipette tip before transfer. For 3D culture, the whole scaffold was 
transferred with the lysate, vortexed for 15 seconds and refrigerated overnight, before 
storing at - 80°C. The lysate samples were thawed (-80C ten minutes, 37°C 15 minutes) 
thrice and centrifuged at 12298 g for 5 minutes immediately before analysis. The 
PicoGreen® working solution was made by mixing the PicoGreen® reagent (1x) with 
dilution assay buffer (200x) in a 10 ml tube then protected from the light. 90 μl of the 
PicoGreen® working solution and 10 μl of lysate were transferred into black 96-well 
plates and using the automated spectrofluorometer mixed for 10 seconds before being, 
incubated at room temperature for 10 minutes to allow the DNA to fully conjugate. The 
level of fluorescence in the samples was measured using a spectrofluorometer with an 
excitation of 480 nm; and an emission of 520 nm (Oliveira et al., 2006). The intensity of 
emission was measured from known DNA concentrations, which were used to create a 
standard curve (n=6) and fluorescence emission intensities extrapolated to the 
approximate cell number of DNA (ng/ml): 
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For 2D: DNA (ng/ml) = (Fluorescence emission – 279.8)/203.6 
For 3D PCL scaffold DNA (ng/ml) = (Fluorescence emission + 215.1)/223.2 
















































(B)-For 3D PCL scaffolds
 
Figure. 2.2.5: Linear quantitation of DNA using PicoGreen® reagent, from 
0 to 80 ng of DNA/µL with linear regression analysis for (A) 2D monolayer 
(0 to 80 ng/µl DNA) and (B) 3D electrospun PCL scaffolds (0 to 60 ng/µl DNA). 
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2.2.6 Assessment of osteogenesis 
2.2.6.1 Alkaline phosphatase activity  
Alkaline phosphatase (ALP) is an enzyme present during bone mineralisation; its activity 
is frequently employed as a marker for initial detection of osteogenic differentiation. ALP 
hydrolyses the inorganic pyrophosphate that causes the inhibition of mineralisation 
through inhibition of hydroxyapatite formation, and supplies inorganic phosphate to 
encourage mineralization. (Douglas et al., 2012; Orimo, 2010). The activity of ALP in 
hBMSCs was determined for monolayer cell culture and 3D electrospun PCL scaffolds 
between days 10 and 14. 
Cells were washed three times with PBS. 500μl of cell digestion buffer was added; 10% 
(v/v) of cell assay buffer (1.5M Tris-HCl, 1mM ZnCL2, 1mM MgCL2 in deionised water, 
diH2O) was diluted in diH2O, and subsequently 1% (v/v) of Triton X-100 was mixed with 
assay buffer and left at room temperature for 30 minutes to produce the cell digestion 
buffer. The cells cultured on tissue culture plates were covered with a known volume of 
cell digestion buffer and incubated for 30 minutes, after this time they were scraped and 
the cell lysate transferred into a microcentrifuge tube, vortexed briefly and left overnight 
at 4°C. The cells were seeded onto electrospun PCL scaffolds were dipped into cell 
digestion buffer, transferred into a micro-centrifuge tube; vortexed briefly, and left 
overnight at 4°C. If not immediately used the samples were then stored at -80°C for longer 
term storage. For analysis all samples were exposed to repeated freeze-thaw cycle where 
lysates were thawed at 37°C for 15 minutes, then incubated at -80°C for 10 minutes and 
this was repeated three times before samples were vortexed for 15 seconds and 
centrifuged at 12298 g for 5 minutes. 180 µl of para-nitrophenylphosphate (pNPP) 
phosphatase substrate was prepared by diluting the buffer and dissolving the tablet in 
diH2O (1 tablet: 1 ml buffer: 4 ml diH2O) the assay buffer was mixed with 20 µL of lysate. 
It was transferred in triplicate to a transparent 96-well plate and incubated at room 
temperature until a colour change from colourless to yellow was observed or 30 minutes 
had passed. Absorbance was calculated spectrophotometrically with an emission 
wavelength of 405 nm every minute for 30 minutes. ALP activity was expressed as nmol 
of para-nitrophenol per minute (nmol pNP/min) where one absorbance value equals 
19.75 nmol product. The ALP activity was normalised by dividing nmol pNP/min by the 
amount of DNA from the same well of cells. 
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2.2.6.2 Alizarin red staining for calcium deposition 
Alizarin red staining is commonly used to evaluate calcium deposition in vitro. Alizarin 
red stain binds to calcium-containing mineral which can be visualised as an orange-red 
colour under a light microscope. The quantity of stain can be evaluated by eluting the red 
dye with 5% (v/v) perchloric acid and reading the optical density of the resulting solution 
spectrophotometrically, as previously described (Hild et al., 2011). 
Both sample types, 2D monolayer and 3D electrospun PCL scaffolds were fixed in 10% 
(v/v) formalin for 20 minutes at room temperature and washed twice with PBS. 1 ml of 
1% (w/v) alizarin red stain (see below) was added to each well and left for 30 minutes, 
after which time the alizarin red stain solution was removed, the sample washed with 
deionised water (diH2O) under gentle orbital shaking, until the water was clear. 1 ml of 
5% (v/v) perchloric acid was added on the fixed samples for 15 minutes to elute the dye 
with gentle orbital shaking. 150 µL of the eluate was read in triplicate in a transparent 96 
well plate at an absorbance of 405 nm. 
The absorbance of alizarin red was converted to a concentration of alizarin red stain 
(µg/ml) using a standard curve. A new standard curve was created for each experiment. 
A stock of ARS solution was prepared by dissolving in diH2O at 1% (w/v). Different 
concentrations of ARS were produced from 1000 µg/mL to 0 µg/mL. Then, 0 µg/mL 
(blank) value was subtracted from all values of the standard curve. 150 µL of different 
concentrations of standard solution was transferred to a clear 96-well plate in triplicate. 
The level of absorbance in the samples was measured using a spectrofluorometer at 405 
nm. A plot of absorbance at 405 nm against concentartion of alizarin red indicated a 
straight line relationship with R2 value ≥ 0.975 (Figure 2.2.6.2). 
Alizarin red concentration (µg/ml) = (Absorbance – 0.03046)/0.002892 
  
































Figure 2.2.6.2: The linear concentration of alizarin red staining, from 0 to 1000 µg of 
ARS/mL with linear regression analysis. n=3 
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2.2.6.3 Analysis of cell-deposited collagen using sirius red staining 
Sirius red staining is frequently employed to stain collagen and quantitatively measure 
the amount of collagen deposited in vitro. This stain is an anionic dye and can bind to a 
cation (the guanidine group of arginine) on the collagen molecules. This is a simple 
method for explicitly labelling of collagen type I and III (Tullberg-reinert and Jundt, 
1999). 
After the sample was assayed for calcium using alizarin red staining, they were washed 
thrice with diH2O.  The sirius red solution was prepared by dissolving 1 mg/ml of sirius 
red powder in saturated picric acid. 1 ml of the working solution was added to each well 
for 18 hours with orbital shaking at 100 rpm. After incubation, the solution was removed 
and washed with diH2O until the water was clear. 1ml of 0.2 M sodium hydroxide (NaOH) 
and methanol in a ratio 1:1 NaOH: MeOH (v/v) was added for 20 minutes, with orbital 
shaking at 100 rpm, to elute the stain. 150 µL of the destain solution was read using a 
spectrometer in triplicate in a transparent 96 well plate at an absorbance of 405 nm. 
The absorbance of sirius red was converted to a sirius red stain concentration (µg/ml) 
using a standard curve. As described for alizarin red. The intensity of absorption from 
known sirius red concentrations was used to create a standard curve of absorbance at 
405 nm against concentration of SRS this gave a straight line relationship with an R2 value 
≥ 0.975 (Figure 2.2.6.3). 
Sirius red concentration (µg/ml) = (Absorbance – 0.0546)/0.02596 
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Figure 2.2.6.3: The linear concentration of sirius red staining, from 0 to 100 µg of SRS/mL 
with linear regression analysis. n=3  
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2.2.6.4 Analysis of calcium deposition using xylenol orange staining  
Xylenol orange binds to calcium ions and is considered to be a non-toxic fluorochrome 
label (van Gaalen et al., 2010; Wang et al., 2006). The staining method is a widely accepted 
technique for labelling sequential bone formation in vivo by the intraperitoneal 
parenteral method at different time points (van Gaalen et al., 2010) and in vitro to identify 
mineralised osteoblastic cells matrix (Kuhn et al., 2010). Merits of this dye include; 
continuing observing of osteogenic formation without the need for sacrificing the 
specimens, it is an easy procedure and is high-throughput. 20 mM of stock xylenol orange 
solution was dissolved in diH2O and saved at 4oC. The stock solution of xylenol orange 
was diluted with the basal culture medium in ratio 1:1000 to produce a final working 
solution had the concentration of 20 µM with using within 12 hours before imaging (Kuhn 
et al., 2010). The xylenol orange solution was eliminated and washed with PBS two times 
and supplanted with new medium without β-GP to eliminate the fluorescent background 
from unbound stain. xylenol orange dyeing Images were visualised using a confocal 
microscope at an excitation wavelength of 543nM. Non-cell control scaffolds were dyed 
to determine whether there was any background xylenol orange staining. 
2.2.7 Cell proliferation measured using EdU by flow cytometry 
EdU is a nucleoside analogue to thymidine and incorporates into DNA during the active 
period of DNA synthesis. Therefore, it is an accurate approach for measuring cell 
proliferation. 
EdU levels were measured using a Click-iTTM EdU Flow Cytometry Assay Kit as per the 
manufacturer’s instructions. Briefly, 2 x 105 of hMSC were seeded in 6 well plates, after 
four days EdU (10 µM) was added to the culture media. After one hour, the cells were 
harvested using trypsin and transferred into a microcentrifuge tube, washed with PBS 
containing 1% (v/v) bovine serum albumin (BSA) and 100 µL of Click-iTTM fixative 
added for 15 minutes at room temperature in the dark. After this time, the cells with 
washed with PBS containing 1% (v/v) BSA, and resuspended in 100 µL of 1X Click-iTTM 
saponin-based permeability and incubated for 15 minutes at room temperature in the 
dark, followed by the addition of 0.5 mL of Click-iTTM with the reaction cocktail and 
incubated for a further 30 minutes at room temperature. After an additional three 
washes, EdU levels were measured by detection of Alexa FlourTM 488 picolyl azid using 
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a FACS Calibur flow cytometer using a 488 nm excitation wavelength and measuring 
emission at (530/30 nm). 
2.2.8 Electrospinning rig set up and fabrication of PCL scaffolds 
Electrospun Polycaprolactone (PCL) scaffolds were produced from a 10% (w/w) 
polymer concentration. 6g of polymer pellet, which is a semi-crystalline hydrophobic 
biodegradable polyester, were dissolved in with 54 g of DCM (Dichloromethane= 
1.33g/cm3) to create a 10% (w/w) solution. For tri-layer scaffolds PCL was dissolved in 
a mixture of DCM and methanol ratio 9:1. The solutions were placed in a water bath at 
37oC for 1 hour and then left on a magnetic stirrer plate overnight to ensure homogeneity. 
The electrospinning apparatus was set up as shown in Figure. 2.2.9. Scaffolds were 
constructed at 17 kV, a working distance of 17 cm, with a flow rate of 40μL/min, and a 
drum rotation speed of 300 rpm. The solutions were released by 12 needles (0.64 mm 
internal diameter) to the rotating drum, ground collector. Aluminium foil was used to 
cover the collector to support a fibrous sheet. The fibrous sheets collected were stored 
under vacuum at room temperature for 24 hours to evaporate any excess solvent before 
being stored in a self-sealed plastic bag at 4oC and used within six months (fabrication of 
tri-layer scaffolds will be described in chapter five). 
   
Figure. 2.2.8: The electrospinning apparatus used to produce the 3D electrospinning PCL 
scaffolds as discussed in Chapter 1. 
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2.2.9 Characterisation of electrospun PCL Scaffold using SEM 
The morphology of electrospun PCL scaffolds was analysed by measuring fibre diameter 
by SEM. SEM can be used to visualise the surface topography and composition of material 
with a magnification capacity from 10 to 500,000 times. The scanning process uses 
electrons emitting from the electron gun to interact with the sample surface, while the 
emanated secondary electrons are detected. Electrospun scaffold samples were cut into 
10 mm squares and mounted onto a specimen stub using electrically conductive double-
sided adhesive tape. An ultrathin gold layer was sputter coated onto the scaffolds to 
enable the sample to be electrically conductive. The measurement set up will be 
described in chapter four. 
2.2.10 Cell seeding onto polycaprolactone scaffolds 
Different cell seeding techniques have been used to evaluate the effectiveness of cell 
attachment and differentiation within the scaffolds. Puwanun (2014) used different 
methods for cell seeding and mentioned that there were no meaningful differences 
among the methods however the large volume procedure presented less variation 
compared with other methods. Consequently, a significant volume medium procedure 
was carried out. The equilibrium was achieved through the media leaked to the outer, 
middle, and inner parts of PCL scaffolds to augment cell attachment. A day before seeding 
cells, the scaffolds were placed in a culture dish using a sterile stainless steel ring (Daud 
et al., 2012) (Figure 2.2.10 A) or within a CellCrownTM (Figure 2.2.9 B and C). Scaffolds 
were sterilised with 80% (v/v) ethanol for 2 hours, before washing three times in PBS. 
The samples were then immersed in the three different basal culture media (XF2, 10% 
(v/v) FBS, and 5% (v/v) HPL) overnight at 37oC to enhance cell attachment. After 
overnight incubation, the media were removed from the well/plate, a small volume 
suspension of the hMSC (cell density 2 X 105 and no more than 100 µL) was directly 
seeded on the top of electrospun PCL scaffold and immediately incubated for 1 hour for 
cell attachment, after that 2 ml of each experimental media was added and left 24 hours 
in a cell incubator. The following day the PCL scaffolds were removed to the new 
well/plate which divided into different groups, and the scaffolds were then submerged in 
a fresh culture media along with the required supplements on day 1. 
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Figure 2.2.10: (A) with sterile stainless steel ring was glutted with PCL scaffolds. (B) 
electrospun PCL scaffolds were cut into rectangular shape with CellCrownTM. (C) The 
scaffolds were inserted into the CellCrownTM. Scale bar = 1.38 mm 
 
2.2.11 Scanning electron microscopy (SEM) analysis of cells-seeded onto 
electrospun PCL scaffolds 
After 21 days, culture media was removed, and scaffolds washed with PBS thrice and 
fixed with 3.7% (v/v) formaldehyde for 20 minutes (2D monolayer)/ 30 minutes (3D 
scaffolds) at room temperature to fix the cells. A dehydration step was undertaken to 
interchange water in the cells with ethanol. The samples were immersed in the following 
series of ethanols (v/v): 50%, 70%, 80%, 90% diluted in diH2O, followed by 100% 
ethanol for 10 minutes. Following this, the samples were immersed in 100% (v/v) 
Hexamethyldisilazane (HMDS) for 3 minutes. The samples were left to air dry in a fume 
cupboard and subsequently sputter coated with gold and visualised using the SEM. 
2.2.12 Assessment of vascular endothelial growth factor secretion by ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a quantification technique applied to 
ascertain the concentration of specific cytokines in cell conditioned media. Supernatants 
were collected to quantify VEGF secretion by cells 48 hours after the media was changed. 
The assessment protocol was pursued according to the manufacture’s guidelines. Briefly, 
50µL of diluent assay RD1 was added to the 96-well immunomicro plates, then 200 µL of 
standard, control and samples were added to each well. The well was sealed with an 
adhesive strip and incubated for 2 hours. All procedures were accomplished at room 
temperature. The well was then washed three times with 400 µL wash buffer solution. 
After being washed, 200 µL of VEGF conjugate was added to the well and sealed with a 
new adhesive strip and incubated for 2 hours. The well was washed as previously, and 
A B C C 
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then 200 µL of substrate solution was added to each well and incubated for 20 minutes. 
50 µL of stop solution was added to each well and the plate gently tapped to ensure 
thorough mixing. The optical density was measured by using an absorbance microplate 
reader at a 540 nm wavelength. The intensity of fluorescence emission was converted to 
create a standard curve and the equation from the standard curve used to convert 
fluorescence emission intensities to approximate human VEGF concentration (picogram/ 
ml): (Figure 2.2.12). 






















Figure. 2.2.12: Linear quantitation of human VEGF concentration measured using an 
ELISA from 0 to 1000 pg of VEGF/ml with linear regression analysis. 
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2.2.13 Staining of cell nuclei using DAPI 
DAPI is a fluorescent dye which binds to A-T rich regions on dsDNA. DAPI can quickly 
permealise both live and fixed cells but it stains live cells more strongly (Zink et al., 2003). 
Cells seeded onto scaffolds were fixed in 3.7% (v/v) formaldehyde for 30 minutes at room 
temperature, the fixative solution was removed and washed thrice with PBS. 1% (v/v) 
Triton X-100® in PBS was treated to the specimens and 10 minutes left to enhance cell 
membrane permeabilisation; then specimens were washed with PBS. The PCL mesh 
scaffolds were submerged until the scaffold was covered with 0.1% (v/v) DAPI in PBS; 
scaffolds were well wrapped in aluminium foil and left for 15 minutes. They were washed 
two times with PBS before imaging by ultraviolet absorbs at a maximum wavelength of 
358 nm and emits at a maximum wavelength of 461 nm which is identified using a blue 
filter in the fluorescence microscopy (ImageXpressTM). 
2.1.13 Statistical analysis 
Statistical analysis was performed using Prism7 (GraphPad) to calculate the mean values 
and standard deviation (SD) of each group. Two-way ANOVA with Tukey’s post-test and 
one-way ANOVA were employed to assess significant differences. A p-value of either less 
than or equal to 0.05 (p≤0.05) was considered to be statistically significant. Numbers of 
replicates are identified in each figure legend. “N” represents the number of donors and 
“n” represents a technical repeat within an experiment. Most experiments were repeated 
in triplicate.  
80 | P a g e  
 
Chapter Three: Evaluation of animal-free component culture media on 
monolayer cultured primary human osteogenic cells 
3.1 Introduction 
Paramount requirement of bone tissue engineering for cleft palate management is an 
appropriate culture medium and cells that have osteogenic differentiation capacity. The 
cells that have been used in clinical studies for the repair of bone defects intraorally such 
as alveolar cleft bone grafts for dental implants and maxillary sinus augmentation are 
human bone marrow derived mesenchymal stem cells hBMSCs (Behnia et al., 2009; Hibi 
et al., 2006) and human jaw periosteal HJPs (Trautvetter et al., 2011) as discussed in the 
previous chapter. Consequently, the selected cells to be used in this project are primary 
hBMSCs and HJPs. Animal sera are widely used during in vitro cell culture for hBMSC 
proliferation and differentiation. However, serious shortcomings have been noted such 
as potential contamination, poorly defined components, and potential for disease 
transmission (Freshney, 2010). Recently, xeno-free media have been developed to 
overcome the limitation of animal sera. However, little is known about their ability to 
support osteogenic differentiation and their applications in tissue engineering for cleft 
palate repair and similar craniofacial applications. 
Recently, efforts have been focussed on the development of animal-free formulation 
culture media using human-derived growth supplements, such as human platelet lysates 
(HPL) (Hemeda et al., 2014), and autologous human serum (Dahl et al., 2008). 
Interestingly, the Federal Drug Administration (FDA) sanctioned a commercially 
produced pre-defined xeno-free culture medium particularly formulated for human MSC 
expansion (Oikonomopoulos et al., 2015)(9). 
Osteogenic induction medium is supplemented with ascorbic acid-2-phosphate (AA), β-
glycerophosphate (βGP), and dexamethasone (Dex) (required for osteogenic 
differentiation). (AA) is essential for producing stable collagen that is a substantial 
component of the extracellular matrix of bone (ECM). (βGP) is essential for providing an 
inorganic phosphate during mineralisation of ECM by differentiated cells. Dex is a 
synthetic glucocorticoid drug that can stimulate the differentiation of hBMSCs 
osteogenically (Coelho and Fernandes, 2000). Based on previous experience in the 
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laboratory, for all monolayer experiments cells were seeded at 10,000 cells/well unless 
otherwise stated. 
In craniofacial surgery, autologous graft is the gold standard to an achieve facial bone 
regeneration because it has properties of native bone and integrates into the 
neighbouring tissue. Human jaw periosteum is a thin tri-layered tissue that covers the 
external surface of the jaw bone and contains osteogenic cells which have potential for 
creating of tissue engineered bone in oral and craniofacial surgery (Allen et al., 2004; 
Olbrich et al., 2012). 
Researchers have focussed on hBMSCs for potential clinical regenerative medicine and 
tissue engineering because these cells can differentiate into osteoblasts and form bone. 
However, their osteogenic potential is adversely affected by various factors such as: 
donor-to-donor variability, donor age, in vitro expansion (Kretlow et al., 2008), 
physiological status of the patient, age and gender, the methods of cell collection, and 
source of isolation of hMSCs (Siddappa et al., 2007). 
The aims of work in this chapter were to evaluate the effectiveness of different xeno-free 
media for expansion of hBMSCs and to obtain preliminary data about whether these 
media would also be suitable for culture of HJPs. All experiments were performed in 
standard 2D monolayer, culture with the long-term aim of establishing xeno-free culture 
protocols for future clinical applications of cleft palate repair. In order to do this, I set out 
the following objectives: 
1. To investigate the effect of different commercial media containing animal-free 
components on the growth of hBMSCs.  
2. To investigate the interaction between media formulations and the osteogenic 
supplements Dex, Ascorbate-2-phosphate and β-glycerophosphate, separately 
and in combination, on cell proliferation of hBMSCs. 
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Table 3.1: Experimental culture media with their abbreviations used in the project all 
basal media supplemented with antibiotics as described in section 2.2.1 
  
Basal culture medium  Abbreviation 
Foetal bovine serum (FBS) + α-
MEM 
10% FBS (v/v) 
Stem X VivoTM xeno-free human 





Human platelet lysate + α-MEM 5% HPL (v/v) 
FBS + α-MEM + Insulin-transferrin-
selenium 
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3.2 Appraisal of various culture media formulations on the seeding    
efficiency and growth of hBMSCs in monolayer 
The purpose of these experiments was to assess how varying the concentration of animal 
serum foetal bovine serum (FBS), and human platelet lysate (HPL) affected the metabolic 
activity of hBMSCs at different times-points. 
Cell metabolic activity was investigated using the resazurin reduction assay after days 1, 
4, and 7. On day 1 and 4, cell metabolic activity increased in all conditions except the non-
serum formulation. While on day 7, the non-serum condition was significantly lower than 
the other conditions. Although there is no significant difference between 5% (v/v) and 
10% (v/v) FBS, the 5% (v/v) FBS group underwent a decrease of cell metabolic activity 
over time (P<0.05). All the concentrations below 10% (v/v) FBS caused a decrease of cell 
metabolic activity over the time-points. Therefore, this project used a 10% (v/v) of 
animal-serum concentration (FBS) as gold standard control in all experiments (Figure 3.2 
A). 
A metabolic activity assay was also carried out to evaluate the most effective HPL 
concentration for hBMSCs. There was no significant difference between any media 
formulations on day one. However, significant differences were seen on days 4 and 7 
between the conditions. Cell metabolic activity was significantly higher for both 5% (v/v) 
and 10% (v/v) HPL compared with other conditions and also increased over time for 7 
days (P<0.05) (Figure 3.2 B).  
Overall, the below results provided sufficient evidence that both 10% (v/v) FBS and 5% 
(v/v) HPL basal culture media formulations can support the growth of hBMSCs. 
  











































































Figure 3.2: Metabolic activity of hBMSCs donor 3 under different FBS concentrations and 
human platelet lysate (HPL) concentrations from day 1 to day 7. Symbol indicates mean and 
standard deviation for each condition Mean±SD. (A) Effect of varying concentrations of FBS, 
(B) Effect of varying concentrations of HPL (*) significantly higher than the other media at 
all-time points. (#) Significantly lower. (P <0.05). n=3. Two-way ANOVA, Tukey’s multiple 
comparison test. 
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3.3 Assessment of cell metabolic activity in a range of experimental media 
formulations 
These experiments aimed at identifying some promising xeno-free media formulations to 
support hBMSCs, which could be taken forward for further work throughout this thesis. 
Donor 3 was used. 
After 24 hours of cell seeding, the resazurin reduction assay was used to evaluate cell 
metabolic activity on day 1, which gave an indication of how many cells attached on the 
well plate. Statistically, most media enabled the same levels of cell attachment except the 
MSC-NutriStem that supported a higher cell attachment (Fig 3.3-Basal culture media). 
Moreover, the cells grown in SR1 (chemically defined medium) had significantly lower 
cell metabolic activity at 24 hours and then throughout the experiment. After 24 hours of 
culture, the supplements were added. Therefore, there is no day 1 data for supplemented 
media groups. 
Metabolic activity on days 4 and 7 indicated how the different media formulations 
affected cell growth. The metabolic activity of cells cultured in XF2 (2% (v/v) human 
serum) increased sharply approximately 12 folds with significant differences compared 
to the other conditions over time for 7 days (P<0.05). Cell metabolic activity also 
increased with 10% (v/v) FBS throughout the 7 days; however, there was no significant 
difference between days 4 to 7. Although the XF1 (human plasma) initially exhibited 
suitable cell attachment at 24 hours, cell numbers declined steadily over the rest of the 
culture period (Figure 3.3). 
When supplemented with Dex 10 nM, on day 4 and 7, the metabolic activity of the 
metabolic cells cultured in XF2 increased over time at the highest rate indicating XF2 had 
a stronger effect on cell proliferation compared to the other groups the next fastest 
growth was seen in 10% (v/v) FBS followed by MSC-NutriStem. On the other hand, the 
XF1 and SR1 had a significantly lower cell growth (P<0.05) (Figure 3. 3). 
When supplemented with (AA) 50 µM and (βGP) 10 mM (without Dex), day 4 
(represented with a grey outline bars in figure 3.4), the metabolic activity for cells 
cultured in XF2 suggested a high cell proliferation rate (increase in metabolic activity 
over time) compared to the other groups, followed by 10% (v/v) FBS. On the other hand, 
the other media supported significantly slower cell growth (P<0.05). 
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On day 7 (represented with coloured dot plots), XF2 media formulations improved the 
hBMSCs proliferation as indicated by increased cell metabolic activity. The growth of cells 
cultured in XF2 was augmented approximately 2.5-fold over 3 days after day 4. However, 
cells grown in 10% (v/v) of animal serum supplement reduced to 2-fold less over the 
same time (P<0.05). XF1 and chemical-defined medium (MSC-NutriStem and SR1) poorly 
encouraged the growth of hBMSCs (Figure 3.3). 
When grown in full osteogenic media (Dex 10 nM, AA 50 µM, and βGP 10 mM), on day 4, 
the metabolic cell activity of cells cultured in XF2 suggested a higher cell proliferation 
compared to the other groups, followed by 10% (v/v) FBS and 2% (v/v) FBS+ITS. On the 
other hand, the XF1 and SR1 supported a significantly less cell proliferation (P<0.05)  
Overall, the results informed that the substitution of animal serum formulation by the 
human serum could accelerate the hBMSCs growth in all conditions.































































































































































Figure 3.3: Metabolic activity of hBMSCs donor 3 cultured in different culture media from day 
1 to day 7. Each symbol represents a single well, and the line indicated the mean and standard 
deviation for each condition. Media supplemented with Dex 10 nM, ascorbic acid-2-phosphate 
(AA) 50 µM and β-glycerophosphate (βGP) 10 mM. (*) Significantly higher than the other 
media at the same time-point. (Φ) Significantly higher than all the other media formulations at 
all-time points. (ns) There is no significant difference. (P <0.05). n=3. ANOVA, Brown-
Forsythe and Two-way ANOVA, Tukey’s multiple comparison tests.
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3.4 The effects of different basal culture media on cell metabolic activity 
of cells from different donors and passages 
This experiment aimed to investigate differences between donors and effects of passage 
on cell metabolic activity when cultured in two commercial xeno-free media compared 
with 10% (v/v) animal serum formulation. I used XF2 and XF1 for this next set of 
experiments as media that showed promising and less promising results in the previous 
preliminary experiments to investigate if these differences were consistent across a 
range of donors. 
Resazurin metabolic activity assay was used to indicate metabolic activity of cells from 
different adult donors and passages of hBMSCs, with groups cultured in xeno-free basal 
culture medium and measured after 1,4 and 7 days. 
The cell metabolic activity after 24 hours showed that the donor-1 and passage-1 cells 
cultured in all experimental culture media were significantly higher compared with cells 
from other donors and passages particularly in the XF2 basal culture medium. This 
suggests that a higher number of cells had attached. The next highest metabolic activity 
was seen in the donor-4 cells cultured in all experimental culture media. While passages 
2, 3, and 4 exhibited significantly lower cell attachment with no significant differences 
(Figure 3.4 A and B). 
On day 4, donors 1 and 4 cultured in XF2 exhibited an increase around 2-fold compared 
to their donors cultured in 10% (v/v) FBS with significantly higher cell metabolic activity 
compared to all other donors cultured in the same and different media (P<0.05). Both 
donors 1 and 4 cultured in 10% (v/v) FBS and donor-1 cultured in XF1 appeared to have 
higher cell metabolic activity compared to donor-4 cultured in XF1. However, these 
differences were not statistically significant.  (Figure 3.4 C). 
On day 7, the donors cultured in XF2 showed significantly higher metabolic activity 
compared with cells from the same donors cultured in other experimental media. While 
there were no significant differences between cells from donor-1 and -4. Donor-1 cells 
cultured in both 10% (v/v) serum medium and XF1 displayed significant difference 
compared with donor-4 cultured in the same experimental media. Whereas, the poorly 
cell metabolic activity indicated in donor-4 cultured in XF1 (Figure 3.4 D). 
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Overall, cell metabolic activity increased over the culture period (comparing figure 3.4 A 
with C and D) except for donor-4 cells culture in XF1. 
When examining cells from passages on day 4 and 7, the cell metabolic activity for both 
passages 3 and 4 had the lowest metabolic activity in xeno-free and 10% (v/v) FBS 
culture medium. Whereas the cell metabolic activity of both passages 1 and 2 cultured in 
XF2 were significantly different from the other passages cultured in the same and 
different culture media. Furthermore, these passages cultured in XF2 had a high 
metabolic rate, nearly 1.5-fold on day 7and 2.2–fold on day 4more with XF1 respectively 
(P<0.05) (Figure 3.3 E and F).  
In summary, cells from passages 3 and 4 did not exhibit increases in metabolic activity 
under any conditions. This indicates that these cells are not appropriate to examine 
differences between media. Therefore, for further analysis passage 3 and 4 cells are 
excluded from my experiments and all donor cells reported for the following experiments 
were from passage 1 and 2 only. The results from passage 1 and 2 cells do indicate that 
the media containing human serum (XF2) supported a sustainable increase in cell 
metabolic activity compared with other experimental media. 
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Figure 3.4: Metabolic activity of different donors of hBMSCs using different media in 
monolayer culture from day 1 to day 7. Symbols indicate mean and standard deviation for each 
condition. (*) Higher than the other cells cultured in the same medium. (#) Significantly lower. 
(Φ) Significantly higher than the same cells in all the other culture media. (ns) There is no 
significant difference. (P <0.05). n= 3. Two-way ANOVA, Tukey’s multiple comparison test. 
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3.5 The effects of dexamethasone supplementation on culture of hBMSCs 
in monolayer in various media 
Because I aim to induce osteogenesis in these cells and osteogenic supplements may also 
affect cell growth the interaction between osteogenic supplements separately and in 
combination are examined in the next set of experiments. Initially I examined 
dexamethasone alone at two different concentrations. Dexamethasone was added after 
24 hours when cells were well attached on the well plate. 
3.5.1 The effects of two different xeno-free basal culture medium supplemented 
with Dex 10 nM on cell metabolic activity of different donors 
The cell metabolic activity of cells from donor-1 and -4 cultured in XF2 and donor-1 
cultured in XF1 indicated significantly enhanced cell growth compared toc ells cultured 
in 10% (v/v) serum medium and the donor-4 cells cultured in XF1 (P<0.05) increasing 
about 2 folds over the same donors and passages cultured in 10% (v/v) FBS. Donors-1 
and -4 cultured in 10% (v/v) FBS also showed higher metabolic activity compared with 
donor-4 cultured in XF1. However, the donor-4 cultured in XF1showedvery low 
metabolic activity indicating lower cell numbers (Figure 3.5.1 A). 
On day7, the cell metabolic activity of both donors 1 and 4 cultured in XF2 supplemented 
with 10 nM were significantly higher than the same donors cultured in both 10% (v/v) 
FBS and XF1 culture media supplemented with 10 nM Dex. Moreover, the donors cultured 
in XF2 supplemented with 10 nM Dex had a high metabolic activity around 2-fold 
compared with 10% (v/v) FBS and XF1; while it was approximately 3.5 times higher than 
donor-4 when cultured in 10% (v/v) FBS (P<0.05) (Figure 3.5.1 B). 
Overall, the results showed that when supplemented with Dex 10 nM the media 
containing human serum (XF2) supported the cells better than both the human plasma 
and animal serum medium formulations. Even though human plasma (XF1) enhanced cell 
proliferation in donor-1 initially, cell growth diminished overtime for 7 days. 
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Figure 3.5.1: Metabolic activity of different donors of hBMSCs in different xeno-free media 
supplemented with Dex 10 nM on monolayer culture from day 4 to day 7. The scatter dot plots 
indicated individual wells and horizontal lines mean and standard deviation for each condition. 
(*) Higher than the other groups in the same donor. (#) Significantly lower. (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests. 
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3.5.2 The effects of two different xeno-free basal culture medium supplemented 
with Dex 100 nM on cell metabolic activity of different donors 
Cells from donors on day 4, donor-1 cultured in human-derived formulations exhibited a 
significantly higher cell proliferation compared to donor-4 cultured in all experimental 
media as well as donor-1 cultured in 10% (v/v) FBS. The metabolic activity of cells from 
donor-4 cultured in XF2 supplemented with Dex 100 nM indicated a steady upward trend 
of nearly 1.5-fold and 13 folds when cultured in 10% (v/v) FBS and XF1 respectively 
(P<0.05) (Figure 3.5.2A) 
On day7, the cell metabolic activity of donor-1 cells cultured in XF2 media supplemented 
with 100 nM was significantly enhanced compared to all other groups cultured in 
experimental culture media. Donor-1 cultured in XF2 supplemented with 100 nM had a 
high cell growth of around 2.5-fold and 1.5-fold compared to when cultured in 10% (v/v) 
FBS and XF1 respectively. Moreover, when donor-1 cells were cultured in XF1 metabolic 
activity was 1.5 times higher compared to 10% (v/v) FBS (P<0.05). Cells of Donor-1 had 
significantly higher cell proliferation compared to donor-4 cells cultured in the same 
media (Figure 3.5.2 B). 
Overall, the results demonstrated that the human serum supplemented with Dex 100 nM 
supported cell growth better than the human plasma and animal serum medium 
formulation cultured in the same circumstances. 
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Figure 3.5.2: Metabolic activity of different donors of hBMSCs in different xeno-free media 
supplemented with Dex 100 nM on monolayer culture from day 4 to day 7. The symbols indicate 
individual wells and horizontal lines the mean and standard deviation for each condition. (*) 
Significantly higher than the other groups in the same medium. (#) Significantly lower. (Φ) 
Significantly higher than all the other conditions. (ns) There is no significant difference. (P 
<0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
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3.6 The effects of two different xeno-free basal culture medium supplemented 
with ascorbic acid-2-phosphate (AA) and β-glycerophosphate (βGP) on cell 
metabolic activity of different donors 
The ascorbic acid-2-phosphate 50 µM and β-glycerophosphate 10 mM were added after 
24 hours when the cells were well attached to the well plate. 
Donor-1 cells cultured in XF2 exhibited enhanced cell growth, about 2-fold, compared to 
when grown in animal-derived growth supplements and significantly higher than all the 
other conditions in the different media, followed by donor-4 (Figure 3.6 A). 
On day7, the cell metabolic activity of cells cultured in XF2 exhibited substantially higher 
metabolic activity indicating high proliferation compared to the other groups. However, 
these were not significantly different compared with DONOR-1 treated with 10% (v/v) 
FBS. Whereas the cell metabolic activity of DONOR-4 cultured in XF1 was significantly 
impaired in all conditions (P<0.05) (Figure 3.6 B). 
Overall, the results showed that human serum supplemented with (AA) 50 µM and (βGP) 
10 mM performed better of metabolic activity than the human plasma and animal serum 
medium formulations cultured in the same conditions. 





































































Figure 3.6: Metabolic activity of different donors of hBMSCs in different xeno-free media 
supplemented with ascorbic acid-2-phosphate (AA) 50 µM and β-glycerophosphate (βGP) 10 
mM on monolayer culture from day 4 to day 7. The symbols indicated individual wells and the 
horizontal lines the mean and standard deviation for each condition. (*) Significantly higher 
than the other groups in the same medium. (#) Significantly lower. (Φ) Significantly higher 
than all the other conditions in the different media. (ns) There is no significant difference (P 
<0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
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3.7 The effect of osteogenic-inductive supplements on cell metabolic activity of 
a monolayer cultured hBMSCs 
The osteogenic-inductive substances Dex, AA, and βGP were added after 24 hours when 
the cells were well attached on the well plate. 
3.7.1 The effects of two different xeno-free basal culture medium supplemented 
with osteogenic-inductive elements Dex 10 nM, AA 50 µM, and βGP 10 mM 
on cell metabolic activity of different donors 
The cell metabolic activity of donor-1 cells cultured in human-derived substitutes was 
higher, nearly 2-fold, compared to the same donors cultured in 10% (v/v) FBS. They had 
a significant difference compared to donors cultured in 10% (v/v) FBS and donor-4 
cultured in XF1. Even though donor-4 cells cultured in XF2 appeared to have lower cell 
metabolic activity compared to donor-1 cultured in XF2 and XF1, there was no significant 
difference (P<0.05). Significant differences were seen between donor 4 cells cultured in 
XF2 with both donors cultured in 10% (v/v) FBS (Figure 3.7.1 A). 
On day7, the cell metabolic activity of both donors cultured in XF2 indicated a substantial 
enhancement of potential cell proliferation; there were no significant differences 
between them but they had significantly higher metabolic activity compared to cells 
grown with different media. Consequently, they were about 2.5-fold higher compared to 
the same donors treated with XF1 and 10% (v/v) FBS. Donor-4 cells cultured in 10% 
(v/v) FBS had a rise in cell growth, but retained a low cell number (P<0.05) (Figure 3.7.1 
B). 
Overall, the results demonstrated that the human serum supplemented media with 
traditional osteogenic-inductive factors supported high cell proliferation compared to 
the human plasma and animal-serum supplementations cultured in the same conditions. 








































































Figure 3.7.1: Metabolic activity of different donors of hBMSCs on a different xeno-free 
medium supplemented with osteogenic-inductive ingredients {Dex 10 nM, ascorbic acid-2-
phosphate (AA) 50 µM and β-glycerophosphate (βGP) 10 mM} on monolayer culture from day 
4 to day 7. The symbols represent an individual well and the horizontal lines mean and 
standard deviation for each condition. (*) Higher than the other donors in the same medium. 
(#) Significantly lower. (Φ) Significantly higher than all the other conditions. (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests. 
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3.7.2 The effects of two different xeno-free basal culture medium supplemented 
with osteogenic-inductive elements Dex 100 nM, AA 50 µM, and βGP 10 mM 
on cell metabolic activity of different donors 
Similarly, at the higher dose of Dex in the osteogenic medium the cell metabolic activity 
of donor-1 cultured in human-derived formulations was significantly higher compared to 
other donor cultured in the same media and 10% (v/v) serum medium. Donor-1 cells 
cultured in human-derived media were nearly 2.5-fold higher compared to culture in 
10% (v/v) FBS and compared to donor 4 cells cultured in XF2 and 10% (v/v) FBS. There 
was no significant difference between donors cultured in 10% (v/v) FBS and donor-4 
cultured in XF2 (P<0.05) (Figure 3.7.2 A). 
On day7, the metabolic activity of donor-1 cultured in XF2 increased dramatically 
compared to day 4 indicating proliferation. Moreover, donor-1 exhibited higher cell 
numbers around 2.5-fold and 4.5-fold compared to when cultured in 10% (v/v) FBS and 
XF1 respectively (P<0.05) (Figure 3.7.2 B). 
Overall, the results informed that the human serum supplemented with osteogenic-
inductive media containing the higher dose of Dex 100 nM also supported higher cell 
proliferation compared to the animal serum medium formulation. 
 






































































Figure 3.7.2: Metabolic activity of different donors of hBMSCs on a different xeno-free 
medium supplemented with osteogenic-inductive ingredients {Dex 100 nM, ascorbic acid-2-
phosphate (AA) 50 µM and β-glycerophosphate (βGP) 10 mM} on monolayer culture from day 
4 to day 7. The symbols represent an individual well and the horizontal lines mean and 
standard deviation for each condition. (*) Higher than the other donors in the same medium. 
(#) Significantly lower. (Φ) Significantly higher than all the other conditions. (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests. 
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Summary of the effect of osteogenic medium on cell metabolic activity 
In the previous reporting I deliberately kept the different supplemented groups separate 
to examine the effect of the different media within groups. However, it is also important 
to examine the overall effects of the osteogenic supplements on metabolic activity. For 
this the metabolic activity at day 7 is compared between the basal media groups and the 
OM-10 groups (Dex 10 nM, AA 50 μM, and βGP 10 mM), this shows that there is no 
consistent effect of Dex containing osteogenic media on metabolic activity 
Table 3.7.2: Examination of the effect osteogenic supplements (Dex 10 nM, AA 50 μM, 
and βGP 10 mM) on the metabolic activity of cells. “Higher” indicates osteogenic-
inductive medium caused significantly higher resazurin fluorescence when comparing 
data in figure 3.7.1 and figure 3.7.2 “Lower” indicates osteogenic-inductive medium 
caused significantly lower fluorescence and “NS” indicated no significant difference 
between basal media and OM within this group on day 7 
Media Donor 1 Donor 4 
BCM-OM10 Higher NS 
XF1-OM10 Higher Lower 
XF2-OM10 NS Higher 
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3.8 Determining the quantity of DNA 
Because the resazurin assay depends on both cell number and metabolic rate of cells, a 
DNA assay was also performed for some of the conditions investigated. The aim of this 
experiment was to assess the DNA content through the binding of a fluorescence dye with 
double-stranded (dsDNA) and assess which xeno-free medium can support high numbers 
of hBMSCs to be presented by day 10.  
These experiments were used to investigate the cell numbers independently of metabolic 
changes. As the metabolic activity results for XF1 were disappointing some additional 
conditions were used in the preliminary experiments including 2% (v/v) FBS+ITS and 
5% (v/v) HPL. 
3.8.1 Assessment of cellular DNA in animal-derived supplemented serum media 
and human-derived culture media 
DNA was analysed quantitatively on day 10, the cells grown in XF2 basal medium had 
undoubtedly more cells present as the quantity of DNA was significantly higher (P <0.05) 
compared with all other media at all-time points. Although the 5% (v/v) HPL culture 
medium also supported higher cell number reaching around 13-fold compared to the 
animal-derived formulations, it was about 5-fold lower compared with XF2. 10% (v/v) 
FBS, 2% (v/v) FBS+ITS and XF1 basal medium all supported notably lower cell number 
(P <0.05). 
On supplementation with dexamethasone at 10 nM, the higher growth rate of hBMSCs 
grown in XF2 culture media was evident and statically higher compared to the other 
media with the next highest amount of DNA being seen in 5% (v/v) HPL. Even though the 
5% (v/v) HPL culture media supported higher DNA than the animal-derived 
formulations, it supported about 1.5 less compared with XF2. On the other hand, the 
remaining groups grown in XF1, 2% (v/v) FBS+ITS, and 10% (v/v) FBS media supported 
lower DNA content (P <0.05). 
When the basal culture media was supplemented with ascorbic acid-2-phosphate (AA) 
50 µM and β-glycerophosphate (βGP) 10 mM, the cells grown in XF2 had increased cell 
proliferation as seen by 25-fold and 2-fold higher DNA content than the animal-derived 
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media and 5% (v/v) HPL respectively. Whereas the cell grown in 5% (v/v) HPL were 
about 13-fold higher compared to the animal-derived media (P <0.05). 
When supplemented with complete osteoinductive ingredients (AA, βGP and Dex) the cells 
grown in human-derived media, particularly XF2 and 5% (v/v) HPL had significantly 
higher DNA compared to these grown in the animal-derived osteogenic medium and XF1. 
In contrast, the quantity of DNA in animal-derived and XF1 osteoinductive culture 
medium indicated lower cell proliferation (P <0.05). 
As we have seen above, the findings provided evidence that the human-derived media 
formulations and particularly XF2 and 5% (v/v) HPL media could augment the 
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Figure 3.8.1: DNA quantification of hBMSCs donor-3 passage-2 cultured with different 
animal-serum concentrations, and commercial human-derived basal culture medium measured 
by Quant-iT™ PicoGreen® on monolayer on day 10. The symbols indicate individual wells and 
the horizontal lines mean and standard deviation for each condition. (*) Significantly higher 
than the other media at all-time points. (#) Significantly lower. (P <0.05). n=3. ANOVA, 
Brown-Forsythe test. 
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3.8.2 The effects of different basal culture medium on the DNA content of 
different donors 
Further experiments were undertaken using selected culture media (10% (v/v) FBS as a 
standard, XF1 as a poorly performing media and XF2 and a good performing media) on a 
range of donor numbers to see if the effects of the culture media would be consistent 
across donors. DNA assay was undertaken at 10 days. 
The donors’ cells cultured in 10% (v/v) FBS and three out four donors cultured in XF1 
generally had lower DNA content. It is noteworthy that all donors cultured in XF2 
contained more DNA than all other groups, and each donor sample had significantly more 
DNA when cultured in XF2 compared to its respective cells cultured in other media. 
Furthermore, donor-1 and donor-2 cultured in XF2 were indicated significantly different, 
nearly 8-fold higher in DNA content, compared to cells cultured in 10% (v/v) FBS 
(P<0.05) (Figure 3.8.2). 
Overall, it can be seen that the DNA content was the highest in human serum (XF2) and 
lowest in animal-derived and human plasma (XF1) basal culture media for all donors. 
 
  








































Figure 3.8.2: DNA quantification of hBMSCs cultured in standard FBS, and commercial 
human-derived basal culture medium measured by Quant-iT™ PicoGreen® on monolayer on 
day 10. The symbols indicate individual wells and the horizontal lines mean and standard 
deviation for each condition. (*) Higher than the other donors in the same medium. (#) 
Significantly lower. (Φ) Significantly higher than all the other conditions. (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests. 
  
111 | P a g e  
 
3.8.3 The effect of varying concentrations of dexamethasone supplemented with 
basal culture medium on the amount of DNA of a monolayer cultured 
hBMSCs 
Dexamethasone was added after 24 hours after the cells had attached on the well plate. 
3.8.3.1 Determine total DNA content in two different xeno-free basal culture 
media supplemented with Dex 10 nM on different donors 
Three donors out of four cultured in XF2 treated by Dex 10 nM contained statistically 
significantly higher cellular DNA content than cells from the same donors cultured in the 
different culture medium supplemented with Dex 10 nM (P<0.05) (Figure 3.8.3.1).  
Overall, the results demonstrated that when treated with Dex 10 nM cells cultured in XF2 
also contained higher numbers compared with other media as was seen in basal culture 
media alone. 
 










































Figure 3.8.3.1: DNA quantification of hBMSCs cultured on two commercial human-derived 
basal culture media compared with 10% (v/v) animal-serum concentration treated with Dex 
10 nM and measured by Quant-iT™ PicoGreen® on monolayer on day 10. The symbols 
indicate individual wells and the horizontal lines mean and standard deviation for each 
condition. (*) Higher than the other donors in the same medium. (#) Significantly lower. (Φ) 
Significantly higher than all the other conditions. (P <0.05). n=3. Two-way ANOVA, Tukey’s 
multiple comparison tests.  
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3.8.3.2 Determine total DNA content in two different xeno-free basal culture 
media supplemented with Dex 100 nM on different donors 
On supplementation of the basal culture media with Dex 100 nM, peak DNA content was 
lower than in 10 nM Dex indicating there may have been some inhibition of cell growth 
at the higher Dex concentration. However, the pattern of behaviour of different donor 
numbers were similar with effect of Dex 10 nM except in cultured XF2. Donor-1cells 
cultured in human-derived media and Donor-2 cells cultured in XF2 contained 
significantly higher DNA over the others (P<0.05) (Figure 3.8.3.2). 
Overall, the results confirmed that also in Dex 100 nM cells of donor 1 and 2 cultured in 
XF2 usually had significantly more DNA content than the same cells cultured in other 
media, the exception being Donor-1 that had just as high DNA content in XF1. 
 
  







































Figure 3.8.3.2: DNA quantification of hBMSCs cultured on two commercial human-derived 
basal culture media compared with 10% (v/v) animal-serum concentration that treated by Dex 
100 nM and measured by Quant-iT™ PicoGreen® on monolayer on day 10. The symbols 
indicate individual wells and the horizontal lines mean and standard deviation for each 
condition. (*) Higher than the other donors in the same medium. (#) Significantly lower. (Φ) 
Significantly higher than all the other conditions. (P <0.05). n=3. Two-way ANOVA, Tukey’s 
multiple comparison tests.  
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3.8.4 The effects of two different xeno-free basal culture medium supplemented 
with ascorbic acid-2-phosphate (AA) and β-glycerophosphate (βGP) on the 
amount of DNA in different donors 
When the basal culture media was supplemented with (AA) 50 µM and (βGP) 10 mM, the 
amount of DNA in all donors cultured in XF1 and donor-4 cultured in 10% (v/v) serum 
medium was lower. Donor-2 cells cultured in XF2 exhibited distinctly higher DNA, 
approximately 20-fold compared to when cultured in 10% (v/v) FBS. While cells from 
DONOR-1 had high DNA indicating cell proliferation (about 2-fold and 3.5-fold compared 
to those cultured in   10% (v/v) FBS and XF1) respectively (P<0.05) (Figure 3.8.4). 
Overall, the results confirmed that also when supplemented with (AA) 50 µM and (βGP) 
10 mM, which are added to media to support matrix production, cells generally grew 
better in XF2 human derived serum than in human-derived plasma and animal-derived 
serum medium formulations, although there is donor to donor differences affecting 
whether the ells are responsive to XF2. 
  





































Figure 3.8.4: DNA quantification of hBMSCs cultured on two commercial human-derived 
basal culture media compared with 10% (v/v) animal-serum concentration that treated by 
ascorbic acid-2-phosphate (AA) 50 µM and β-glycerophosphate (βGP) 10 mM and measured 
by Quant-iT™ PicoGreen® on monolayer on day 10. The symbols indicate individual wells and 
the horizontal lines mean and standard deviation for each condition. (*) Higher than the other 
donors in the same medium. (#) Significantly lower. (Φ) Significantly higher than all the other 
conditions. (P <0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
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3.8.5 The effect of osteogenic-inductive supplements on the quantity of DNA on a 
monolayer cultured hBMSCs 
The osteogenic-inductive substances Dex, AA, and βGP were added after 24 hours when 
the cell was entirely attached on the well plate. 
3.8.5.1 DNA content in culture media supplemented with osteogenic-
inductive substances at a Dex concentration 10 nM. 
When the basal culture media was supplemented with the full set of osteogenic-inductive 
substances including Dex 10 nM, the cell numbers of DONOR-1 cultured in XF2 were again 
very high and significantly from other donors. Whereas all donors cultured in 10% (v/v) 
serum media and three of four donors cultured in XF1 had very low DNA content. There 
was no significant difference among the donors when cultured in 10% (v/v) FBS (P<0.05) 
(Figure 3.8.5.1). 
Overall, the results demonstrated that human serum supplemented with osteogenic-
inductive media induced higher cell numbers compared to human plasma and animal-
derived growth supplementation, cultured in the same conditions. It is interesting to note 
that the effect of XF2 media there is higher DNA content in with osteogenic supplements 
compared to in basal culture media alone (Table 3.8.5.1). 
  







































Figure 3.8.5.1: DNA quantification of hBMSCs cultured on two commercial human-derived 
basal culture media compared with 10% (v/v) animal-serum concentration that treated by Dex 
10 nM, ascorbic acid-2-phosphate (AA) 50 µM, and β-glycerophosphate (βGP) 10 mM and 
measured by Quant-iT™ PicoGreen® on monolayer on day 10. The symbols indicate individual 
wells and the horizontal lines mean and standard deviation for each condition. (*) Higher than 
the other donors in the same medium. (#) Significantly lower. (Φ) Significantly higher than all 
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Table 3.8.5.1.: The effect of osteogenic media (containing Dex 10 nM and 100 nM) on DNA 
content within the media groups examined. “Higher” indicates osteogenic-inductive 
medium caused significantly higher when comparing data in figure 3.8.5.1 and figure 
3.8.5.2 “Lower” indicates osteogenic-inductive medium caused significantly lower DNA 
and “NS” indicated no significant difference between two OM within this group. There 
was only a consistent effect of osteogenic media for XF2. 
Media Donor 1 Donor 2 Donor 3 Donor 4 
10% (v/v)FBS-OM10 Lower Higher Higher Lower 
XF1-OM10 Higher NS NS NS 
XF2-OM10 Higher Higher Higher Higher 
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3.8.5.2 DNA content in culture media supplemented with osteogenic-
inductive substances at a Dex concentration 100 nM 
Because some researchers recommend 100 nM Dex for osteogenic culture medium but a 
high concentration of Dex may inhibit cell proliferation I also examined the effects of a 
higher Dex concentration in the osteogenic media. Overall, the results gave similar results 
to osteogenic medium with 10 nM Dex concentration although the donor cells that 
yielded the highest amounts of DNA in 10 nM Dex did have lower DNA in 100 nM Dex. 
Two out four donors’ cells supplemented with human serum and osteogenic media 
containing 100 nM Dex had higher cell numbers than all other donors cultured in XF1 and 
10% (v/v) serum medium (P<0.05) (Figure 3.8.5.2). 
 
  







































Figure 3.8.5.2: DNA quantification of hBMSCs cultured on two commercial human-derived 
basal culture media compared with 10% (v/v) animal-serum concentration t treated by Dex 
100 nM, AA 50 µM, and βGP 10 mM and measured by Quant-iT™ PicoGreen® on day 10. The 
symbols indicate individual wells and the horizontal lines mean and standard deviation for 
each condition. (*) Higher than the other donors in the same medium. (#) Significantly lower. 
(Φ) Significantly higher than all the other conditions. (P <0.05). n=3. Two-way ANOVA, 
Tukey’s multiple comparison tests. 
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3.9 Human jaw periosteum as an alternative source (preliminary data) 
The target of this experiment was to assess the HJP behaviour when grown in xeno-free 
culture media and treated by different supplements as an alternative source of cells. 
3.9.1 Appraisal of various culture media formulations on the seeding efficiency 
and growth of HJPs in monolayer 
In the basal culture media after 24 hours of cell, seeding the resazurin reduction assay 
was used to evaluate cell attachment on the well plate. HJPs grown in all media attached, 
and there was no significant difference in cell number between media types. On day 4, the 
cell metabolic activity illustrated how different media formulation affect cell metabolic 
activity. The cell metabolic activity cultured in human-derived formulation media was 
higher with a significant effect compared to the other conditions. 
The cell metabolic activity was 2.5-fold higher compared with 24 hours and 1.5-fold 
higher compared with 10% (v/v) FBS (P<0.05). There was no significant difference 
between XF2 and XF1. There was no significant difference in cell metabolic activity 
between the human-derived growth media on day 4 and XF2 on day 7. For the remaining 
culture media, the cell metabolic activity dropped nearly 3-fold, indicating cell death. 
Although the XF1 had high the cell metabolic activity on day 4, this declined by day 7 
(P<0.05) (Figure 3.9.1 A). 
For basal culture media treated with Dex 10nM the cell metabolic activity of cells cultured 
in human-derived growth media was noticeably increased about 3-fold by day 7 
compared with 10% (v/v) FBS at the same time (P<0.05) (Figure 3.9.1 B). 
For basal culture media treated with Dex 100nM on day 4, the cell metabolic activity 
cultured in XF2 was significantly higher about 2-fold and 2.5-fold over the 10% (v/v) FBS 
and XF1 respectively (P<0.05) (Figure 3.9.1 C). 
In the basal culture media treated by AA 50 µM and βGP 10 mM. On day 4, the cell 
metabolic activity in XF1 was about 1.5-fold significantly higher than in the other media. 
While the 10% (v/v) FBS culture medium supported nearly 2-fold cell metabolic activity 
over the XF1 culture medium, which was unable to support good cell metabolic activity. 
By day 7 cell metabolic activity in XF2 was two times higher compared with all conditions 
on day 4 (P<0.05) (Figure 3.9.1 D). 
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In culture media containing with osteogenic supplementations with Dex 10nM the 
human-derived growth media supported slightly higher cell numbers compared to 
animal-derived serum medium, but there was no significant difference. By day 7, the cell 
metabolic activity in XF2 was about 2.5-fold and 8-fold higher over the 10% (v/v) FBS 
and XF1 respectively. While the 10% (v/v) FBS culture medium supported nearly 3.5-fold 
metabolic activity compared to XF1 culture medium (P<0.05) (Figure 3.9.1 E). 
In culture media containing with osteogenic supplementations with Dex 100nM all 
conditions supported lower of the cell metabolic activity and there was no significant 
difference among them at day 4 but by day 7, the cell metabolic activity in XF2 was 4.5-
fold higher than in 10% (v/v) FBS (P<0.05) (Figure 3.9.1 F). 
  


























































































































































































































F: BCM treated by Dex 100 nM, AA 50 m, and GP 10 mM
 
Figure 3.9.1: Metabolic activity of HJPs cultured in commercial human-derived growth basal culture 
medium compared with 10% (v/v) animal-serum concentration measured by resazurin reduction assay 
on monolayer over time for 7 days. The scatter dot plot manifests mean and standard deviation for each 
condition. (*) Significantly higher than the other media at all-time points. (#) Significantly lower. Φ) 
Significantly higher than all the other conditions. (ns) There is no significant difference (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests. 
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3.9.2 Evaluation of the total amount of DNA of HJPs 
In the basal culture media on day 10, the amount of DNA in XF2 was a noticeably different 
compared with other conditions. It was boosted about 1.5-fold and 3-fold compared with 
10% (v/v) FBS and XF1 respectively, whereas the 10% (v/v) FBS had higher DNA, nearly 
2-fold, over the XF1 and the XF1 groups had lower DNA quantity on day 10 (P<0.05) 
(Figure 3.9.2 A). 
For the media supplemented with Dex 100 nM; XF2 was revealed to increase the DNA 
quantity significantly about 13-fold and more compared with 10% (v/v) FBS and XF1 
respectively (P<0.05). For medium supplemented with Dex 10 nM; the human-derived 
formulations supported about 5-fold times the DNA (cell number) compared with animal-
derived serum. In this group although the XF2 medium augmented the cell proliferation 
over the XF1, there was no significant difference. The human-derived growth media 
treated with 10 nM Dex in general supported higher DNA content compared to Dex at 100 
nM (P<0.05) (Figure 3.9.2 B). 
In media supplemented with AA 50 μM and βGP 10 mM, DNA in the XF2 group was a 
significantly different from the other conditions ,7-fold and 25-fold, compared with10% 
(v/v) FBS and XF1 respectively. Whereas the 10% (v/v) FBS increased the quantity of 
DNA approximately 3.5-fold compared to XF1, and XF1 was the poorest performing 
media in terms of supporting cell numbers (P<0.05) (Figure 3.9.2 C). 
When full osteoinductive supplements were added at Dex 10 nM, the XF2 was revealed 
to increase the DNA quantity about 4-fold and 9-fold compared with 10% (v/v) FBS and 
XF1 respectively. 10% (v/v) FBS supported twice the DNA content, compared to XF1 
(P<0.05). At the higher Dex concentration of100 nM, the XF2 supported higher DNA, 
almost 24-fold and 11-fold over the 10% (v/v) FBS and XF1 respectively. On comparing 
between the two groups with osteoinductive supplementation for the 10% (v/v) FBS 
group Dex at 10 nM supported more cells compared to Dex at 100 nM 10 (P<0.05) (Figure 
3.9.2 D). 
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D: BCM supplemented with Dex 10 and 100 nM, AA and GP
 
Figure 3.9.2: DNA quantification of HJPs cultured on two commercial human-derived basal 
culture media compared with 10% (v/v) animal-serum concentration measured by Quant-iT™ 
PicoGreen® on monolayer on day 10. The scatter dot plot manifests mean and standard 
deviation for each condition. (*) Significantly higher than the other media at all-time points. 
(#) Significantly lower. Φ) Significantly higher than all the other conditions. (ns) There is no 
significant difference (P <0.05). n=3. ANOVA, Brown-Forsythe test. Moreover, two-way 
ANOVA, Tukey’s multiple comparison tests. 
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3.10 EdU proliferation assay for monolayer culture 
The therapeutic application of hBMSCs in craniofacial bone regeneration requires rapid 
proliferation and expansion of cells in a medium that does not compromise the cells. The 
resazurin and DNA assays both indicated higher cells numbers in XF2 and HPL media, 
however neither of these assays directly measures cells proliferation. Thus, we 
investigated the effect of human-derived media on hBMSCs proliferation via EdU 
incorporation assay on day 4. EdU is a nucleoside analogue to thymidine and incorporates 
into DNA during the active period of DNA synthesis. We excluded the XF1 (human plasma 
containing) and chemically derived media from the experiments because they had shown 
low resazurin and DNA values, indicating poor cell growth. 
EdU labelling experiments were performed for three adult donors. Although the animal-
derived serum supplements are commonly used to support cell proliferation, lower 
amounts of newly synthesised DNA were seen in animal serum compared with human-
derived supplements. Two out of three donors cultured in XF2 were shown to proliferate 
more rapidly compared to in other media particular cells from donor-1 that were 
statistically significantly different from the other donors. In donor-3, the amount of newly 
synthesised DNA was shown to be higher in 5% (v/v) HPL rather than other media. 
Although the amount of newly synthesised DNA in 5% (v/v) HPL was significantly 
different from 10% (v/v) FBS, it was not different from XF2 (P<0.05) (Figure 3.10). 
Overall, the human-derived growth supplements enabled higher synthesis of DNA 
particularly XF2 compared to the animal-derived serum supplements. The donor effect 
and types of media played a crucial role in determining the rate of cell proliferation. 
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Figure 3.10: Fluorescence Signal from Alexa Fluor® 488 Click-iT® EdU Flow Cytometry 
Assay Kits. The figures show proliferating cells that have incorporated EdU. (A) 10% (v/v)FBS 
showed few cells proliferation, (B) 5% (v/v)HPL showed upregulation of cells proliferation, 
(C) XF2 showed higher cells proliferation.  
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3.11 Discussion 
Bone tissue engineering presents a considerable opportunity for clinical cleft palate 
repair. The essential ingredients for this strategy to be effective are the osteoinductive 
cell source and the biochemicals for bone formation. Bone marrow derived cells have 
demonstrated therapeutic potential for the treatment of cleft palate and other disorders 
and diseases because they contain a subpopulation of cells called “precursor cells” which 
have the natural ability to differentiate toward bone forming cells (Coelho and Fernandes, 
2000; Manolagas, 1995) and also present self-renewal capacity with multi-potency 
(Solmesky et al., 2010). It has been predicted that bone marrow contains only between 
0.001 to 0.01% mesenchymal stem cells (MSCs) as a sub-population of whole bone 
marrow mononuclear cells (Pittenger et al., 1999; Schallmoser et al., 2007). While a 
sufficient amount of MSCs that are considered to be a clinical dose is at least 2 x 106 
MSCs/kg body weight of the adult patient (Ringdén et al., 2006; Schallmoser et al., 2007). 
Therapeutically human bone marrow MSCs (hBMSCs) to be used in a patient need 
comprehensive in vitro cell expansion, usually using animal-serum components Foetal 
Bovine Serum (FBS) as the fundamental growth supplement. However, there are 
problems related to employing animal component medium. Thus, the purpose of this 
research is to identify satisfactory media to support hBMSCs and move from animal 
component media to a defined xeno-free product. In addition, the aim was to evaluate this 
in different donors, since there is well-demonstrated variability in the responses of 
hBMSCs to media supplements. Human serum and human platelet lysate could be 
clinically used and have been approved by the US Federal Drug Agency (FDA) and are 
considered as safe alternative media for hBMSCs. 
The majority of studies have been focused on cell proliferation, and expansion and recent 
endeavours have been aimed at isolation and expansion of MSC in short culture times 
using xeno-free components (Battula et al., 2007). A minority of researchers have 
investigated the ability of xeno-free conditions to facilitate expansion and differentiation 
of hBMSCs over long term culture (Lindroos et al., 2009). Therapeutic implementation of 
hBMSCs in cleft palate requires rapid expansion and proliferation of cells in a medium 
that does not compromise the cell properties. Prosperous bone tissue engineering 
utilising hBMSCs primarily depends on cell quality, the capability of proliferation, 
differentiation in vitro, and bone formation in vivo (Siddappa et al., 2007). This study 
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concerns xeno-free media that will support osteogenic cell differentiation with the long-
term aim of establishing xeno-free cultures for clinical applications of craniofacial bone 
defects in particular cleft palate repair. The first step was to see how the interaction 
between the different media compositions and the different osteogenic supplements 
would affect cell numbers and cell proliferation in culture conditions. Resazurin 
reduction assay was performed on seeded hBMSCs in 2D monolayer to infer cell 
attachment and metabolic activity while PicoGreen was used to evaluate the DNA content. 
I initially compared five commercial xeno-free media and a reduced concentration of 
animal serum supplemented with ITS (Insulin-Transferrin-Selenium) compared with 
10% (v/v) FBS. These media include three media derived from human sources such as 
XF2 (2% (v/v) human serum), XF1 (human plasma), 5% (v/v) HPL, and two chemically 
defined media herein denoted as SR1 and MSC-NutriStem. It is noteworthy that hBMSCs 
cultured in two chemically defined media showed lower numbers and slower growth. 
The ITS culture supplement provides insulin, transferrin, and selenium as required in 
cultured cells, and has been shown to enable lower animal serum concentration to be 
used for example the FBS concentration to 2% (v/v). ITS has been routinely 
supplemented in most serum or a low concentration of bovine serum-free culture media 
(Jeong et al., 2008). However, in this study cells cultured in ITS with 2% (v/v) serum 
showed poor cell growth and therefore the use of this supplement was not continued. 
Resazurin reduction assay was performed after 24 hours to understand the cell 
attachment to well plate base, and the results showed no significant difference among 
different media. Cells grown in xeno-free media particularly in 5% (v/v) HPL and XF2 
adopted a spindle-shaped morphology with evidence of cell proliferation. These media 
allowed cells to grow at much higher densities over a short time compared to the cells 
grown in 10% (v/v) animal-serum supplemented media. 
As  would be expected the standard formulation basal culture medium had allowed good 
cell proliferation (Kyllönen et al., 2013) with the time. Surprisingly XF1 which also 
contained human-derived ingredients did not support cell growth as well as XF2, 5% 
(v/v) HPL or even 10% (v/v) FBS. 
hBMSCs cultured in 10% (v/v) FBS and human-derived media (except XF1) supported 
upregulation of metabolic activity at a later time-points of the culture period. The reason 
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for this may be that these formulations containing human-derived media sustain the 
hBMSCs by delivery of growth factors required for hBMSCs proliferation and expansion. 
Chase et al., (2010) cultured primary hBMSCs in serum-free supplemented with growth 
factors, the authors concluded that there was a synergistic effect between them. Thus, our 
human-derived media have growth factors because they are extracted from human blood. 
However, the amount and types of growth factors are unknown. Because these media 
come from commercial sources and are protected by intellectual property rights, the 
company does not give the precise composition of the media. This makes it difficult to 
understand why XF1 supports cell growth much less than other formulations. Chemically 
defined media offers advantages in that the concentration of each growth factor and 
biochemical is consistent however in this study the chemically defined media could not 
support the primary hBMSC expansion, probably due to deficiency of essential bioactive 
factors.  
Currently, there is limited consensus and conflicting information regarding the effects of 
donor variability and cell processing on adult mesenchymal stem cell function. Some 
previous researchers have revealed no age-related differences in differentiation using 
human BMSCs (Leskelä et al., 2003). However, several studies have seen changes in 
proliferation, attachment, senescence or self-renewal in hBMSCs although they have not 
seen effects on differentiation (Mareschi et al., 2006). Here there was a clear difference 
between donors and cell passage number in their ability to attach during 24 hours. For 
example, cells from donor one and passage one when cultured in XF2 media attached 
significantly better than others donors and passages cultured in the same and different 
media. Proliferation rates seemed to also differ between donors for example the highest 
cell number was achieved in XF2 basal culture medium and was the most different from 
other media at day 4. The cell metabolic activity was lower at higher cell passage 
numbers, whereas the human serum (XF2) showed a sustainable increase in cell 
metabolic activity compared with other media. However, our findings are disagreement 
with Kyllönen et al., (2013) who demonstrated that the proliferation of cell cultured in a 
basal medium of 10% (v/v) FBS was marginally higher than xeno-free media. 
In my present study, I used the synthetic, glucocorticoid steroid hormone dexamethasone 
as the main biochemical to induce osteogenesis (Delaine-Smith and Reilly, 2011). it is 
clinically employed as anti-inflammatory pharmaceutical but long-term use of 
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dexamethasone or any types of steroid may give rise to many severe diseases  such as 
hypertension, cushing’s syndrome, osteoporosis, and diabetes mellitus type two (Yuasa 
et al., 2015). Dexamethasone is commonly used for MSC differentiation toward the 
osteogenic lineage (Oshina et al., 2007). Although dexamethasone stimulates 
osteogenesis, it can inhibit cell proliferation. The results revealed that a low 
concentration of dexamethasone supported hBMSCs proliferation better than a high 
concentration, which was particularly notable in XF2. Although dexamethasone has been 
used to promote osteogenesis, it was shown to have an adverse effect on cell metabolic 
activity when used at a high dose, hBMSCs cultivated in low dexamethasone 
concentration conserved a higher proliferation potential (Xiao et al., 2010). In this study, 
the high concentration of dexamethasone of 100 nM inhibited growth of hBMSCs 
measured at day 4 and 7. In contrast, our data indicated that hBMSCs cultured without 
dexamethasone maintained their proliferation status better than cultivated with 
dexamethasone. It is noteworthy that Wang et al., (2012) mentioned that apoptosis levels 
correlated with dexamethasone concentration. Their data demonstrated that a high 
concentration of dexamethasone (10-8, 10-7 and 10-6 mol/L) in xeno-free media induced 
apoptosis of UC-MSC, while apoptosis was protected when a lower concentration of 
dexamethasone (10-10 and 10-9 mol/L) was used. Seong et al., (2010) observed that both 
concentrations have been used by researchers and reported no difference in the effects 
on cells whereas Alm and colleagues (2012) noted 100 nM dexamethasone treatment for 
1 week reduces intra- and inter-donor variation during osteogenesis. Walsh et al., (2001) 
stated that the optimal concentration of dexamethasone to achieve proper mineralisation 
of bone nodules is similar to the physiological concentration of glucocorticoids (10 nM). 
AA is an enzymatic cofactor for the hydroxylation of lysine and proline in pro-collagen 
(Vater et al., 2011). In the absence of ascorbic acid,  proline hydroxylation processing 
does not occur which leads to improper helical structure of the collagen chain 
(Langenbach and Handschel, 2013). βGP is considered as a source of inorganic phosphate 
for bone-like hydroxyapatite mineral synthesis and facilitates osteogenic induction 
(Chang et al., 2000; Langenbach and Handschel, 2013). In routine culture of MSCs for 
bone formation cells are subjected to the combination of Dex, AA and βGP and this termed 
‘osteogenic media’. Therefore, in this study I examined the effects of these supplements 
separately and combined. The metabolic activity in most of the experiments described 
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for cells cultured in XF2 was higher. AA and βGP support high proliferation of hBMSCs, 
more importantly, the concentration of both AA-2-Ph and βGP may promote proliferation 
without a reciprocal reduction of differentiation potential indicating that MSC 
proliferation or differentiation seems to depend on the concentration of ascorbic acid. 
Choi and co-workers (2008) reported that the proliferation and cell differentiation 
depends on the AA concentration, the absence of cell density reduction is consistent with 
metabolic activity, and the toxicity recognised with 5-250 µM concentrations of AA. The 
results here showed that the combination of human-derived ingredients and (AA 50 µM 
and βGP 10 mM) components indicated to accelerate the hBMSCs growth over the all 
groups. Where Dex, AA, and βGP are combined and added to the media this is termed 
‘osteogenic media’ while AA and βGP are combined and added to the media, this is termed 
‘non-osteogenic media’ throughout this thesis. The metabolic potency of cells in 
osteogenic media containing dexamethasone at 10 nM was approximately the same as 
results of non-osteogenic media on 4 and 7-day.  
As well as assessing cell number by resazurin assay of metabolic activity, I used a DNA 
assay to assess cell number at a specific end-point. The advantages of the DNA assay are 
that the amount of DNA per cell for a given cell type should be constant and it would not 
be affected by factors that may affect metabolic rate within cell culture. However, the DNA 
assay does not reflect the health of the cells and would measure dead cells if they are still 
present in the culture. Therefore, it is helpful to include both assays to get an overall 
picture of the cell number in a culture situation. In these experiments, some cell culture 
wells did not contain sufficient measurable levels of DNA and were below the detection 
limit of my assay therefore these are not included in the data reported. All donors and 
passages cells cultured in XF2 basal culture medium with or without supplements 
contained more DNA and therefore more cells then when cells from the same donors and 
passages were cultured other media. Most significantly, for the passages 1, 3, 4 and 1, 2 
cells supplemented with Dex at 10 and 100 nM respectively with all donors. The DNA 
results verified the metabolic activity data showing that XF2 media supported higher cell 
number. In osteogenic media, the cellular DNA quantity was also affected by Dex 
concentration. The results showed that decreased DNA content is consistent with the 
increase of Dex concentration. It is known that Dex inhibits hBMSCs proliferation and 
increases osteogenic differentiation. Overall, results may provide strong evidence that 
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xeno-free media and particularly XF2 can augment the quantity of DNA. Furthermore, 
XF1 did not support good cell growth in terms of total DNA in a donor-4. 
The results of resazurin metabolic activity tests and DNA assay indicated that XF2 was 
having a strong effect on proliferation, however neither of these assays directly measure 
cell proliferation. Therefore, to investigate this hypothesis I used the EdU test on selected 
samples. EdU is a nucleoside thymidine analogue that incorporates into the DNA during 
functional DNA synthesis. Cell culture in human-derived media, particularly XF2 showed 
two out of three donors underwent faster cell proliferation. In donor 3 this effects were 
only observed using XF2 which induced higher cell proliferation than 10% (v/v) FBS. As 
described by Oikonomopoulos et al., (2015), who used 10% (v/v) HPL, media can 
increase the cell proliferation of hBMSCs as measured by BrdU incorporation rate. 
Interestingly, my results are in agreement with this data although XF2 culture medium 
showed an even better ability to induce proliferation compared to 5% (v/v) HPL. 
Therefore, this study agrees with Oikonomopoulos et al., (2015) that the xeno-free media 
is a promising substitute for animal-derived media, reducing the number hBMSCs needed 
and the manufacturing time. 
3.12 Conclusions 
My results indicate that media containing human serum can have a significant impact on 
hBMSCs behaviours, such as proliferation, expansion, and cell metabolic activity. 
Metabolic activity of hBMSCs was weakest in stem x vivoTM xeno-free human MSC 
expansion media (XF1). However, human mesenchymal-XF expansion medium (XF2) was 
able to enhance metabolic activity and support proliferation of hBMSCs strongly 
compared to the standard media conditions commonly used in the media of 10% (v/v) 
FBS. 5% (v/v) human platelet lysate also supported hBMSCs proliferation with increased 
the amount of DNA although not well as XF2. 
Importantly, both 5% (v/v) HPL and XF2 are a therapeutically meaningful pre-clinic 
media and a safe substitute for FBS proliferation, expansion. I further identify that XF2 
may be a trustworthy medium in which to grow human mesenchymal stem cells for 
clinical bone repair such as repairing of the bone defect in cleft palate. 
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3.13 Summary of results  
A significant factor in the success of tissue engineering is the cell source and culture 
medium chosen, which should enhance the cell growth potential. This chapter aimed to 
evaluate suitable xeno-free culture conditions for both hBMSCs and HJPs for increasing 
the proliferation and encouraging a new DNA synthesis with maintenance of cells potency 
to undergo osteogenic differentiation, with the long-term aim of establishing xeno-free 
cultures for clinical applications of cleft palate repair. From these studies, I established 
that; 
 A suitable commercially available xeno-free media for proliferation compared to 10% 
(v/v) FBS is human mesenchymal-XF expansion medium (XF2) which contains 2% 
(v/v) human serum then basal media containing 5% (v/v) human platelet lysate. 
Thus, these were used as an alternative media compared to 10% (v/v) FBS. 
 XF2 augmented the metabolic activity and enhanced the DNA quantity of hBMSCs 
compared to any other culture condition tested here.  
 XF2 may be a useful xeno-free pre-clinical medium for the expansion and proliferation 
of hBMSCs towards therapeutically bone differentiation for tissue engineering 
applications. 
 It was confirmed that suitable concentration of Dex for hBMSCs is 10 nM that induces 
the highest cell maintenance, while the 100 nM of Dex concentration causes a 
reduction in cell number. 
 A low concentration of animal serum supplemented with ITS did not well support the 
cell proliferation. Therefore, I discontinued this for further experiments. 
 Donor variability, media composition and supplements all contributed a vital role in 
determining cell proliferation, preservation cell potency and DNA synthesis. 
 There is lower metabolic activity with increased passage number.  
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CHAPTER FOUR: EVALUATION OF THE ABILITY OF ANIMAL-FREE 
COMPONENT CULTURE MEDIA TO SUPPORT DIFFERENTIATION OF 
OSTEOGENIC PRECURSOR CELLS  
4.1 Introduction 
Osteogenic differentiation medium is treated with ascorbic acid-2-phosphate (AA), β-
glycerophosphate (βGP), and dexamethasone (Dex) (required for osteogenic 
differentiation). (AA) is essential for producing stable collagen that is a substantial 
component of the extracellular matrix (ECM) of bone. (βGP) is essential for providing an 
inorganic phosphate during mineralisation of ECM by differentiated cells. Dex is a 
synthetic glucocorticoid drug that can stimulate the osteogenic differentiation of hBMSCs 
(Coelho and Fernandes, 2000). Recently, cell therapy and tissue-engineering application 
have been performed in dental regenerative surgery to repair the soft tissue damage and 
skeletal defects to considerable attaint outcomes.  
HJPs have been identified as auspicious provenance cells of osteogenesis (Kawase et al., 
2009). The remarkable characteristics of HJPs are described: (1) deposition of ECM 
(Uematsu et al., 2013). (2) Support the osteogenesis through the significant achievement 
of osteogenic cell differentiation. (3) Promising origin of osteoinduction. (4) significant 
sources of growth factors that control the metabolism of bone (Kawase et al., 2009). (5) 
HJPs can be still functionally active in the ageing donor over hBMSCs (Kawase et al., 
2014). The isolation of HJP is achieved from an aseptically dissection of a healthy buccal 
region of the different part of the oral cavity, particularly during the surgical removal of 
third molars and retromolar area of the mandible. Then the cells collections are grown in 
10% (v/v) FBS. 
The purposes of work in this chapter were to find out whether the various media 
examined in chapter 3 can support differentiation of hBMSCs and HJP cells and to obtain 
preliminary data about the induce of osteogenesis in HJPs. All experiments were 
performed using the experimental set up described in chapter 3, in standard 2D 
monolayer. The long-term aim is to establish xeno-free culture protocols capable of 
supporting bone matrix production and angiogenesis for future clinical applications in 
craniofacial repair. In order to do this, I set out the following objectives; 
139 | P a g e  
 
1. To determine whether xeno-free media that have been predominantly advertised as 
promoting cell expansion are suitable for the cell types, hBMSCs and HJPs, and also 
affect osteogenic differentiation with and without the commonly used osteogenic 
supplement combinations Dex, AA and βGP.  
2. To elucidate whether animal component free media can support extracellular matrix 
production of osteogenic cells by measuring collagen and calcium production. 
3. To determine whether HJPs may be an alternative cell source to bone marrow MScs 
by assessing their differentiation potential under the same conditions. 
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4.2  The effects of two different xeno-free basal culture medium on ALP assay of 
different donors  
ALP activity was measured to indicate whether cells were progressing along the 
osteogenic differentiation pathway. This was undertaken using four adult donors 
(Chapter 2, Table 2.2.3) on day 10. These experiments were performed to compare the 
osteogenic potential of XF1 and XF2 compared to standard 10% (v/v) FBS supplemented 
media.   
Although animal-derived serum supplements are commonly used for osteogenic 
differentiation in in vitro, lower ALP activity was seen in 10% (v/v) FBS compared with 
XF2, even when no osteogenic supplements were added. Three out of four donors 
cultured in XF2 had higher ALP activity in XF2 versus 10% (v/v) FBS and for donors 1 
and 3 this was statistically significant. Although ALP activity in cells from donors 1 and 3 
was higher than for donor 2, cells from donor 2 also exhibited significantly higher ALP 
activity in XF2 compared to other basal culture media. Cells cultured in 10% (v/v) FBS 
and XF1 had low ALP activity, and there was no significant difference between them (P < 
0.05) (Figure 4.2). 
Overall, the human-derived serum growth supplements (XF2) appeared to stimulate 
osteogenic differentiation over the animal-derived serum and the other human-derived 
plasma media formulation (XF2) on day 10.  




















































Figure 4.2: Normalized ALP activity of hBMSCs from different adult donors cultured with two 
commercial human-derived basal culture media compared with 10% (v/v) animal-serum 
concentration on monolayer on day 10. Each point represents a single well and the horizontal 
bar indicates Mean±SD for each donor in that condition. (*) Higher than the other donors 
in the same medium. (#) Significantly lower. (Φ) Significantly higher than all the other 
conditions. (ns) There is no significant difference (P <0.05). n=3. Two-way ANOVA, Tukey’s 
multiple comparison tests. 
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4.3 The effects of dexamethasone alone on osteoinduction of hBMSCs 
The culture media was treated with two dose dependent concentrations of Dex 10 and 
100 nM to test whether there is an osteogenic effect of Dex alone on the ALP production 
in hBMSCs. 
Within the groups treated with only Dex at 10 nM the differences in ALP due to the 
different media compositions was similar to that in Basal Media. In human-derived serum 
supplementation (XF2), three out of four donors had higher ALP activity. Although the 
donor-3 presented statistically higher ALP compared to the other donors cultured in XF2 
and other media, it was not significantly different from donor-2 (P < 0.05) (Figure 4.3). 
Because it was not known whether the different media compositions would lead to the 
need for a different concentration of Dex all ALP experiments were also performed with 
100nM Dex. Within the groups treated with 100nM Dex three out of four donors cultured 
in 10% (v/v) FBS and XF2 had upgraded ALP activity. While two out of four cultured in 
XF1 showed elevated ALP activity. Cells from donor-2 had higher ALP activity compared 
to the other donors in 10% (v/v) FBS, and cells from donor-2 cultured in XF2 had 1.5-fold 
and 4-fold ALP compared with 10% (v/v) FBS and XF1 respectively. All donors cultured 
in 10% (v/v) FBS and XF1 exhibited no significant effects of supplement or differences 
between each other. The amount of ALP secretion in donor-1 cultured in XF2 showed 4.5-
fold and 1.5-fold increase compared with 10% (v/v) FBS and XF1 respectively. Whereas 
donor-3 cells cultured in XF2 increased ALP activity around 4.5-fold and more compared 
with 10% (v/v) FBS and XF1 respectively (Figure 4.3). 
Overall, although Dex had a small effect on the promotion of ALP activity in hBMSCs 
compared to basal media without supplements, there was no significant difference. 
Indicating that Dex alone is not sufficient to induce differentiation. 
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Table 4.3: The effect of dose dependent dexamethasone (containing Dex 10 nM and 100 
nM) on normalised ALP activity within the media groups examined. “Higher” indicates 
Dex caused significantly higher ALP activity when comparing data in figure 4.2. “Lower” 
indicates osteogenic-inductive medium caused significantly lower ALP activity and “NS” 
indicated no significant difference between Dex compared with BCM within this group. 
Media-Donors 
Dex (nM) 
Donor 1 Donor 2 Donor 3 Donor 4 
10  100 10  100 10  100 10  100 
10% (v/v)FBS NS NS NS NS NS Higher Higher Lower 
XF1 Higher NS NS Higher NS NS NS NS 
XF2 NS Lower NS Higher Higher Higher NS Lower 














Figure 4.3: Normalized ALP activity of hBMSCs from different adult donors cultured on two commercial human-derived basal culture 
media compared with 10% (v/v) animal-serum concentration were treated with Dex 10 and 100 nM on monolayer on day 10. The 
scatter dot plot manifests mean and standard deviation for each condition. (#) Significantly lower. (ns) There is no significant 
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4.4  The effects of two different xeno-free basal culture medium supplemented with 
AA 50 µM, and βGP 10 mM on osteoinduction of different donors 
The culture media was treated with AA 50 µM and βGP 10 mM alone, this was to test 
whether dexamethasone supplementation was necessary to support osteogenic 
differentiation in the xeno free media. AA 50 µM and βGP 10 mM support bone matrix 
formation but they are not expected to stimulate ALP at day 10. As seen in the other 
conditions three out of four donors cultured in the human-derived serum supplements 
had higher ALP activity compared to other media with the same supplements. Donor-2 
cultured in XF1 had significantly higher 7-fold ALP activity than cells from the other 
donors that was not seen in the basal conditions. All cells cultured in animal-derived 
serum supplementations had a little ALP activity, and there was no significant difference 
between them. The highest ALP activity was seen in cells from donor-2 cultured in XF2 
that was significantly different from all other donors that were cultured in both the same 
and different culture media, it had about 18.5-fold increase of ALP activity over the 10% 
(v/v) FBS and approximately 3-fold compared with XF1. Both cells from donor1 and 
donor-3 cultured in XF2 also exhibited a high ALP activity, about 13-fold compared with 
these cells cultured in XF1 and 10% (v/v) FBS (P<0.05) (Figure 4.4). 




















































Figure 4.4: Normalized ALP activity of hBMSCs from different adult donors cultured on two 
commercial human-derived basal culture media compared with 10% (v/v) animal-serum 
concentration were treated by AA 50 µM and βGP 10 mM on monolayer on day 10. The scatter 
dot plot manifests mean and standard deviation for each condition. (*) Higher than the 
other donors in the same medium. (#) Significantly lower. (Φ) Significantly higher than all 
the other conditions. (ns) There is no significant difference (P <0.05). n=3. Two-way ANOVA, 
Tukey’s multiple comparison tests. 
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4.5 Effect of full complement of osteogenic-inductive substances on ALP activity of 
hBMSCs on 2D monolayer 
The most standard mixture of osteogenic supplements used for hBMSCs is Dex, AA, and 
βGP, therefore the three media were supplemented with this combination after 24 hours 
of culture when the cells were entirely attached on the well plate. ALP was measured at 
day 10. 
Osteogenic-inductive substances with Dex 10 nM, as expected ALP activity increased 
overall in osteogenic media Three out of four donors cultured in the human-derived 
serum supplements (XF2) had higher ALP activity than in other media. Additionally, 
donor-2 cultured in XF1 had higher ALP activity compared to in 10% (v/v) FBS and 
significantly higher than the other donors which were cultured in the same medium. The 
ALP activity increased about 12-fold compared with the same donor cultured in animal-
derived serum supplementations. Although there was a nearly 2.5-fold increase of ALP 
activity compared with the same donor and donor-3 cultured in XF2, there was no 
significant difference among them. Likewise, the ALP activity rose about 5-fold and 
experienced a statistically significant difference compared with donor-1 cultured in XF2. 
Whereas the all donors cultured in animal-derived serum supplementations had a little 
ALP activity, and there was no significant difference among them. Even though the three 
out of four donors cultured in XF2 had high ALP activity approximately 10-fold over their 
donors cultured in 10% (v/v) FBS, they had no significant difference among them 
(P<0.05) (Figure 4.5). 
To check whether a higher dose of Dex was needed in the osteogenic differentiation 
media to stimulate ALP 100 nM Dex was also applied to the cells. Donor-2 cultured in all 
different medium exhibited an upward trend of ALP activity. Besides, cells cultured in 
XF2 presented a significant increase of ALP compared to cells that all donors were 
cultured in the same media and other media. Although ALP was nearly 1.25-fold higher 
than for cells cultured in XF1, there was no significant difference. 
Additionally, ALP activity increased 10 times compared to culture in 10% (v/v) FBS and 
9 times compared with donor-3 cultured in the XF2. Whereas the donor-3 cultured in XF2 
showed the augmentation of ALP activity nearly 3 times and more compared with when 
was cultured in 10% (v/v) FBS and XF1 respectively. Donor-2 cultured in XF1 had about 
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8-fold increase of ALP activity and more compared with its donor and with other donors 
cultured in 10% (v/v) FBS respectively. While there was no significant difference 
throughout all the donors cell that were cultured in 10% (v/v) FBS (P<0.05) (Figure 4.5). 
Overall, within the osteogenic supplemented groups the human-derived serum growth 
supplements (XF2) supported the hBMSCs to osteogenic differentiation better than the 
animal-derived serum supplements, although there is high door variability in this 
response. 
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Table 4.5: The effect of osteogenic media (containing Dex 10 nM and 100 nM) on normalised ALP activity within the media groups 
examined. “Higher” indicates osteogenic-inductive medium caused significantly higher when comparing data in figure 4.2. “Lower” 
indicates osteogenic-inductive medium caused significantly lower ALP activity and “NS” indicated no significant difference between two 






Donor 1 Donor 2 Donor 3 Donor 4 
10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 
10% 
(v/v)FBS 
NS NS NS NS NS Higher Higher NS 
XF1 Higher NS NS Higher NS NS NS NS 
XF2 NS Lower NS Higher Higher Higher NS Lower 














 Figure 4.5: Normalized ALP activity of hBMSCs from different adult donors cultured on two commercial human-derived basal culture 
media compared with 10% (v/v) animal-serum concentration were treated by Dex 10 and 100 nM, AA 50 µM, and βGP 10 mM on 
monolayer on day 10. The scatter dot plot manifests mean and standard deviation for each condition. (Φ) Significantly higher than 
all the other conditions. (*) Higher than the other donors in the same medium. (#) Significantly lower. (ns) There is no significant 
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4.6  Appraisal of extracellular matrix formation 
One of the most important aims of the experiments in this chapter was to assess the late 
stage of osteogenic differentiation of hBMSCs to examine their bone-like matrix 
production.  
I investigated both the calcium formation and collagen deposition for detection of the 
extracellular matrix formation by cells from the four adult donors with different passages 
on day 21. Because cells grown in XF1 showed disappointing results in both the 
proliferation and differentiation assays these experiments were not performed with XF1. 
However due to its promising effects on cell proliferation shown in chapter 3 selected 
cells were supplemented with 5% (v/v) HPL to compare this to the other media 
formulations. 100nM Dex was not used in this set of experiments as it had not shown any 
beneficial effect on ALP activity and inhibited proliferation for some donor types. 
4.6.1 Effect of varying media components and supplements on collagen production of 
hBMSCs 
Although animal-derived serum supplements are commonly used for osteogenic 
differentiation and collagen formation in in vitro, there was lower collagen production 
compared with cells grown in human-derived growth supplementation particularly in 
XF2 in basal culture media.  
In basal media the amount of collagen production by both donor-1 and donor-3 cells 
cultured in XF2 and 5% (v/v) HPL was higher, about 3-fold, compared with the same 
donor cells cultured in 10% (v/v) FBS. Whereas cells from donor-4 deposited about 9-
fold and 2.5-fold more collagen in XF2 media compared with in 10% (v/v) FBS and 5% 
(v/v) HPL respectively (Figure 4.6.1 A). 
In culture media treated with Dex 10 nM alone all donors cultured in the human-derived 
growth supplementations had higher collagen production compared with animal-derived 
serum supplements. However, they were no significant difference between them. 
Although donor-4 cells produced less collagen than all others donor cells cultured in 
human-derived growth media, they still produced statistically more collagen compared 
with any donor cells cultured in 10% (v/v) FBS. Whereas the donors cultured in 10% 
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(v/v) FBS had lower collagen formation, and there was no significant difference among 
them (P<0.05) (Figure 4.6.1 B). 
When the culture media was treated with AA 50 μM and βGP 10 mM donor-4 cells again 
exhibited lower collagen formation, however when these were cultured in XF2 the 
collagen formation was improved about 3-fold compared to the same donor cultured in 
either 5% (v/v) HPL or 10% (v/v) FBS. Moreover, cells from both donor-1 and donor-3 
cultured in all different media produced high amount of collagen and this was 
significantly higher than for donor-4. Furthermore, cells cultured in 5% (v/v) HPL 
showed significantly higher collagen production compared with all other donors cultured 
in different media (P<0.05) (Figure 4.6.1 C). 
The culture media was treated with the osteogenic supplementations that are Dex 10 nM, 
AA 50 µM, and βGP 10 mM. Both donor-1 and donor-3 cultured in the human-derived 
growth supplements upregulated collagen formation, significantly higher than donor-4 
cultured in the same medium, and all donors cultured in animal-derived serum 
supplementations. Collagen production increased about 4-fold compared with the donors 
cultured in animal-derived serum supplementations. For cells cultured in 5% (v/v) HPL, 
collagen formation was about 3-fold higher compared to donor-4 cultured in the same 
medium. While for cells cultured in XF2 collagen deposition was about 2-fold higher 
compared to donor-4 cultured in the same medium (P<0.05) (Figure 4.6.1 D). 
Overall, the human-derived growth media treated by various supplements supported the 
hBMSCs to produce collagen and enhance the extracellular matrix over the animal-
derived serum supplementation when assayed on day 21. Notably, the effect of donor and 
varieties of media played a vital role in enhancing the late osteogenic cell differentiation 
via promoting the cells to form the collagen. 
 
































































































Figure 4.6.1: Collagen formation by hBMSCs as measured with Sirius Red in day 21, 
cultured in three different media. The scatter dot plot manifests mean and standard 
deviation for each condition. (*) Significantly Higher than the other donors in the 
same medium. (#) Significantly lower. (ns) There is no significant difference (P 
<0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
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4.6.2 Effect of varying media components and supplements on calcium deposition of 
hBMSCs 
In the basal culture media. Although the animal-derived serum supplements are often 
used for osteogenic differentiation and calcium deposition in in vitro, there had lower 
calcium deposition compared with cell in human-derived growth supplementation. Thus, 
two out of three donors cultured in XF2 and 5% (v/v) HPL were statistically higher 
throughout all donors cultured in 10% (v/v) FBS and donor-4 cultured in both XF2 and 
5% (v/v) HPL. 
The amount of calcium deposition in donor-1 cultured in XF2 showed an increase of about 
2.5-fold and 16-fold compared with two out of three donors and donor-4 cultured in 10% 
(v/v) FBS. Whereas donor-4 cultured in XF2 increased calcium deposition about 5-fold 
compared with the same donor cultured in 10% (v/v) FBS and 5% (v/v) HPL. Donor-1 
and donor-3 cells cultured in 5% (v/v) HPL both improved the calcium deposition nearly 
1.5-fold compared with the same donors cultured in 10% (v/v) FBS. The donors cultured 
in 10% (v/v) FBS and donor-4 cultured in 5% (v/v) HPL exhibited low calcium 
deposition, and there was no significant difference between them (P<0.05) (Figure 4.6.2 
A). 
The culture media was treated with Dex 10 nM. Two out of three donors cultured in the 
human-derived growth supplementations increased the calcium deposition compared 
with other donors cultured in the same media and animal-derived serum supplements. 
In addition, they showed an increase of calcium deposition around 3-fold and 6-fold over 
the same donors and donor-4 cultured in 10% (v/v) FBS respectively. Whereas all the 
donors cultured in 10% (v/v) FBS had low the calcium deposition, donor-1 displayed a 
significant difference compared to donor-4, while it was shown no significant difference 
with donor-3 (P<0.05) (Figure 4.6.2 B). 
The culture media was treated with AA 50 µM and βGP 10 mM. Although the donor-4 
cultured in different conditions had low calcium deposition, cells cultured in XF2 calcium 
deposition was about 2.5-fold higher over the same donor cultured in both 5% (v/v) HPL 
and 10% (v/v) FBS. Moreover, both donor-1 and donor-3 cultured in all different media 
had high calcium deposition and significantly higher than donor-4. The donor-1 cultured 
in animal-derived serum supplementations significantly upgraded calcium deposition 
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nearly 1.5-fold and 11-fold over the donor-3 and donor-4 cultured in the same medium 
respectively (P<0.05) (Figure 4.6.2 C). 
The culture media was treated with the osteogenic supplements are Dex 10 nM, AA 50 
µM, and βGP 10 mM. Both donor-1 and donor-3 cultured in the human-derived growth 
supplements had higher calcium deposition and were significantly different compared to 
the donor-4 cultured in the same medium and all donors cultured in animal-derived 
serum supplementations. However, there was no significant difference between them. 
Furthermore, calcium deposition increased about 3-fold compared with the donors 
cultured in animal-derived serum supplementations. Cells cultured in 5% (v/v) HPL 
increased the calcium deposition about 7-fold over donor-4 cultured in the same medium 
(P<0.05) (Figure 4.6.2 D). 
Overall, the human-derived growth media treated by various supplements supported the 
hBMSCs to produce the calcium deposition and extracellular matrix compared to the 
animal-derived serum supplementations particularly when supplemented with AA 50 
µM, and βGP 10 mM on day 21. 
 
Table 4.6.2: The effect of osteogenic media on collagen formation and calcium deposition 
within the media groups examined. “Higher” indicates osteogenic-inductive medium 
caused significantly higher. “Lower” indicates osteogenic-inductive medium caused 
significantly lower, and “NS” indicated no significant difference of OM-10 compared with 
BCM within this group. 
Media-Donors 
Donor 1 Donor 3 Donor 4 
Collagen Calcium Collagen Calcium Collagen Calcium 
10% (v/v) FBS NS NS NS NS NS Higher 
XF2 Higher NS NS NS Lower  Lower  
5% (v/v) HPL NS NS NS Higher NS Higher 
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Figure 4.6.2: The calcium deposition of hBMSCs cultured on an animal-derived serum 
supplementation, and commercial human-derived basal culture medium measured by 
alizarin red staining on monolayer on day 21. The scatter dot plot manifests mean and 
standard deviation for each condition. (Φ) Significantly higher than all the other 
conditions. (*) Higher than the other donors in the same medium. (#) Significantly 
lower. (ns) There is no significant difference (P <0.05). n=3. Two-way ANOVA, Tukey’s 
multiple comparison tests. 
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4.7 Evaluation of varying supplementation on ALP activity of a monolayer cultured 
HJPs 
For human jaw periosteal cells (HJPs), the amount of ALP activity in BCM-XF1 was a 
noticeably significantly higher than in other BCM, 29-fold and 5-fold compared with 10% 
(v/v) FBS and XF2 respectively. Whereas the XF2 increased the ALP activity nearly 5.5-
fold over the 10% (v/v) FBS (P<0.05) (Figure 4.7), what basal culture media was treated 
by varying dexamethasone concentrations the XF1 medium again supported the highest 
ALP activity but only in Dex 10 nM, 11-fold and 4-fold compared with 10% (v/v) FBS and 
XF2 respectively (P<0.05) (Figure 4.7). 
In basal culture media treated by AA 50 µM and βGP 10 mM. ALP activity in XF1 also 
appeared to be higher than for other conditions however, there was no significant 
difference between them. While the amount of ALP activity in BCM-XF1 appeared 
significantly higher than XF1 treated by AA and βGP only. 
In osteoinductive, media with different dexamethasone supplements ALP was 
surprisingly lower with no clear effect of media although Dex 100nM supported higher 
ALP than Dex 10nM. Whereas, all groups supplemented with osteogenic reagents had 
significantly lower of ALP activity compared with BCM-XF1. 
  






























































































































































































Figure 4.7: Normalized of ALP activity of HJPs cultured on two commercial human-
derived basal culture media compared with 10% (v/v) animal-serum concentration on 
monolayer on day 10. The bar manifests mean and standard deviation for each 
condition. (*) Significantly higher than the other media at all-time points. (Φ) 
Significantly higher than all the other conditions. (ns) There is no significant 
difference (P <0.05). n=3. ANOVA, Brown-Forsythe test. Moreover, two-way ANOVA, 
Tukey’s multiple comparison tests. 
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4.8  Discussion 
Bone tissue engineering presents a considerable opportunity for clinical cleft palate 
repair. The essential ingredients for this strategy to be effective are the osteoinductive 
cell source and the biochemicals for bone formation. Bone marrow derived cells have 
demonstrated therapeutic potential for the treatment of cleft palate and other disorders 
and diseases because they contain a subpopulation of cells called “precursor cells” which 
have the natural ability to differentiate toward bone formatting cells (Coelho and 
Fernandes, 2000; Manolagas, 1995) and also present self-renewal capacity with multi-
potency (Solmesky et al., 2010). 
 The aims of this chapter were to identify whether the various xeno-free culture condition 
can support osteogenic differentiation of cells including hBMSCs and HJPs. ALP activity 
and mineralisation tests analysed the capacity of osteogenic induction. In early stages of 
hBMSCs osteogenic differentiation ALP activity increases, while later stages are marked 
by the formation of collagen type 1 and calcium phosphate deposition. The peak in ALP 
activity was clearly seen in three out four donors when cultured in the XF2 basal culture 
media. Donor-3 cultured in XF2 demonstrated the highest ALP activity over all donors 
cultured in different basal culture media. Contrary to expectations, the amount of 
osteogenic differentiation was the lowest in 10% (v/v) FBS basal media as measured by 
ALP activity. Where supplements were applied separately, dexamethasone had effects on 
osteogenic induction by the elevated ALP activity either used alone (Fig 4.3) or combined 
with AA and βGP (Fig. 4.5). The inductive effect of non-osteogenic media was most 
evident in XF2 cultures and resulted in increased ALP activity, even without osteogenic 
supplements.  
Prior researchers have established the importance of AA-2PH and βGP in the osteogenic 
differentiation of hBMSCs and osteoblast formation (Choi et al., 2008; Takamizawa et al., 
2004; Wang et al., 2012). βGP plays a crucial role in providing phosphate for 
mineralisation by differentiation of hBMSCs to the osteogenic lineage. However,  βGP 
supplementation can lead to false-positives by enabling chemical (non-cell-controlled) 
mineralisation via precipitation of calcium phosphate salts, that it means the 
investigation result improperly indicates the presence of osteogenic differentiation 
(Langenbach and Handschel, 2013). The concentration of dexamethasone plays a crucial 
role to induce the initial osteogenesis. However, over the long term Dex in high 
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concentrations has shown to suppress the osteogenic lineage (Wang et al., 2012) whereas 
low concentrations of Dex seem to be necessary for the efficient osteoinduction of MSCs 
(Atmani et al., 2002; Wang et al., 2012) this may be related to its suppression of collagen 
formation in many studies. In this study, variation between individuals was notably 
observed in ALP activity. Jaiswal and his colleagues (1997) detected that the level and 
peak time of ALP varied remarkably between different donors regardless of donor age. 
Similar results have been observed with human adipose stem cells (Bieback et al., 2012; 
Zuk et al., 2011). The microenvironment of culture medium compositions may 
significantly affect the results, the heterogeneity of the sample, the variation in the 
composition during aspiration and committed progenitor’s population (Siddappa et al., 
2007). The other possibility of interpretation is that differential procedure, and various 
physicians collecting the bone many may result in different heterogeneity (Phinney et al., 
1999a). 
In the present study, in my initial tests it became clear that the constituents of XF1 were 
insufficient to differentiate the hBMSCs towards the osteogenic lineage. Therefore, I used 
5% (v/v) HPL as an alternative to XF1 basal culture medium. Higher calcium deposition 
and collagen formation were detected in human-derived media alone with and without 
supplementation compared to animal serum components. Notably, the results showed 
that the cells from two out of three individual donors cultured in human-derived media 
exhibited an elevation in in vitro mineralisation and more ECM compared with 10% (v/v) 
FBS. Donor 4 cells cultured in 5% (v/v) HPL had weak ECM formation, while they 
produced even less ECM when cultured in XF2. Human-derived growth media treated by 
various supplements enabled the hBMSCs to form collagen and deposit calcium and 
enhance extracellular matrix formation compared to animal-derived serum 
supplementation, which was measurable by day 21. However, in the same donor, there 
was no significant effect of the supplementations for augmenting the calcium deposition 
and collagen formation. The variability between donors show that there may be 
differences due to the variety of physiological behaviours and clinical background of the 
patients (Siddappa et al., 2007). 
The components of the XF2 media have not been disclosed by the company but it contains 
2% (v/v) human serum in which there is likely to be extracellular matrix elements 
including vitronectin, hyaluronic acid, fibronectin, and other components, which permit 
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cell attachment, prevent apoptosis (Uhm et al., 1999) and support mineralisation. 5% 
(v/v) HPL is also a successful medium for mineralisation and this may be because it 
contains the alpha granules which are a fundamental source of growth factors. 
Periosteal-derived jaw cells have osteogenic potential and can also be considered as a 
suitable cell source for tissue engineering. In a clinical setting, the principal advantages 
of using the periosteum for bone tissue engineering are that it is comparatively accessible 
and easy to collect (Park et al., 2008; Young-Mo Ryu et al., 2011). There are limited 
previous studies on the use of xeno-free culture formulations for osteogenic 
differentiation of HJPs. Therefore, I cultured HJPs in two types of xeno-free culture media. 
The limitation of this study was that accomplished only one experiment in triplicate and 
only assessed the early-stage marker of osteogenic differentiation, ALP. However, some 
interesting information was obtained. HJP cell morphology in three different basal 
culture media was similar with cells exhibiting a small, spindle-shaped and characteristic 
fibroblast-like morphology, they were flattened. The HJPs attachment was the same in all 
conditions at 24 hours. As shown for hBMSCs the media XF1 was not able to support the 
cells over long-term culture. Although a significant difference was observed in XF1 
compared to 10% (v/v) FBS basal medium on day 4, there were much lower numbers of 
cells when cultured in XF1 at day 7 (chapter 3). The cell number of HJPs was higher with 
Dex 10 nM supplementation compared to the same medium supplemented with 100 nM 
in which the cells distinctly dropped in numbers by the end of the period. This result 
indicated that the higher Dex concentrations were toxic to the cells. HJP cells have 
recently utilised in several researchers as the alternative sources for bone regeneration 
because they have the osteogenic progenitor cells (Samee et al., 2008). Marolt and his 
colleagues (2010) and Cicconetti and co-workers (2007) informed that HJPs extracted 
from the patients' jaws expressed nearly the same surface markers of MSC. While 
Akintoye and his groups (2006, 2003) mentioned that in their assessment of periosteal 
cells site-specific markers expression varied, added facts that the development of 
craniofacial bones differ from the other bones formation in the body (Simonds et al., 
2002). The existence of orofacial periosteal surface markers variations is based on the 
basic anatomy of extraction sites and donors’ variableness and is affected by issues such 
as donor tissue-samples age, health and habit. My studies indicated that HJPs produced 
higher levels of ALP activity than the hBMSCs indicating that the HJPs may be more 
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responsive to osteogenic induction than hBMSCs. It will be essential to understand 
whether HJPs extracted from the mature donor could have a subpopulation of cells that 
undergo osteogenic differentiation in vitro (Arnold I. Caplan, 2005). hMSCs derived from 
bone marrow have been demonstrated to contain a heterogeneous populations of cells in 
terms of their osteoinduction potential (Akintoye et al., 2006; Anagnostou et al., 2005). 
MSCs cell surface marker expression can be different based on the harvested sites; for 
example the observation that MSCs from craniofacial bone marrow display better 
osteogenesis and regenerative capacity compared to iliac crest hBMSCs (Akintoye et al., 
2006; Osyczka et al., 2009). Orofacial bone marrow comprises a smaller amount of 
hematopoietic marrow precursors and tissue than iliac bone marrow. Park et al., (2012) 
performed comparisons of four different cell sources from rabbits; mandible bone 
marrow and periosteum, tibia bone marrow and periosteum. They found that these cells 
all had potential to be stem cells in vitro. Their study indicated that periosteum from the 
mandible exhibited the highest osteoblastic lineage differentiation.  
Chen and co-workers (2011) analysed the osteogenesis induction between human MSCs 
extracted from both periosteal and bone marrow harvested from at the same donors and 
site, they saw that the periosteal MSCs had expressed more osteogenic genes such as 
BMP-2, OPN and OCN with high mineralization potential compared to hBMSCs. HJPs 
might be implemented as an alternative of autologous cells in cleft palate healing because 
they have capacity for promoting osteogenically induction in vitro which is an important 
step for pre-clinical application. Accordingly, it would be interesting in future studies to 
investigate the osteogenesis of HJPs from adult and child donors to compare their ability 
to act as a cell source for tissue engineering. 
  
163 | P a g e  
 
4.9  Conclusions 
My results indicate that human serum has a significant impact on hBMSCs osteogenic 
potency. Osteogenic differentiation of hBMSCs was weakest in stem x vivoTM xeno-free 
human MSC expansion media (XF1). However, human mesenchymal-XF expansion 
medium (XF2) was able to enhance and support osteogenic differentiation of hBMSCs 
more strongly compared to the standard media conditions commonly used in the media 
of 10% (v/v) FBS. Although in standard FBS conditions osteogenic components are 
essential for differentiation along the osteogenic lineage, the human mesenchymal-XF 
expansion medium has measurable effect on osteogenesis even without osteogenic 
supplements compared to the 10% (v/v) serum medium. 5% (v/v) human platelet lysate 
also supported hBMSCs differentiation to the osteoblast cells. 
Importantly, both 5% (v/v) HPL and XF2 are a therapeutically meaningful pre-clinic 
medium and a safe substitute for FBS proliferation, expansion, and differentiation of 
hBMSCs. I further identify that XF2 may be a trustworthy medium in which to grow 
human mesenchymal stem cells for clinical bone repair such as repairing of the bone 
defect in cleft palate. 
4.10 Summary of results  
A significant factor in the success of bone tissue engineering is the cell source and culture 
medium chosen that should be had osteogenic differentiation. This chapter aimed to 
assess suitable xeno-free culture conditions for hMSCs and HJPs for osteogenic induction 
with the long-term aim of establishing xeno-free cultures for clinical applications of cleft 
palate repair. From these studies, we established that; 
● A suitable commercially available xeno-free media for osteogenic differentiation is 
human mesenchymal-XF expansion medium (XF2) and basal media containing 5% 
(v/v) human platelet lysate. Thus, these were used as an alternative media compared 
to 10% (v/v) FBS in osteogenic differentiation. 
● XF2 augmented increased the ALP and mineralised ECM construction.  
● XF2 may be a useful xeno-free pre-clinical medium for osteoblast-like cells 
differentiation of hBMSCs towards therapeutically bone differentiation for tissue 
engineering applications. 
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● Although osteogenic inductive XF2 medium treated by Dex 10 nM induced osteogenic 
differentiation of hBMSCs by increasing ALP activity compared to 10% (v/v) serum 
medium, collagen formation and calcium deposition showed no difference compared 
to 10% (v/v) serum medium. 
● The human-derived growth media (XF2 and 5% (v/v) HPL) supported hBMSCs to 
synthesis ECM at higher levels than the animal-derived serum supplementations.  
● Cell source (donor), media composition and supplements all played a vital role in 
determining osteogenic cell differentiation and ECM deposition. 
● HJPs were also shown to have strong osteogenic potential in human derived culture 
conditions and in these cells cultured in XF1 could support proliferation and 
differentiation showing different outcomes to the hBMSCs. 
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CHAPTER FIVE: GROWTH AND OSTEOGENIC DIFFERENTIATION OF PRIMARY 
HUMAN BONE MARROW MESENCHYMAL STEM CELLS AND HUMAN JAW 
PERIOSTEAL STEM CELLS IN 3D POLY (ɛ -CARPOLACTONE) ELECTROSPUN 
SCAFFOLDS IN XENO-FREE MEDIA 
5.1  Introduction 
Tissue engineering is a novel method which may achieve improvements in bone 
reconstruction for repair of the cleft palate. The three basic strategies of tissue 
engineering include firstly; selection of a relevant cell source, then; the design of an 
engineered scaffold and lastly; identification and use of suitable biologic signalling 
molecules. The selection of an appropriate cell source and use of suitable biologic 
signalling molecules were discussed in the previous chapters. This chapter will use the 
conditions identified in the previous chapter to create thin 3D bone-matrix constructs. 
The aim is to synthesise xeno-free bone-like tissue in electrospun poly (ɛ-caprolactone) 
(PCL) scaffolds.  
Electrospinning is a simple uncomplicated technique to fabricate fibre's mats in different 
diameters from nanometres to many micrometres ( Zargarian and Haddadi-Asl Haddadi-
Asl, 2010). The impact of the physical characteristics of such scaffolds has recently been 
of considerable interest to the biomaterials community and there has been an evolution 
of innovative scaffold materials with distinctive features determined by the chemistry of 
polymer. Meanwhile, the target is engineered bone tissue, ingredients should have the 
necessary strength, be easy to manufacture, flexible, biodegradable, biocompatible, easy 
to sterilise, and be able to be handled in the operating room. Such scaffolds should 
support the attachment and proliferation of osteoprogenitor cells.  
In some clinical scenarios the scaffold would be implanted alone with the aim to prompt 
host cell migration to the injury site and initiate tissue regeneration. Other scaffolds, may 
be considered as a carrier for cells to achieve an appropriate cell replacement therapy. In 
recent studies, poly(ɛ-caprolactone) (PCL) has been assessed as biocompatible and 
biodegradable for tissue engineering materials. PCL is also approved by the U.S. FDA for 
medical use. PCL polymer was chosen for this project because it has higher mechanical 
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strength and a and has a minimise rate of biodegradable compared with natural materials 
like collagen type I (Hutmacher et al., 2001). 
Bone is a natural composite material containing cells and the extracellular matrix that is 
formed from protein (mostly collagen) and calcium-phosphate based mineral plates 
(mostly hydroxyapatite). As mentioned in the introduction of chapter one, bone is a 
dynamic tissue that requires adequate nutrients to maintain its activity. It has mentioned 
in a few kinds of research that the osteogenic differentiation of human osteoprogenitor 
cells is improved by xeno-free formulation media (Lindroos et al., 2009). The cells 
cultured on electrospun PCL scaffolds are bounded by fibres and attach to others in 
different directions, which could better mimic the in vivo environment. Thence, by 
culturing cells on human-derived growth supplements in 3D culture, the results may be 
more comparable to in vivo than monolayer culture, and this may be contemplated as a 
good strategy for creating a layer of bone. 
VEGF is a vasculogenesis growth factor construct that is secreted by numerous cells such 
as osteoblasts. Vasculogenesis is an essential process for the bone tissue engineering to 
survive in vivo and to encourage the blood vessels construction to bring oxygen and 
nutrients to cells within the implanted scaffold. 
In chapters 3 and 4 it was demonstrated that human osteoprogenitor cells including; 
hBMSCs and HJPs cultured in a human-derived xeno-free medium with and without the 
supplement Dex, AA and βGP, (osteogenic media) exhibited enhanced osteogenesis and 
mineralisation compared to when grown in 10% (v/v) bovine serum medium. There was 
an effect of donors and human-derived growth supplements on ALP activity (an early 
marker of osteogenic differentiation) and mineralisation (calcium deposition and 
collagen type I formation). Therefore, the studies presented here will further assessed 
the potential of human-derived growth supplements to stimulate hBMSCs in 3D PCL 
scaffolds culture to stimulate osteogenic differentiation. 
The objective of this chapter were to:  
1) Investigate hBMSCs distribution and growth when seeded on the electrospun micro 
fibre scaffolds of PCL for bone tissue engineering. 
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2) Enhance osteogenic differentiation of mesenchymal progenitors using human-
derived supplements incorporated into the cell culture media. 
3) Identify whether there are donor-specific effects on the differentiation potential of 
cells incorporated into electrospun PCL scaffolds. 
 




5.2.1 Fabrication of poly (ɛ-caprolactone) electrospun scaffold 
Six g of polymer pellet of PCL was added into 54 g of DCM (density of DCM = 1.33g/cm3). 
The mixture was left in the water bath for less than 1 hour then a mixture of 10% (w/w) 
of polymer solution was achieved using a magnetic stirrer at room temperature. The 
solution was then spun employing the technique of electrospinning (see chapter 2). The 
scaffold morphology and fibre diameter was evaluated from SEM images. Fibre diameter 
was measured utilising ImageJ-image analysis software. To ensure fibres were selected 
randomly a grid was designed comprising of intersections spaced at 35 X 35 micron 
evenly spaced points. Each image was overlaid with this grid (Figure 5.2.1). Then fibres 
diameter was measured only at the point where the intersection was present over the 
fibre. 
 
Figure 5.2.1: Schematic of fibre diameter assessments from SEM images. The grid was 
overlaid on the images utilising an automated image J function. The elected 35 points 
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5.2.2 Optimising cell seeding on 3D PCL scaffolds 
The PCL electrospun scaffolds were cut to a diameter of 1.5 cm and a sterile stainless steel 
ring was adhered using PCL solution (Figure 2.2.9 A). The PCL scaffolds were sterilised 
with 80% (v/v) ethanol in PBS for 2 hours inside the cell culture hood and washed thrice 
with PBS to remove the ethanol. Then, the scaffolds were immersed in the respective 
culture media overnight in the incubator at 37°C, 5% CO2, in a humidified atmosphere. 
Two different cell densities (100,000 and 200,000) of hBMSCs were seeded on top of PCL 
scaffolds using a small volume technique of no more than 100 µL of cell suspension. 
Scaffolds were then left for 1 hour in an incubator, subsequently 2 mL of the appropriate 
media was added into the well plate to cover the scaffolds and the plates were left for 24 
hours for cell attachment in the cell culture incubator. The cell-cultured scaffolds were 
transferred to new well plates after 1 day; the resazurin reduction assay for metabolic 
activity was used to assess the cell seeding efficiency. The quantity of cells, as estimated 
by metabolic activity, that attached on the original tissue culture wells was compared 
with the number of viable cells attached to the PCL scaffolds. The quantity of viable cells 
in the PCL scaffolds was measured by resazurin reduction assay on day 4 and 7, which 
indicated the efficiency of cell proliferation. 
5.2.3 Evaluation of osteogenesis of various donors of hBMSCs cultured in different xeno-
free culture media on PCL scaffolds 
Circular PCL scaffolds with a diameter of 1.5 cm were cut and cultured on 2 X 105 hBMSCs; 
passage number is 1. Samples were divided into main two groups the basal culture 
medium (BM) which contained basal α-MEM for all media except XF2, and the BM 
medium treated by osteogenic supplementations which were 10 nM of Dex, 50 µM of AA, 
and 10 mM of β-GP (OM_10). The osteogenic differentiation of hBMSCs was measured 
using PicoGreen fluorescence (dsDNA) and alkaline phosphatase activity as the initial 
osteogenic differentiation indicator test after day 14, and alizarin red and picro-sirius red 
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5.3  Results 
5.3.1 Fabrication of poly (ɛ-caprolactone) electrospun scaffold 
A smooth fibre morphology of PCL was successfully produced with very little bead 
formation (Figure 5.3.1 B). The result of fibre diameter measurements of ten scaffolds 
indicated that 76% of fibres had a diameter less 15 µm, 20% of fibres had diameters 
between 15 to 30 µm, and only 4% of fibres had a diameter over 30 µm (Figure 5.3.1 A). 
The average fibre diameter of PCL was 9.76 µm.  
 
  
Figure 5.3.1: 10wt% PCL electrospun scaffold characterisation; A: the percentage of fibres 
at different diameter ranges B: SEM image of electrospun fibre morphology and 
diameter. The polymer pellets were dissolved in DCM and spun in the 40µL/min flow 
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5.3.2 Optimising cell seeding on 3D PCL scaffolds 
Two different cell densities (100,000 and 200,000) were tested for seeding the 
electrospun PCL scaffolds. Resazurin colour change for the background control (scaffold 
without cells cultured in αMEM) was measured then removed from the individual values 
for each scaffold during the time of data collection. After 24 hours, resazurin assay 
indicated that cell attachment to the scaffold was high for both seeding densities 
compared with quantity of cells that had come off the scaffold and attached to the 
underlying well plates. As expected, higher cell numbers were seen for cells seeded at 2 
X 105. XF2 and 5% (v/v) HPL media supported statistically significantly more viable cells 
on the scaffolds than 10% (v/v) FBS at the high cell density. While 10% (v/v) FBS 
supported slightly more cells on the scaffolds than the other conditions when seeded at 
1 X 105 cells per scaffold (P<0.05) (Figure 5.3.2 B). 
The amount of cells that did not attach to the PCL scaffolds (attached to the plastic well 
plates rather than the scaffolds) was higher in XF2 followed by 10% (v/v) FBS at a cell 
density 200,000. Very few non-attached cells were observed in 5% (v/v) HPL at the same 
density. At the lower cell density very few viable cells were found not attached to the 
scaffold in any condition with no significant difference among them (P<0.05) (Figure 5.3.2 
A). 
On day 4, XF2 medium for both cell densities was observed to better support cell growth 
as seen by approximately 4-fold higher metabolic activity compared to the other groups. 
Cell metabolic activity was also slightly but significantly higher than for the 100,000 cell 
density. Although the cell metabolic activity in 5% (v/v) HPL was about 2-fold higher than 
10% (v/v) FBS at cell density 100,000, there was no significant difference between them 
(Fig. 5.3.2 C). 
By day 7, cells that had grown in XF2 media exhibited much higher cell metabolic activity, 
about 8 fold, compared to the other groups and there was no difference between 5% (v/v) 
HPL and 10% (v/v) FBS (P<0.05) (Figure 5.3.2 D). 
The cell metabolic activity in XF2 indicated cell proliferation between days 4 and 7 but 
the cell metabolic activity in both 10% (v/v) FBS and 5% (v/v) HPL showed a gradual 
decrease this implies that these cell numbers could be not supported in these media. 







































































































































































Figure 5.3.2: The ability of 3D PCL electrospun scaffolds to support cell metabolic activity over 
7 days. The metabolic activity of cell was assayed by resazurin reduction test after 1, 4 and 7 
days. Bar indicates Mean ± S.D for each condition. (K=1000).  (*) Significantly higher than 
the other media at the same cell density and time point. (Φ) Significant higher than the other 
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conditions at that time point. (ns) There is no significant difference (P <0.05). n=3. Two-way 
ANOVA, Tukey’s multiple comparison tests.  
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5.3.3 Determining the cellular DNA in a different cell density 
DNA was analysed quantitatively on day 14, picoGreen fluorescence for the of 
background control (scaffold without cells cultured in αMEM) was measured, then 
removed from the individual values. The cells seeded at density of 100,000 in XF2 
contained 9-fold and 4-fold the number of cells compared to the 10% (v/v) FBS and 5% 
(v/v) HPL groups respectively. Furthermore, at the seeding cell density of 200,000 in 
cultures grown in XF2 there was a statistically higher amount of DNA (indicating cell 
number) about 13-fold and 21-fold over the 10% (v/v) FBS and 5% (v/v) HPL 
respectively. There was no higher DNA seen at the higher cell seeding densities in 10% 




























Figure 5.3.3: DNA quantification of hBMSCs seeded on 3D PCL scaffolds cultured on a 
different commercial human-derived basal culture medium measured by Quant-iT™ 
PicoGreen® on monolayer on day 14. Horizontal line indicates Mean ± S.D for each condition, 
each point is a single scaffold. (*) Significantly higher than the other media at the same cell 
density. (#) Significantly lower. (Φ) Significantly higher than all the other cultured in different 
cell density overtime for 14 days. (P <0.05). n=3. Two-way ANOVA, Tukey’s multiple 
comparison tests. 
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5.3.4 Evaluation of alkaline phosphatase activity at different cell densities 
ALP activity was analysed on day 14 in the basal culture media; the results indicated that 
despite the absence of dexamethasone the ALP activity in both groups of cell densities 
was higher in XF2 over the other conditions and statistically higher in the 200,000 cell 
seeding density compared to 100,000 cell density. ALP is normalised to DNA so the higher 
ALP activity in the 200K group indicates ALP activity per cell is higher and this is not just 
















































Figure 5.3.4: The ALP activity of hBMSCs cultured on two commercial human-derived basal 
culture media compared with 10% (v/v) animal-serum concentration on 3D PCL scaffolds on 
day 14. Bar indicates mean ± S.D for each condition. (*) Significantly higher than the other 
media at the same cell density. (Φ) Significantly higher than all the other cultured in different 
cell density overtime for 14 days. (P <0.05). n=3. Two-way ANOVA, Tukey’s multiple 
comparison tests. 
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5.4 Evaluation of primary hBMSCs metabolic activity of cells from different donors 
cultured in basal media on electrospun PCL scaffolds 
To identify whether there are donor-specific effects of the media under investigation in 
this study cells from different donors at the cell density of 200,000 per scaffold were 
cultured in the two commercial media containing human-derived components and with 
10% (v/v) animal serum on 3D PCL scaffolds. The resazurin reduction test was used to 
assess the cell attachments on day 1 and the metabolic activity of cells on day 4 and 7. 
hBMSCs from both donors 4 and 5 exhibited higher cell attachment on PCL scaffolds 
particularly in the XF2 culture medium followed by 10% (v/v) FBS culture media. 
However, the 5% (v/v) HPL supported a lower cell attachment. 
Furthermore, rapid increase of cell metabolic activity was seen for cells cultured in XF2 
in both donors, particularly between days 1 and 4. While the metabolic activity in 10% 
(v/v) FBS was slightly reduced over time for donor-4 and marginally increased for donor-
5. In the meantime, the cell metabolic activity in 5% (v/v) HPL was increased over the 
first 4 days, and then appeared to slightly decrease at the end of the period (P<0.05) 
(Figure 5.4). 
In donor-7, a sharp increase of cell metabolic activity in both of the media containing 
human-derived components was observed over the first 4 days of culture, which then 
levelled. Although cell metabolic activity increased in 10% (v/v) FBS culture media over 
the first 4 days, it deteriorated between day 4 and day 7 (P<0.05) (Figure 5.4). 
Overall, metabolic activity of cells from donor-7 cultured on 3D PCL scaffolds was higher 
than the other donors cultured in the same conditions which implies that the hBMSCs of 




































































































































Figure 5.4: Metabolic activity of three different donors of hBMSCs seeded on 3D PCL 
scaffolds cultured in two different xeno-free basal media from day 1 to day 7. The 
superimposed symbols with connecting line indicate mean±SD for each condition. (*) 
Higher than the other media with cells from the same donor. (#) Significantly lower. (P 
<0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
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5.5 Effects of osteogenic supplements on cell metabolic activity for different donors 
To test whether osteogenic supplements affected cell metabolic activity, media were 
supplemented with Dex 10 nM, AA 50 µM, and βGP 10 mM. After 24 hours, the cells were 
expected to be entirely attached on the 3D PCL scaffolds. The resazurin reduction test 
was used to assess the metabolic activity of cells on day 4 and 7. 
hBMSCs of donor 4 cultured in XF2 media exhibited statistically higher cell metabolic 
activity on PCL scaffolds over time for 4 days, the metabolic activity then slightly reduced 
at day 7 but was significantly higher compared to the other conditions. Cells cultured in 
5% (v/v) HPL also exhibited higher cell metabolic activity than 10% (v/v) FBS but there 
was a gradual decline to day 7. The cell metabolic activity in 10% (v/v) FBS indicated a 
marginal increase on day 7. Metabolic activity in OM-10 was lower compared with the 
BCM and there was a significant difference. However, XF2-OM-10 had a significantly 
higher metabolic activity of cells compared with its BCM. 
Donor-5, cells cultured in 5% (v/v) HPL showed statistically higher cell metabolic activity 
over time for 4 days and then the metabolic activity remained steady to the end of the 
period. Cells cultured in both human-derived formulations also exhibited higher cell 
metabolic activity than 10% (v/v) FBS but they remained stable to day 7 (P<0.05) (Figure 
5.5).  
In donor-7, the results were slightly different from the other two donors, overall this 
donor exhibited higher cell metabolic activity at all time-points and the cell metabolic 
activity in both human-derived media was higher compared to 10% (v/v) FBS at day 4. 
Although a significant difference was observed between 5% (v/v) HPL and 10% (v/v) 
FBS, there was no significant difference between XF2 and 10% (v/v) FBS.  In all conditions 
the cell metabolic activity increased between days 4 and 7 in both human-derived media 
supporting significantly higher cell metabolic activity than 10% (v/v) FBS at day 7 
(P<0.05) (Figure 5.5). When comparing OM-10 and its BCM OM-10 of 10% (v/v) FBS 
decreased metabolic activity of cells and there was a significant difference. On the other 
hand, OM-10 of human-derived medium revealed no significant difference compared 
with their BCM on day 7. 
Overall, there was no consistent effect of osteogenic media on cell metabolic activity as 
previously seen in monolayer in chapter 3 (Table 5.5) 
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Table 5.5: The effect of osteogenic supplements on the metabolic activity of cells in PCL 
scaffolds. “Higher” indicates osteogenic-inductive medium caused significantly higher 
resazurin fluorescence when comparing data in figure 5.4 and figure 5.5. “Lower” 
indicates osteogenic-inductive medium caused significantly lower fluorescence and “NS” 
indicated no significant difference between basal media and OM within this group. 
Media-Donors 
Donor 4 Donor 5 Donor 7 
Day 4 Day 7 Day 4 Day 7 Day 4 Day 7 
10% (v/v) FBS Higher Higher NS Higher NS Higher 
XF2 Lower Lower NS NS NS NS 
5% (v/v) HPL Higher Higher NS Higher NS NS 
 

























































































































Figure 5.5: Metabolic activity of cells from three different donors of hBMSCs seeded 
on 3D PCL scaffolds cultured in two different xeno-free basal medium treated with 
osteogenic media (OM-10) containing Dex 10 nM, AA 50 µM, and βGP 10 mM from 
day 1 to day 7. Horizontal line indicates Mean ± S.D for each condition, each point is 
a single scaffold. (*) Significant higher than the other condition. (#) Significantly lower. 
(P <0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
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5.6 Comparison of osteogenesis of various donors of hBMSCs cultured in different 
xeno-free culture media on PCL scaffolds 
5.6.1 Alkaline phosphatase activity 
Alkaline phosphatase (ALP) is an enzyme found in bone mineralisation, and its activity is 
frequently employed as a marker for initial detection of osteogenic differentiation. ALP 
activity was divided by the amount of DNA after converting to approximate cell number 
ng/mL= {(Fluorescence emission + 215.1)/223.2} (Figure 5.6.1 A) as described in 
chapter two.  
In all donors, total DNA content was very high in XF2 basal culture medium and higher in 
5% (v/v) HPL compared to 10% (v/v) FBS basal culture medium. The human-derived 
basal culture media had a significant difference compared to the 10% (v/v) FBS basal 
culture media. 
In donor-4, even though there was no significant difference between both types of 
human-derived osteogenic media, they were 2-fold higher compared to 10% (v/v) FBS 
osteogenic media (P<0.05).  
In donor-5, the quantity of DNA increased rapidly in all osteogenic media. There was no 
significant difference between the 10% (v/v) FBS osteogenic medium and 5% (v/v) HPL 
osteogenic medium or the XF2 basal culture medium. XF2 osteogenic medium had high 
cell proliferation and was significantly different compared to all conditions while the 
basal culture medium of 10% (v/v) FBS supported a lower number of cells. 
In donor-7, the osteogenic human-derived media supported high numbers and was 
significantly different compared to 10% (v/v) FBS osteogenic medium. There was no 
significant difference between XF2 basal culture medium and 5% (v/v) HPL osteogenic 
medium. The growth of hBMSCs was augmented in XF2 osteogenic culture medium over 
the other conditions throughout all donors. Although 10% (v/v) FBS osteogenic media 
supported higher cell numbers over 10% (v/v) FBS basal culture medium, they revealed 
lower potential cell growth (P<0.05) (Figure 5.6.1 B). 
In all donors, the ALP activity was normalised to ng/DNA and standardised to 10% (v/v) 
FBS basal culture medium for each donor. The normalised ALP activity was expressed 
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highly in both groups of human-derived culture medium over 10% (v/v) FBS basal and 
osteogenic culture medium. However, there was no significant difference between basal 
culture media and their osteogenic media in all donors. Meanwhile, hBMSCs of donor-4 
exhibited high ALP activity over other donors and followed donor-5. Similarly, hBMSCs 
cultured in 10% (v/v) serum osteogenic media revealed the lowest ALP activity for all 
donors and was significantly different compared to XF2 osteogenic medium and human-
derived osteogenic media in donors 4 and 5 respectively. While there was no significant 
difference between all osteogenic media in donor 7 (P<0.05) (Figure 5.6.1 C).  
These data confirmed the results in monolayer culture which showed osteogenic medium 
containing Dex 10 nM to increase the osteogenic cells differentiation (Table 5.6.1). 
Although ALP in 10% (v/v) FBS media is relatively low a significant effect on osteogenic 
medium can be seen. Whereas in the media containing human-derived ingredients where 
the ALP is much higher even when there are no supplements present the effect of 
supplements is smaller and not significant for all donor. 
Overall, the normalised ALP activity and DNA quantity of hBMSCs on 3D PCL scaffolds 
was highest in both human-derived growth media and even higher than all donors from 
any groups (basal and osteogenic) with 10% (v/v) animal serum supplementation. This 
implied that the primary hBMSCs seeded on 3D PCL scaffolds and cultured in human-
derived basal and osteogenic media had undergone osteoblast differentiation. 
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Figure 5.6.1: hBMSCs from different adult donors seeded on 3D PCL scaffolds cultured on 
two commercial human-derived basal and osteogenic culture media compared with 10% (v/v) 
animal-serum concentration on day 14. The bar indicates mean±SD for each condition (n=3). 
(*) Significantly higher than the other groups in the same donors. (#) Significantly lower. (Φ) 
Significantly higher than the other groups in the different donors. (ns) There is no significant 
difference (P <0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
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Table 5.6.1: The effect of osteogenic supplements on the amount of DNA and ALP activity 
of cells in PCL scaffolds respectively. “Higher” indicates osteogenic-inductive medium 
caused significantly higher. “Lower” indicates osteogenic-inductive medium caused 
significantly lower and “NS” indicated no significant difference between basal media and 
OM within this group 
Media Donor 4 Donor 5 Donor 7 
BCM Higher Higher Higher 
XF2 NS Higher Higher 
5% (v/v) HPL Higher Higher Higher 
ALP activity 
Media Donor 4 Donor 5 Donor 7 
BCM Higher NS Higher 
XF2 Higher NS Lower 
5% (v/v) HPL NS NS NS 
 
5.6.2 Assessment of extracellular matrix formation 
The aim of this study was to assess the late stage of osteogenic differentiation of primary 
hBMSCs on 3D PCL scaffolds, in terms of production of extracellular matrix (ECM) and 
then identify media containing only xeno-free ingredients as an alternative formulation 
to FBS supplements to repair bone defects in the cleft palate. 
5.6.2.1 Collagen production 
Collagen was measured using Sirius Red as described in chapter 2. It was interesting to 
observe that the media containing supplements supported higher deposition of collagen 
on PCL scaffolds over basal culture media. As was expected osteogenic media, which 
contains ascorbic acid increased collagen production in 10% (v/v) serum medium 
(evident in donors 4 and 7). The xeno-free media XF2, even without osteogenic 
supplements also supported significantly higher collagen production on PCL scaffolds 
compared to other conditions. When XF2 media was supplemented with typical 
osteogenic supplements collagen deposition was even higher (P<0.05) (Figure 5.6.2.1). 
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There were some differences in collagen production between donors. In donors 4 and 5, 
the total collagen production of cells cultured in XF2 osteogenic media on 3D PCL 
scaffolds was significantly higher than all the other groups and but for donor-7 cells 
cultured in osteogenic and FBS supplemented media collagen production was as high as 
in osteogenic 5% (v/v) HPL media. In donor-4, the collagen production in osteogenic 
media in both 5% (v/v) HPL and 10% (v/v) FBS was about 3-fold higher compared to 
basal media. (P<0.05) (Figure 5.6.2.1).  
In donor-5, 5% (v/v) HPL osteogenic medium supported higher collagen production, 
approximately 1.5-fold, compared to basal culture medium while collagen production 
from both 10% (v/v) FBS basal and osteogenic media on PCL scaffolds remained steady 
(P<0.05) (Figure 5.6.2.1). Cells from donor-7 were the only cells in which osteogenic 
supplements in XF2 media did not increase collagen production over basal XF2. 
These results imply that collagen production by primary hBMSCs seeded on 3D PCL 
scaffolds can be supported to produce collagen ECM in human-derived osteogenic media. 
 
 

















































Figure 5.6.2.1: The ability of primary hBMSCs from different adult donors to produce collagen 
when seeded on 3D PCL scaffolds cultured on two commercial human-derived basal and 
osteogenic culture media compared with 10% (v/v) animal-serum on day 21. The bar indicates 
mean±SD (n=3) for each condition. (*) Significantly higher than the other groups in the same 
donors. (ns) There is no significant difference (P <0.05). n=3. Two-way ANOVA, Tukey’s 




187 | P a g e  
 
5.6.2.2 Calcium deposition 
Calcium deposition was assessed using Alizarin red staining (ARS) as described in 
chapter 2.   
There was considerable variety in mineral deposition between different donors which 
has also been shown in other studies (Sittichokechaiwut et al., 2010). In donors 4 and 7, 
the total calcium deposition by hBMSCs cultured in XF2 osteogenic media on 3D PCL 
scaffolds was highest followed by XF2 basal culture medium. As expected, osteogenic 
supplements supported higher calcium deposition on PCL scaffolds (P<0.05) (Figure 
5.6.2.2).  
Cells from donor-5 exhibited significantly lower mineralisation than the other donors in 
all media and differences were small. For this donor the amount of calcium measured by 
ARS was highest in osteogenic media with FBS which was significantly higher than the 
other media conditions (P<0.05) (Figure 5.6.2.2). 
Table 5.6.2.2: The effect of osteogenic-inductive media on collagen formation and 
calcium deposition within the media groups examined. “Higher” indicates osteogenic-
inductive caused significantly higher when comparing data in figure 5.6.2.1. “Lower” 
indicates osteogenic-inductive medium caused significantly lower and “NS” indicated no 
significant difference between osteogenic-inductive compared with BCM within this 
group. 
Media-Donors 
Donor 4 Donor 5 Donor 7 
Collagen Calcium Collagen Calcium Collagen Calcium 
10% (v/v) FBS Higher Higher NS Higher Higher Higher 
XF2 Higher Higher Higher NS NS Higher 
5% (v/v) HPL Higher Higher Higher NS Higher Higher 
  















































Figure 5.6.2.2: The ability of primary hBMSCs from different adult donors seeded on 3D PCL 
scaffolds to deposit calcium, when cultured in two commercial human-derived basal and 
osteogenic culture media compared with 10% (v/v) animal-serum n on day 21. The bar 
indicates mean ± SD for each condition. (*) Significantly higher than the other groups in the 
same donors. (Φ) Significantly higher than all the other donors. (#) Significantly lower. (ns) 
There is no significant difference (P <0.05). n=3. Two-way ANOVA, Tukey’s multiple 
comparison tests. 
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5.7 Nuclei staining 
The PCL scaffolds were stained with a fluorescent cell nucleus dye after 21 days. In all 
groups, the results showed some DAPI fluorescence signals with different brightness that 
depended on the depth and spread of cell in the PCL scaffolds. A significant build-up of 
DAPI fluorescent signals was observed on the PCL scaffolds treated by XF2 osteogenic 
media rather than the other conditions this supports the resazurin and DNA data (Figure 
5.7). 
 
     
 
     
 
Figure 5.7: The fluorescent microscopy images of 3D PCL scaffolds stained with DAPI in two 
commercial human-derived basal and osteogenic culture media compared with an animal-
serum concentration on day 21. Bar = 10 µm.  
10% (v/v) FBS 5% (v/v) HPL XF2 
10% (v/v) FBS-OM10 5% (v/v) HPL-OM10 XF2-OM10 
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5.8 Scanning Electron Microscope (SEM) evaluation of extracellular matrix on PCL 
scaffolds 
The SEM images of hBMSCs cultured on the 3D PCL scaffolds after 21 days 
indicated that the cells were well-attached, extended on the large surface area and 
underside of the scaffolds. For hBMSCs grown in XF2, in both osteogenic and basal culture 
media there was bone-like matrix formation over the surface of PCL scaffolds, which 
covered all the scaffold fibres. Although cells grown in 5% (v/v) HPL also produced a 
bone-like layer which covered most of the surface area of PCL scaffolds, it did not cover 
the whole surface. Although cells grown in 10% (v/v) FBS formed a thin layer of bone on 
the surface of PCL scaffolds, it did not cover all the fibres of PCL scaffolds and round 
structures which appeared to include ECM were presented underneath the scaffold 
surface. However, in 10% (v/v) FBS osteogenic media bone-like layer was thicker than in 
basal culture media. These results indicate that the presence of human-derived media 
either with or without osteogenic supplementation could lead to enhanced ECM 
deposition and create a new layer of pre-bone matrix compared to 10% (v/v) FBS. 
Moreover, the PCL scaffolds and human-derived supplementation could encourage bone 
repair for craniofacial bone defects, particularly in cleft palate (Figure 5.8). 
  










Figure 5.8: The SEM images of the hBMSCs donor 4 seeded on 3D PCL scaffolds cultured on 
two commercial human-derived basal and osteogenic culture media compared with 10% (v/v) 
animal-serum concentration on day 21. The bone layer formation with mineralised ECM. Scale 
bar = 10µm to 1mm  
10% (v/v) FBS 5% (v/v) HPL XF2 
10% (v/v) FBS-OM10 5% (v/v) HPL-OM10 XF2-OM10 
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5.9 Xylenol orange fluorescence staining 
Xylenol orange (C31H28N2O13SNa4) is a non-toxic fluorochrome which binds to calcium 
ions. This staining has been using to detect the mineralised matrix by live osteoblastic 
cells in vitro. 
CLSM fluorescence images of cultured hBMSCs confirmed that mineral deposition 
occurred on the PCL scaffold. The PCL only control did not give off a signal indicating that 
there was no non-specific binding of Xylenol orange on the PCL.  Xylenol orange could be 
seen in all groups but was considerably higher in those that had been subjected to 
osteogenic supplementation. Moreover, the xylenol orange staining confirmed that XF2 
osteogenic media supported substantial mineral deposition compared to other 
conditions. Human-derived basal media also enhanced mineral deposition on the PCL 
scaffolds compared to 10% (v/v) FBS. Xylenol orange staining confirmed the alizarin red 
results indicating that XF2 basal media supports mineralisation even without osteogenic 
supplements (Figure 5.9). 
  




   
   
 
Figure 5.9: CLSM fluorescence images of cultured hBMSCs on 3D PCL scaffolds. The matrix 
mineralisation of hBMSCs was measured by labelling using xylenol orange (red colour) 
staining after 21 days of culture. The PCL scaffold with no staining was imagined to show that 
it was not auto-fluorescent (no cells or mineralisation). Scale bar = 10 µm, n=2. 
  
PCL scaffolds control 
10% (v/v) FBS 5% (v/v) HPL XF2 
10% (v/v) FBS-OM10 5% (v/v) HPL-OM10 XF2-OM10 
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5.10 Assessment of vascular endothelial growth factor (VEGF) secretion from 
commercial human-derived media using enzyme-linked immunosorbent assay 
(ELISA) 
The aim of this study was to assess the ability of the human-derived media to enhance 
vasculogenesis through the secretion of VEGF. The importance of the blood supply for 
bone regeneration is well-known during oral and maxillofacial surgery. Impairment of 
the vascular supply considers diminished growth and repair, bone loss, and eventually, 
necrosis. 
hBMSCs from both 10% (v/v) FBS and 5% (v/v) HPL basal culture media had significantly 
higher VEGF levels compared to XF2 basal culture medium. However, there was no 
significant difference between them. Whereas, XF2 basal medium seemed to support 
particularly low VEGF secretion(P<0.05) (Figure 5.10 A). After subtraction of the amount 
of VEGF of basal culture media from each experimental media, the results indicated that 
the amount of VEGF per cell cultured in 10% (v/v) FBS and 5% (v/v) HPL basal medium, 
and 5% (v/v) HPL osteogenic medium was significantly higher compared to the other 
groups, and there was no significant difference among them. XF2 basal culture medium 
did not supported cell VEGF secretion, while the XF2 osteogenic medium augmented 
VEGF secretion approximately 5-fold compared to basal culture medium. A considerable 
reduction of the VEGF secretion in 10% (v/v) FBS osteogenic medium was observed over 














































































Figure 5.10: Effect of two commercial human-derived basal and osteogenic culture 
media on VEGF secretion of hBMSCs seeded on 3D PCL scaffolds on day 21 (during 
48 hours of collection period). The bar manifests mean±SD for each condition. (A) The 
amount of background VEGF in medium without cells, (B) the amount of VEGF per cell 
(not different scale bars). (*) Higher than the other conditions. (ns) There is no 
significant difference (P <0.05). n=3. One-way ANOVA, Brown-Forsythe test, and 
Two-way ANOVA, Tukey’s multiple comparison tests. 
196 | P a g e  
 
5.11 The ability of Human jaw periosteum cells to grow on 3D PCL scaffolds 
(preliminary alternative cell sources) 
As the 2D culture results indicated that HJPs may be a promising osteogenic cell these 
were also cultured on PCL scaffolds to determine their ability to support bone tissue 
engineering. Experiments were performed as described for hBMSCs in this chapter. In 
terms of cell attachment, cells in XF2 had the highest amount of cell detachment as 
detected by resazurin reduction assay on 2D well plate, there was no cells detected on 
the 2D well plate from in either 5% (v/v) HPL or 10% (v/v) FBS (P<0.05) (Figure 5.11 A). 
On days 1 and 4, the cells from both human-derived growth basal culture media were 
attached to the PCL scaffold fibres and numbers increased significantly. However, there 
was no significant differences between them. There was a sharp increase of cell metabolic 
activity for cells cultured in both human-derived growth basal media on PCL scaffolds 
compared to 10% (v/v) FBS basal medium.  On day 7, both human-derived basal media 
supported higher cell metabolic activity compared to 10% (v/v) FBS basal medium. In 
XF2 basal medium cell number was significantly higher, about 1.5-fold and 3-fold 
compared to both 5% (v/v) HPL basal and 10% (v/v) FBS basal media respectively 
(Figure 5.11 B). 
In osteogenic media, on days 4 and 7, the cells from both human-derived growth basal 
culture media on PCL scaffolds had robust growth and cell metabolic activity was 
significantly higher 3-fold and 2-fold compared to 10% (v/v) FBS on days 4 and 7 
respectively. Then, cell metabolic activity in 5% (v/v) HPL appeared to reach a plateau, 
while the cells in XF2 continued to increase in number towards the end of the period. 
Although the metabolic activity of the cells in 10% (v/v) FBS increased gradually, they 
were significantly lower compared to other media throughout the period (P<0.05) 
(Figure 5.11 C). 
Overall, the results indicated that both human-derived basal and osteogenic culture 






























































































Figure 5.11: The ability of 3D PCL electrospun scaffolds to support HJPs cell 
metabolic activity cultured in two commercial human-derived basal and osteogenic 
culture media over 7 days. The cell metabolic activity was assayed by resazurin 
reduction test after 1, 4 and 7 days. (A) cell detected on tissue culture plastic on day 1, 
(B) cell metabolic activity of attached cells in basal culture media on 3D PCL scaffolds 
on days 1, 4, and 7 (C) cell metabolic activity of attached cells culture in osteogenic 
media on 3D PCL scaffolds on days 4 and 7 respectively. (*) Significantly higher than 
the other media. (#) Significantly lower than other media. (P <0.05). n=3.  One-way 
ANOVA, Brown-Forsythe test, Two-way ANOVA, Tukey’s multiple comparison tests. 
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5.11.1 Alkaline phosphatase activity of HJP cells 
In both groups the basal culture media (BCM) and osteogenic media at a concentration of 
10 nM (OM10), the results showed that both human-derived media had a high ALP 
activity and this was significantly higher than for cells in10% (v/v) FBS. Although the 
level of ALP activity in XF2 appeared to be higher than 5% (v/v) HPL, it was not 
significantly different. The ALP activity increased in 5% (v/v) HPL-OM10 compared to 
XF2-OM10, however, there was no significant difference. No ALP activity was seen in 10% 
(v/v) FBS-BCM while only a low amount of ALP activity was observed in 10% (v/v) FBS-
OM10. As expected the osteogenic supplementation increased ALP activity in both 10% 
(v/v) FBS and 5% (v/v) HPL, while in XF2 ALP activity was no higher in osteogenic 



























































Figure 5.11.1: The Alkaline phosphatase activity of HJPs seeded on 3D PCL scaffolds 
cultured on two commercial human-derived basal and osteogenic media compared with 
10% (v/v) animal-serum on day 14. Mean±SD for each condition. (#) Significantly 
lower than other conditions. (P <0.05). n=3. One-way ANOVA, Brown-Forsythe test. 
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5.12 Discussion 
The purpose of bone tissue engineering is to make available a biocompatible material as 
an alternative to the well-regarded of surgical procedures that uses the autologous bone 
grafts for stimulating bone regeneration and implant fixation. The requirements for a 
polymer scaffold are to be biodegradable and to have sufficient mechanical strength, 
biological and medical properties to stimulate the cell proliferation and adhesion to form 
a temporary mineralised ECM until the regeneration of bone has occurred. The 
relationship between the mineralised ECM and the surrounding conditions affect the cell 
behaviours by direct and indirect signal transmission. The foremost goals of this chapter 
were to construct electrospun PCL scaffolds to regenerate cleft palate osseous defect that 
would be stimulated normal development of orofacial bones. To perform this aim, firstly, 
the selection of biodegradable polymer electrospun scaffold was undertaken utilising 
FDA confirmed PCL polymer and the efficiency of hBMSCs to grow and mineralise within 
this scaffold was investigated. Secondly, commercial xeno-free culture media derived 
from human blood were evaluated as a media, for the pre-clinical culture of tissue-
engineered bone in cleft palate and other craniofacial applications, such as human serum 
media (XF2) and human platelet lysate. Finally, the variability of donor populations in 
growth characteristics and osteogenic potential was assessed.  
In this chapter, the fabrication of PCL micro-fibre non-woven mat scaffolds was 
described. These had a smooth fibre morphology without bead formation and were non-
aligned. Spasova et al., (2006) mentioned that the bead formation is usually dependent 
on the polymer solution surface tension and viscosity during and formed a significant 
defect in electrospun PCL scaffolds. Furthermore, Chen and co-workers (2007) 
mentioned that the beaded structure on the scaffolds had reduced cell proliferation and 
adhesion on the PCL scaffolds uniformly because of the decrease of the volume-to-surface 
area ratio of the PCL scaffold. Consequently, a pure fibre mat of electrospun PCL scaffold 
is essential for optimising tissue engineering.  
To simplify the transition of human MSCs from conventional studies to clinical 
applications, several advances in the reagents used to expand these therapeutically 
relevant cells is needed. One of the essential steps in this study was the transition from 
animal serum supplementations to a better-defined xeno-free media which included 
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human-derived formulation media. Recently, many efforts have demonstrated that 
human bone marrow-derived MSCs can be isolated and expanded over the short term in 
serum-free medium (Battula et al., 2007). However, no published work has shown the 
ability of electrospun PCL scaffolds to support human MSCs under human-derived 
formulation media for long-term culture. To achieve such a feat, the selection of xeno-free 
media was performed as discussed in chapters 3 and 4. It is assumed that a reason these 
xeno-free formulations are able to support MSC expansion is because they contain 
required growth factors and ECM elements. The most significant growth factors and ECM 
reagents that play a crucial role in both hBMSCs proliferation and differentiation are 
PDGF-BB, bFGF, TGF-β1, vitronectin, hyaluronic acid, and fibronectin (Ng et al., 2008; 
Uhm et al., 1999). Interestingly, the combination of any two growth factors seemed to 
provide minimal or no significant improvement of cell proliferation over the single 
factors, however, the combination of all factors ameliorated a noticeable synergistic effect 
(Chase et al., 2010) . 
The variability in hBMSCs ability to sustain their phenotype in long-term has been 
established for a long time (Collins and Dorshkind, 1987; Kuznetsov et al., 1997). Phinney 
and his colleagues (1999) investigated the growth properties, and osteogenic 
differentiation from over 50 donors and the results revealed a striking variation. Donor 
to donor variability is likely to be the consequence of heterogeneity in the population at 
the time of harvest. Consequently, accurate analysis of hMSC donor populations is 
essential before administering cells to patients in need of cell therapy regimens (Phinney 
et al., 1999). Therefore, our study investigated the growth properties and osteogenic 
differentiation of three donor samples cultured in human-derived supplements and 
reported each donor separately to give an overview of the consistency of any effects seen. 
In these projects, I utilised hBMSCs as a cell model to identify cell attachment and 
metabolic activity. Results of the hBMSC cells cultured in PCL scaffolds and cultured in 
human serum basal media (XF2) showed a promoting resazurin assay that indicated the 
cell attachment at 24 hours (see Fig 5.3.2). Furthermore, they exhibited a non-toxic effect 
and supported adherence and proliferation after 7 days. Our results agreed with Xue et 
al., (2017) who found that PCL scaffolds can sustain human MSC metabolic activity and 
proliferation potency. The osteogenic supplementations to the experimental media 
showed increased cell metabolic activity and proliferation potential in human-derived 
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culture media compared to 10% (v/v) FBS media on day 4. It is known that Dex supresses 
the proliferation of mesenchymal stem cells and upregulates differentiation (Taira et al., 
2003) and is required for stimulation of hBMSCs differentiation to osteoblasts in 3D 
culture. Subsequently, the reducing the amount of Dex in the PCL scaffolds culture media 
may be given the opportunity for enhanced cell proliferation. The cell metabolic activity 
in this experiment was assessed while metal, stainless steel rings were placed on the PCL 
scaffolds to prevent scaffolds floating in the media. However, these might minimise the 
reaction between the resazurin salt solution and cells underneath the metal rings. 
Therefore, the metal rings were removed for the cell metabolic activity assessment for 
subsequent experiments. 
To assess longer term growth (14 days) DNA per scaffold was used as a measure of cell 
numbers. This is because this value can be measured in the same lysate as ALP and 
therefore used to normalise ALP to cell number and because resazurin can be difficult to 
measure once extensive ECM has been made and cells are surrounded by ECM. The 
results supported the early metabolic activity measurement using resazurin and showed 
that there were distinct differences in cell populations between scaffolds cultured in 
human-derived media compared to 10% (v/v) FBS. This augmentation in PCL scaffold 
cellularity could be partially interpreted by the large number of cells seeded. However, 
Thibault et al., (2010) mentioned that the augmented cells number could not be 
interpreted by the greater seeding density. The presence of dexamethasone is well known 
to reduce the proliferation of MSC and allows to initiate differentiation of MSCs toward 
the osteogenic lineage (Fromigué et al., 2008; Castano-Izquierdo et al., 2007; Holtorf et 
al., 2005; Thibault et al., 2010). Another interpretation of the observed high DNA could 
be the cellular DNA after cell lysis was kept within a fabricated PCL fibre mesh mats and 
was not likely released in its entirety into the cell lysate solution. Thibault et al., (2010) 
seeded MSC on PCL scaffolds and observed that the amount of cellular DNA increased 
during the first week culture and decreased in the second week of seeding which is 
similar to the results of studies from Datta et al., (2006 and 2005) using titanium as a 
scaffold. Although our studies calculated the cellular DNA after two weeks, the result 
demonstrated the osteogenic media supported the cellular activity of DNA in the 
presence of Dex. A paper by Nishimura et al., (2015) mentioned that there was an 
increase in cell numbers and higher cell distribution density in the scaffolds for 14 days 
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compared to that for 7 days under osteogenic differentiation media. The possible 
explanation for such differences under human-derived media could be either a more 
efficient release of nutrients, and the deterioration of metabolic waste or the eventuality 
of human-derived formulations media effect on the cells might be superior to the 
dexamethasone's effect. 
ALP activity is an initial-stage marker of the osteogenic differentiation of MSCs (Douglas 
et al., 2012), PCL has been suggested to be a promising material for bone tissue 
engineering. However, the shortcomings of PCL are that it can be hydrophobic and does 
not have any demonstrated osteoinductive properties. This study hypothesises that 
hBMSCs seeded into electrospun PCL scaffolds cultured in xeno-free media particular 
human-derived formulations could undergo accelerated osteogenesis compared to in 
10% (v/v) animal-serum supplements. A comparison of ALP activity was investigated 
under both human-derived basal and osteogenic cultivation after 14 days. ALP activity is 
upregulated, and the speed of bone differentiation is promoted in both human-derived 
cultivation compared to that in 10% (v/v) animal-serum cultivation. Although the 
ingredients of osteogenic media increased ALP within 10% (v/v) FBS groups above a very 
low baseline, they appeared to have limited additive effect in the non-FBS media. 
However, in10% (v/v) FBS osteogenic media, ALP activity was significantly lower than in 
human-derived media. This indicates that using human-derived media for culture of 
hBMSCs when in electrospun PCL fibre mesh scaffolds can facilitated osteogenic 
differentiation. The human derived supplement appear to contain substantial 
components which support to differentiate the hBMSCs onto osteogenic lineage. 
Phosphate and calcium ions are an essential factor for supporting osteogenic 
differentiation activity by stimulating osteogenic marker genes; such as ALP, collagen 
type I (Klammert et al., 2009). The xeno-free media used in this study were derived from 
pooled human blood that contains the serum, platelets, growth factors and cytokines. 
Therefore, the possible pathway of human-derived formulations media to induce the 
bone-forming potential of the cells and stimulate genes of the c-Jun and c-fos that 
upregulate of gene expression of ALP at an initial stage of differentiation osteogenically 
(Meyer et al., 1993). Although Lin and colleagues (2009) and Maeno with co-workers 
(2005) informed that an extreme amount of calcium-phosphate deposition in the culture 
medium (˃ 10mM of calcium) might lead to increase cell toxicity, my results did not 
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illustrate drop of metabolic activity of cell even though there was reduced ALP in 10% 
(v/v) FBS osteogenic media cultured PCL scaffolds. Stein and Lian, 1995; Stein with his 
groups (2004) followed ALP activity over time and observed that the maturation of the 
matrix could after maximal ALP levels which then drop during the time of mineralisation. 
Consequently, the low ALP levels do not necessarily indicate slower cell differentiation 
along the osteogenic lineage but could be due to the time points of the sample collection. 
For successful bone tissue engineering, a scaffold is required to be biodegradable and 
osteoconductive, which also can support the attachment and proliferation of bone cells 
as well as guide bone formation. Recently, investigators have looked to use 
hydroxyapatites to enhance the osteoconductive potential of PCL scaffolds. Although HA 
is a constituent of the natural bone, it limits in some applications as a load-bearing 
implant scaffold material (Sun et al., 2011). This study hypothesises that culture of 
electrospun PCL scaffold in xeno-free media derived from human origin could enable 
accelerated osteogenesis compared to the animal serum supplementations. The 
mineralised matrix formation is marked for a later stage of osteogenic differentiation. A 
later-stage of osteogenic differentiation of MSCs are marked by collagen formation and 
the deposition of calcium phosphate. Mineralised matrix formation is commonly 
identified using measurements of calcium content. The assessment of ECM in electrospun 
PCL mesh scaffolds under different commercial human-derived basal and osteogenic 
culture regimes was investigated using SRS and ARS for explicitly labelling of collagen 
and calcium deposition under these conditions. The collagenous matrix formation in 
electrospun PCL mesh scaffolds by hBMSCs cultured in human-derived supplemented 
with osteogenic reagents was much higher than in basal culture media. XF2 basal culture 
medium containing human serum supported significant increased collagen production 
on PCL scaffolds over other conditions except medium treated by osteogenic 
supplements. Calcified matrix formation was also significantly higher in XF2 osteogenic 
media compared to other groups. Mineralisation is an indispensable stage of bone 
formation, taking place after collagenous matrix maturation. Collagen type I is considered 
to be the structural framework for connective tissues and plays a fundamental role in the 
cascade of events and leads to the construction of new bone from stem cells (Ryu et al., 
2011), and it is enforced by calcium deposition on the network of collagen. The high 
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amount of calcium in the scaffold reveals that the matrix has mineralised and the cells are 
trapped within the mineralised matrix. 
Although the dexamethasone maintains the osteogenic differentiation of MSCs, it has a 
complication for prospective in vivo studies because it does not occur naturally in the 
body, includes delays wound healing, includes osteoporosis, increases risk of infection 
and diabetes mellitus (Schäcke et al., 2002; Wagner et al., 2007). Many growth factors are 
associated with bone regeneration and enhance wound healing within short times. They 
are present in plentiful in the platelets and can be used with MSCs for bone regeneration. 
Therefore, the explanation of the mineralised matrix formation in electrospun PCL fibre 
mesh scaffolds may be due to the fibres absorption and retention of growth factors from 
the media for a long time, and continued secretion during the construction of ECM. 
The cellular differentiation typically causes discrepancies in growth rates, which may 
reflect disparities in the number of active cells within each donor hBMSCs population. To 
investigate this possibility, I evaluated levels of ALP activity in each donor population 
following growth for 14 days. The levels of this assay in cultures should reflect the 
number of osteogenic cells differentiation within the population. In our culture system, 
the normalised of ALP activity was expressed highly in both groups of human-derived 
culture medium over 10% (v/v) FBS basal and osteogenic culture medium. However, 
there was no significant difference between the human-derived media in all donors and 
conditions. This implied that the primary hBMSCs seeded on 3D PCL scaffolds and 
cultured in human-derived basal and osteogenic media had considerably undergone to 
osteoblast cells differentiation. My results were supported by Ciapetti and co-workers 
(2006) who reported an increase of ALP on PCL scaffolds under osteogenic stimulation. 
The concentration of Dex 10 nM did not substantially increase ALP activity. It is 
noteworthy that Wang et al., (2012) mentioned that the apoptosis levels correlated with 
high Dex concentration, and Dex dosage 100 nM might deteriorate MSC potential (Malladi 
et al., 2006). Contrary to expectations, our findings showed that human-derived basal 
media supported the initiation differentiation of hBMSCs to the osteogenic lineage even 
in the absence of dexamethasone, this may be because the formulation of human-derived 
culture media could contain intrinsic signalling factors that stimulate osteogenesis. The 
Wnt/β-catenin and Smad3 signalling pathways stimulated in the osteogenesis of human 
MSCs on PCL mesh mats. The Wnt signal can modulate various developmental process 
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like cell adhesion, gene expression, and tissue homeostasis (Clevers and Nusse, 2012; 
Blaschuk et al., 2002). Additionally, the Wnt/β-catenin signalling pathway represents an 
essential role in MSC growth and differentiation (Kim et al., 2013). Mbalaviele co-workers 
(2005) revealed using human and mouse genetics analysis that Wnt/β-catenin signalling 
supports the modulation of bone formation. Therefore, it would be interesting to observe 
the effects of the media examined in this thesis on the Wnt pathway. 
The total collagen production of hBMSCs from different adult donors on 3D PCL scaffolds 
was higher in all osteogenic media in most samples. XF2 basal culture medium supported 
a significant deposition in collagen production on PCL scaffolds. This implies that primary 
hBMSCs seeded on 3D PCL scaffolds and cultured in human-derived osteogenic media 
had deposited an extracellular matrix. The total calcium deposition by hBMSCs cultured 
in XF2 osteogenic media on 3D PCL scaffolds in both donors 4 and 7was significantly 
higher than the other groups and followed by XF2 basal culture medium. The osteogenic 
supplementation ingredients were continually augmented the calcium deposition on PCL 
scaffolds. There were no significant signs of biodegradation of PCL were indicated after 
21 days in vitro which confirms with the observation from Ciapetti co-workers (2006) 
who testified there were no significant signs of biodegradation of PCL were after 28 days 
in vitro. Interestingly, cells of donor-5 had low calcium deposition on PCL scaffolds over 
other donors (P<0.05). As a result, I suggest that the ECM construction was more efficient 
of collagen matrix formation than mineralisation of the ECM, this concluded lead to soft 
and not hard tissue formation. The results of this study showed that the presence of a 
human-derived growth formulation and Dex are significant factors for ameliorating of the 
osteogenic differentiation of hBMSCs cultured in vitro in 3-D culture. Indeed, the 
ingredients presented in human-derived basal culture media could have a sufficient level 
of biological activity to nurture the osteogenic induction of hBMSCs over 10% (v/v) 
animal-serum supplementations in the absence of exogenous osteogenic molecules like 
dexamethasone. Likewise, it might be considered as a novel strategy for delivering the 
bioactive features that support the construction of an ECM by cells in the engineered bone 
circumstances. The characterisation of the proteins and minerals component present 
within the human-derived media is paramount for understanding the compositions 
essential to sustain the osteogenic induction of MSCs and will be the subject of 
forthcoming researches. 
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In clinical tissue engineering, the essential question has been continuously how to 
transfer hMSCs to the bone defect site, and one option is to custom biodegradable 
scaffolds. hBMSCs from both XF2 osteogenic and basal culture media showed the bone 
layer formed on the whole surface of PCL scaffolds and covered all the scaffolds fibres, 
and produced an abundant ECM which well attached with PCL scaffold fibres and 
extended across of the pore architecture. Although 5% (v/v) HPL also produced the bone 
layer and covered the most surface area of PCL scaffolds, it did not cover the whole 
surface of the scaffolds whereas the 5% (v/v) HPL osteogenic media demonstrated more 
bone formation on surface of PCL scaffolds than its basal culture media. These results 
implied that the presence of human-derived formulation either with or without 
osteogenic supplementations could lead to enhance mineralised deposition and create a 
new bone layer better than 10% (v/v) FBS. Based on the SEM image, it is noticeable that 
the human-derived formulations could lead to enhance mineralised deposition. Thibault 
et al., (2010) suggested that the seeded of MSCs on PCL scaffolds cultured in 10% (v/v) 
FBS osteogenic media can create ECM constructs and sustain the osteogenic 
differentiation of cells. Based on my findings, we agreed with this data, and likewise, the 
human-derived basal media constructed ECM even in the absence of Dex. Human serum 
found in XF2 has ECM components such as vitronectin, hyaluronic acid, and fibronectin 
which permit attached cells and prevent apoptosis (Uhm et al., 1999). Therefore, I suggest 
that human-derived media particular XF2 might act as “glue” to increase the adhesiveness 
between the cells and fibres, and secret these crucial elements to sustain the cell potential 
activity, spreading and growth and support gap junction communication between cells 
(Wang et al., 2010; Xue et al., 2013). Schiller and co-workers (2001) and mentioned that 
the gap junctions induced OPN which led to mineralised ECM constructs. 
XO was employed to demonstrate mineralisation of osteogenic cells. Although it has not 
been regularly applied, in tissue engineering it is a robust methodology to visualise tissue 
mineralisation in 3D culture scaffolds. In an animal experiment, the XO stain is applied 
for constant observing of a new bone production through injected stain into the 
bloodstream in the same time where it expected a newly mineralised tissue creation 
(Kuhn et al., 2010; Y. Wang et al., 2006). CLSM fluorescence Xylenol orange stained 
scaffolds confirmed mineral deposition on the PCL scaffolds. The results contain that 
although the mineralisation was formed in all groups, it was considerably increased with 
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osteogenic supplementation. Moreover, the XF2 osteogenic media was confirmed to 
support substantial mineral deposition compared to other conditions. 
Supporting vasculogenesis is a requirement for successful bone repair and is needed to 
replenish nutrients and expel waste. The creation and growth of new blood vessels in PCL 
mesh scaffolds are considered essential for the success of implant (Kanczler and Oreffo, 
2008). VEGF release was analysed to appraise the effect of experimental media on cells 
in electrospun PCL scaffolds. My results showed that hBMSCs from both 10% (v/v) FBS 
and 5% (v/v) HPL basal culture media had significantly higher VEGF level compared 
toXF2 basal culture medium. In contrastXF2 osteogenic medium had augmented VEGF 
secretion, whereas there was a considerable reduction of VEGF secretion in 10% (v/v) 
FBS osteogenic medium compared to its basal medium. Further work could ascertain a 
suitable concentration of Dex for supporting bone mineralisation and secretion of VEGF. 
My findings indicated that a fundamental biological component present in the human-
derived media induced angiogenesis. The adding of stem cell-based therapies to the PCL 
mesh scaffold will ultimately yield vascular and osteogenic precursors that will intensify 
the development of tissue-engineered structure. 
The periosteal layer is considered to be an optimal source of stem cells for augmenting of 
bone healing (Agata et al., 2007; Zhang et al., 2006; Zhu et al., 2006) and clinically, the 
bone does not heal without a periosteal layer (Zhang et al., 2008). The primary essential 
components of periosteum have been grown on hyaluronic acid nanofibers (Ji et al., 
2006). Polymers that permit adherence to bone (or used to manufacture scaffolds for 
bone tissue engineering) will possibly be the more applicable for growing periosteum 
(Reed et al., 2009) though no specific work has examined periosteal growth on PCL 
scaffolds cultured in xeno-free media. HJPs are a suitable stem cell source for future 
studies; the limitation in this study was that there was a limited cell supply for further 
experiments. Schimming and Schmelzeisen, (2004) and Schmelzeisen with co-workers 
(2003) demonstrated that HJP cells seeded in 3D composite scaffolds could form a new 
bone that supports the dental implant and maxillary augmentation. Ryu and colleagues 
(2011) also exhibited that HJP cells enhance the mineralisation of ECM in 3D collagen 
scaffolds in vitro. The results collected from these studies revealed consistently with my 
outcomes that MSC derived from bone marrow and jaw periosteum needs 10 nM of Dex 
to enhance osteogenic differentiation. Reed with colleagues ( 2009) showed that 
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microfibrous PCL scaffolds require mimicking ECM structural design to enhance the cells 
proliferation, adhesion, migration, and differentiation osteogenically. Furthermore, this 
research indicated that HJP cells could proliferate and differentiate to the osteoblasts in 
3D PCL scaffolds. 
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5.13 Conclusion  
The primary objective of this chapter was to assess suitable human-derived medium on 
hMSCs cultured on electrospun PCL scaffolds to sustain growth and osteogenically 
stimulate repair for the bone part of cleft palate. This objective was accomplished that 
PCL scaffolds could be an appropriate material as it exhibited biocompatible and 
permitted progenitor cells differentiation osteogenically. We further supported that the 
long-term goal of using human-derived media to create a bone layer on PCL scaffolds for 
repairing of cleft palate and eventually minimize the quantity of surgical operations 
required for cleft palate reconstruction and drop the postoperative complications. The 
next objective was to investigate the ability of human-derived culture medium for 
increasing osteogenic differentiation of osteoprogenitor cells on electrospun PCL mesh 
scaffolds. This objective was supported that xeno-free media encouraged the human 
serum (XF2) and human platelet lysate could support both hMSC and HJP cell 
proliferation with increased mineralization on electrospun PCL scaffolds even in the 
absence of dexamethasone. The other objective was to evaluate the different donors’ 
differences in cell proliferation, expansion, and osteogenic stimulation to generate the 
ECM construct. Although our results indicated that total mineral deposition of hMSCs 
within the PCL scaffolds in all donors was sustained and increased, there was differential 
results between cells from different donors for example cell of one donor increased in 
collagen formation but reduced in calcium deposition. CLSM fluorescence images of 
culture hBMSCs in human-derived osteogenic media confirmed mineral deposition was 
presented on the cells seeded PCL scaffolds. The VEGF secretion of hBMSCs by osteogenic 
supplementations was inhibited in 10% (v/v) FBS and XF2, while no effect could be seen 
in 5% (v/v) HPL. The human bioactive molecules contained in human-derived 
formulations media particular in XF2 were a therapeutically meaningful pre-clinic 
medium and a safe substitution for propagation, expansion, and osteogenic stimulation 
of hMSCs with and without a requirement of exogenous drugs.  
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5.14 Summary 
● The PCL electrospinning mats are compatible with the engineering of bone tissue.  
● Both hBMSCs and HJPs are suitable for cell sources to create a bone matrix in the 
electrospun PCL scaffolds; therefore, they are a beneficial model cell for further 
research. 
● hBMSCs and HJPs on PCL scaffolds cultured in human-derived media were induced to 
significantly increase mineralization. 
● A completed thin layer of bone covered the top surface of the electrospun PCL 
scaffolds with deeply distributed hBMSCs detected on the SEM images, and the 
greatest amount of ECM was seen in both human-derived media supplemented with 
osteogenic molecules and basal culture of human-derived formulations. 
● The different donors were affected differently by stimulates of vitro-generated matrix 
mineralisation. 
● The application of hBMSCs cultivated on the electrospun PCL scaffolds using human-
derived media can have formed a structural of the bone matrix creation that can 
implant to the bone defect of the cleft palate. 
● CLSM fluorescence images of culture hBMSCs confirmed mineral deposition was 
presented on the PCL scaffold. 
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5.15 Future work 
● Future-upcoming studies could promote appraise osteogenically differentiation of 
cells seeded on electrospun PCL fibres scaffolds cultured in human-derived medium 
by determining osteogenic gene expression. 
● Altered concentrations of PCL scaffolds could be formed to evaluate the suitable PCL 
electrospun scaffold for improving osteogenic differentiation such as 2.5 or 7.5 
wt% PCL. 
● Evaluate the electrospun nanofibers PCL scaffolds as a membrane for improving 
osteogenic differentiation. 
● Different concentrations of human serum and HPL could be applied and the 
osteoblasts-like cell differentiation on 3D culture assessed. 
● To determine the increasing mineralization of cell numbers on the top level of 
scaffolds and VEGF secretion on osteoprogenitor cells in the absence of exogenous 
osteogenic drug delivery such as Dex. 
● The cell distribution should be determined throughout scaffolds culture in human-
derived formulations. 
● The comparison of the effectiveness of PCL scaffolds on the mineralization of cells 
with other scaffolds that use in clinical applications. 
● Future work could be necessary to realise completely the effect of human-derived 
medium on hMSCs biology in vivo. 
● More investigation of HJP cells behave in human-derived media to increase 
propagation and enhance mineralisation.  
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CHAPTER SIX: GENERATION OF TRI-LAYER POLY (ɛ-CARPOLACTONE) 
SCAFFOLDS TO CREATE ORAL MUCOSA AND BONE CO-CULTURES FOR 
CLEFT PALATE REPAIR 
6.1 Introduction 
The common obstacle facing oral and maxillofacial surgeons during palatal closure is 
often the deficiency of oral mucosa. After palatal closure the most important issues are 
midface growth inhibition because of soft tissue intrusion and scar tissue formation at 
the palatal and alveolar regions (Moharamzadeh et al., 2012; Payne et al., 2014). To 
overcome this unmet clinical need evaluation of an alternative cell source for bone 
augmentation to enhance the cleft palate repair is warranted (Bueno et al., 2009; 
Lohberger et al., 2013). Some tissue engineering approaches have focussed on utilising 
the patient’s own MSCs with the results demonstrating much potential for the cells in cleft 
defect repair in the alveolar ridge region. Hibi et al. (2006) successfully undertook a cleft 
repair for a 9-year old female patient, bone formation with the support of the canine 
eruption at the anterior segment of alveolar bone occurred in postoperative two years. A 
successful of the grafted region for repairing of cleft palate need to close the 
communication between the oral and nasal cavities. The repaired region should enable 
healthy orofacial development with bone growth and to avoid soft tissue migration into 
the bony cleft walls inside the cavity.  
PCL electrospun scaffolds should be biocompatible, biodegradable, interconnected pore 
network, and the appropriate mechanical strength to encourage the healthy growth of 
soft and bone tissue (Cipitria et al., 2011; Delaine-smith et al., 2014; Reed et al., 2009). 
Recently, a spinning tri-layer scaffolds technique has been developed using a nanofibre 
layer as a barrier between two microfibre layers (Bye et al., 2013; Puwanun, 2014). The 
tri-layer electrospun PCL scaffolds may be suitable for supporting two different cell types 
while maintaining their separation by the incorporation of the nanofibrous layer 
compared to a specific time of culture media. 
Bone tissue engineering combined with oral mucosa has appreciably been achieved 
autonomously. The essential purpose of this chapter was to create and investigate a novel 
combination of the bone (top layer) and soft tissue (bottom layer) with barrier to 
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separate them to create a multi-tissue PCL scaffolds for reconstruction of cleft palate in 
vitro. The objective of this chapter was to investigate the simple, unique process to 
fabricate 3D trilayer electrospun PCL scaffolds then, to assess whether they can assist cell 
metabolic activity, attachment and adhesion, subsequent proliferation and cells 
differentiation. Thus, I tested whether the tri-layer PCL scaffolds can encourage the 
engineered bone matrix establishment and separate three different types of cells include 
hBMSCs and both immortalised oral keratinocytes (FNB6) with normal oral fibroblast 
(NOF). 
6.2 Methods 
6.2.1 Culture of immortalised oral keratinocytes cell line (FNB6) 
FNB an immortalised oral keratinocyte cell line originally isolated from buccal mucosa, 
which was acquired from the School of Clinical Dentistry, University of Sheffield. Cells 
were chosen to avoid the shortage of gingival tissue resection clinically and the variation 
of inter-donors that construct a beneficial and consistent pattern for normal oral 
epithelial cells. The morphology and proliferation of cell were observed using a light 
microscope. The cells were cultured in Green’s medium and changed every 2-3 days. Cells 
were passaged when they reached 80% confluence. 
6.2.2 Culture of normal oral fibroblasts (NOF) 
Normal oral fibroblasts cells were acquired from the School of Clinical Dentistry, 
University of Sheffield. These cells were selected as an alternative of dermal cell and to 
produce a valuable model of normal oral fibroblasts during tissue engineering of oral 
mucosa construction. The morphology and proliferation of cell were observed using a 
light microscope. The cells were typically cultured in DMEM supplemented with 10 % 
FCS (v/v) and changed every 2-3 days. Cells were passaged when they reached 80% 
confluence. 
6.2.3 Tri-layer PCL scaffolds fabrication 
A 10% (w/w) PCL micro-fibre solution was created by dissolving PCL Mn=80,000 in DCM. 
A 5% (w/w) PCL nano-fibre solution was performed by dissolving PCL in a mixture of 
methanol and DCM in the weight ratio of 1:9 (methanol/DCM). Both solutions were put 
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in a water bath for 1 hour and then left on a magnetic stirrer at room temperature to 
ensure homogeneity. 
The fabricated tri-layer PCL scaffolds were fabricated in an electrospinning rig as 
previously described in chapter 2 (Bye et al., 2013; Delaine-Smith et al., 2014). Briefly; a 
tri-layer of PCL microfibres was fabricated at 17kV, a working distance of 17cm, a flow 
rate of 40μL/min, and a 300 rpm of drum rotation speed at room temperature. The 
solutions were released by 12 needles. The parameters of the nano-fibre electrospinning 
were the same as the microfibre scaffolds (above) except that the working distance was 
10 cm. Scaffolds were developed using 40 mLs of 10% (w/w) PCL polymer solution to 
create the first layer of the micro-fibres. Then 20 mLs of 5% (w/w) PCL polymer solution 
was dispensed to create a middle layer (the nano-fibres), while 40 mLs of 10% (w/w) 
PCL polymer solution was continuously spun to produce the third layer of the micro-
fibres (Figure 6.2.3).  
 
Figure 6.2.3: Schematic of the final tri-layered scaffold created with three layers: microfibers 
(red), nanofibers (black), and microfibers. These layers are made from poly (caprolactone) 
with different concentrations. 
6.2.4 Cell seeding on tri-layer PCL scaffolds 
Three different cell types were used in these experiments: 1) hBMSCs, 2) NOFs and 3) 
FNB6. The scaffolds were cut and mounted on a CellCrownTM and sterilised as previously 
described in chapter 2. Briefly, after sterilisation with 80 % (v/v) ethanol, the samples 
were immersed within a well plate in two different basal culture media (XF2 and Green’s 
media) to enhance cell attachment and incubated at 37oC in 5% CO2 humidified 
environment. Before cell seeding, the basal culture media was removed and hBMSC (2 x 
105) in 100 µL directly seeded onto the top of the electrospun tri-layer PCL scaffold within 
the inner diameter of the CellCrownTM and incubated for 1 hour to enable the cells to 
attach. 2 mL of both of the two experimental media was added and the cultures incubated 
for 24 hours at 37oC. After this incubation period, the PCL scaffolds mounted on the 
CellCrownsTM were moved to fresh well plates and submerged in fresh culture media 
10% (w/w) PCL micro-fibres  
5% (w/w) PCL nano-fibres 
10% (w/w) PCL micro-fibres 
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supplemented with osteogenic supplementation (Dex 10 nM, AA 50 µm, and βGP 10 mM) 
on day 1 and cultured for a further 10 days with twice-weekly media changes.  
At day 10, the media was removed, and NOF (5 x 105) in 100 µL seeded onto the other 
side of tri-layer PCL scaffolds and left for 1 hour for attachment. 5 mL of both of the two 
osteogenic and basal culture media was added and cultured for 24 hours. After 24 hours, 
the CellCrownsTM were transferred to fresh well plates and cultured for 5 days before the 
addition of FNB6 (5 x 105) in 100 µL to the upper layer. After 5 days, the cultures were 
raised to air to the liquid interface for 7 days with media changes twice weekly. 
6.2.5 Fixing the tri-layer PCL scaffolds seeded cells 
The scaffolds were fixed in 2 mL of 4% (v/v) paraformaldehyde (PFA) for 20 min then 
removed it and washed with PBS and finally stored in PBS at 4o C. To prepare 4% (v/v) 
PFA, 100 mL of diH2O was heated to 60oC 4 g of PFA was added and stirred until dissolved 
after which 1 mL NaOH (1M) was added with continual stirring until the solution became 
clear. 
In preparation for cryosection, the scaffolds were bisected. One section was fixed while 
the second section was prepared for cryosectioning. The scaffolds were embedded in 
optimal cutting temperature (OCT) and submerged in liquid nitrogen. 6–30µm thick 
sections were cut using a cryostat at -20oC. The cut sections were immediately 
transferred to Poly-L-lysine-coated microscope slide before staining with DAPI (Fischer 
et al., 2008).  
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6.3  Results 
The purpose was to observe the morphology and evaluate qualitatively the behaviour of 
the cells cultured in different media under a microscope. 
6.3.1 Evaluation of the morphology and growth of immortalised oral keratinocytes cell 
line (FNB6) in osteogenic media 
To ensure that epithelial growth could be supported in the media used within this study, 
the cells were transferred from Green’s media into the experimental media using 
stepwise reductions (v/v): (100%, 50%:50%) compared to a 4-day culture period. Cell 
morphology was assessed using an inverted light microscope. Cell proliferation was 
supported in all conditions, the characteristic features of the morphology of cells at high 
confluence were noted with cobblestone-like in shape and consistent with standard 
culture conditions. (Figure 6.3.1). 
  




   
   
Figure 6.3.1: Morphology of FNB6 cells in a commercial human-derived basal culture media 
(XF2) compared to Green’s media from 1 to 4 days. (A) Control Green’s media at 24 hours 
while (B) control Green’s media on day 4, (C) 10% (v/v) FBS (α-MEM supplemented with 
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6.3.2 Evaluation of the morphology and growth of normal oral fibroblast (NOF) in 
osteogenic culture media 
Normal oral fibroblasts are typically cultured in DMEM supplemented with 10% (v/v) 
FCS. To ensure that the media in this study had no detrimental effect on NOF growth cells 
were transferred into the experimental media using stepwise reductions (v/v): (100%, 
50%:50%) compared to a 4-day culture period. Cell morphology was assessed using an 
inverted light microscope at high confluence cells had an elongated, spindle, fusiform 
morphology, consistent with standard culture conditions. Cell proliferation was 
supported in all conditions with confluence reached quickest in XF2 compared to 10% 
(v/v) DMEM and alpha-MEM (Figure 6.3.2). 
   
   
Figure 6.3.2: Morphology of NOFs cultured in a commercial human-derived basal culture 
media compared with 10% (v/v) FBS-DMEM media (v/v) from 1 to 4 days. (A) control 10% 
(v/v) FBS-DMEM media at 24 hours while (B) control 10% (v/v) FBS-DMEM media on day 4, 
A B 
C D 
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(C) 10% (v/v) FBS (α-MEM supplemented with 10% (v/v) of FBS), and (D) XF2. Scale bar = 
100 µm, n=3 
6.3.3 Evaluation of the morphology and growth of hBMSCs in Green’s media and XF2 
hBMSCs passage 4 were seeded in at a density of 1 x 104 cell/cm2 in Green’s media (as a 
described in chapter two), XF2, and 10% (v/v) FBS (as a control) media for 4 days. The 
morphology of the cells adhesion was similar to NOF cells. The results showed that the 
cells cultured in XF2 had higher cell proliferation compared to both the control media and 
Green’s media. The cells cultured in Green’s media had marginally increased in density 
compared to the control media at the end of the period (Figure 6.3.3).  
       
    
Figure 6.3.3: Morphology of hBMSCs cultured in Green’s media and XF2 media compared 
with 10% (v/v) FBS media from 1 to 4 days. (A) Control 10% (v/v) FBS media at 24 hours while 
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6.4 Examination of the cell seeded tri-layer PCL scaffolds 
Examination of the tri-layer PCL scaffolds using light microscope after 24 days revealed 
a dense dark layer on the middle of scaffolds which represented the nano-fibrous 
separating membrane (Figure 6.4 A, red arrowheads). When, the tri-layer PCL scaffolds 
were visualised using a fluorescence microscope a dense layer could be seen which likely 
represents a barrier region (Figure 6.4 B, red arrowheads). A nuclear stain (DAPI) was 
used to detect cells. Cells were seen on both sides of tri-layer PCL scaffolds in XF2 
osteogenic media (Figure 6.4 C, yellow arrowheads). This implies that XF2 osteogenic 
media with 10 nM Dex supported and encouraged both bone tissue and oral mucosa 
tissue. Although the Green’s osteogenic media also showed a build–up of a layer of cells 
on one side, this was not seen on the other (Figure 6.4 D, yellow arrowheads). The 
limitation of this result was that it difficult to distinguish the layer of bone cells from the 
layer of oral mucosa tissues. Furthermore, I did not perform the characterisation, 
therefore, it seems that the layers differ only in concentration of PCL solution used in the 
dispensing liquid. 
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Figure 6.4: Examination of the lateral aspect of the tri-layer PCL scaffolds co-cultured with 
hBMSCs and NOFs and FNB6 cells. Cell presence was assessed by labelling with DAPI (pale 
blue) after 24 days of culture. (A and B) control scaffolds under an inverted light microscope 
and fluorescent microscope respectively, the red arrowheads indicate the middle layer. (C and 
D) Tri-layer PCL scaffolds after 28 days with cells cultured in osteogenic media (Dex 10 nM) 
XF2 and Green’s media respectively, the yellow arrowheads indicated the layer of cell growth. 
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6.5 Discussion 
The purpose of cleft palate treatment is to repair both the bone and soft tissue. The 
previous chapter discussed how to manage the bone defect via support of the osteoblasts 
and creation of a bone layer in the 3D PCL scaffolds. Consequently, in this chapter, I have 
exhibited the implementation of a tissue engineering method for treating of cleft palate 
through creating a single trilayer electrospun PCL scaffold to encourage osteoblast and 
fibroblast growth with the perspective of filling the cleft defect. 
The notions of segregation of tissue in regenerative treatments are not new. They have 
been recognised in dentistry where a guided tissue has been created to separate the bone 
forming tissue from the soft tissue in periodontal regeneration (Moreau et al., 2007; 
Retzepi and Donos, 2010) such as collagen membrane, guided tissue and guided bone 
regeneration (GTR and GBR), Teflon, and biodegradable polymers (Lundgren and Slotte, 
1999; Sabir et al., 2009). Although the commercial collagen membrane has good 
biocompatibility and a rapid biodegradation rate, it can be problematic to remove if there 
are problems and can introduce a risk of prion disease transmission if extracted from 
animal tissue (bovine or porcine) (51). Consequently, the material sources used in clinical 
tissue engineering treatment must be mindful to avoid any risk of xenoantigens 
transmitted to the recipient (Oikonomopoulos et al., 2015) (51). 
The technique of electrospinning was selected to fabricate the tissue engineered scaffolds 
because it has a versatility for creating the different diameters of polymer fibres from 
nano-fibres to micro-fibres, it can be functionalised for many purposes, has good 
mechanical properties, and can be used with different kinds of polymers such as poly-D-
lactic acid (PLA) and poly-glycolic acid (PGA). However, the drawback of electrospinning 
is the low rate of production (Rim et al., 2013). Bye and colleagues (2013) successfully 
produced tri-layer scaffolds using polyhydroxybutyrate-polyhydroxyvalerate (PHBV) for 
the nano-fibrous membranes and PLA for the micro-fibres membranes. However, the 
polymers used were not optimal for producing bone tissue because of the rapid 
degradation rate of PLA. Many researchers used a composite scaffold for bearing a 
different cell type such as ceramic/collagen. Herein, the technique was adjusted to create 
a trilayer scaffolds from PCL following the methods of Bye and colleagues. 
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Observing of the cryosection of the tri-layer of PCL scaffolds under the microscope 
indicated that the middle layer was dense indicating successful deposition of the nano-
fibrous layer. The aim is that this layer would act as the separation membrane and 
prevent cells to cross to the opposite side of the scaffold. Whereas, the top and bottom 
layers contained mostly micro-fibres and were occupied by hBMSCs on one side and both 
NOF and FNB6 cells on the opposite side, assuming that the cells remained segregated 
according to how they had been seeded. The shortcoming of this research is that it only 
used one experiment in triplicate. Furthermore, although the samples of PCL cryosection 
were immediately transferred to the Poly-L-lysine-coated microscope slide, they were 
physically unstable, fragile and easily removed from the coated slide. 
In soft tissue regeneration, Puwanun (2014) and Hutmacher et al., (2001) previously 
chose human dermal fibroblasts (HDFs which are responsible for repairing connective 
tissue in skin injury) to produce the soft tissue layer on PCL scaffolds, and the result 
showed that the PCL scaffolds could encourage HDFs growth. However, in the clinical 
application of the soft tissue correction it would be better to use oral fibroblasts 
harvested from oral mucosa which can be collected from either gingival biopsies or the 
first surgical step for the closure of cleft lip (cheiloplasty). 
Prior to this study it was not known how the NOF and FNB6 cells would grow in the xeno-
free media used in this study. The cell proliferation of NOF and FNB6 cells indicated that 
the human-derived formulation media support them in a similar way to control media 
and supported superior growth of cells compared to 10% (v/v) FBS basal media. These 
results agreed with Tsugeno et al., (2014) who suggested that human gingival fibroblasts 
grow well when cultured in STK media (chemically-defined serum-free media) during 4 
days. 
DAPI fluorescent staining was utilised to detect and visualise the position of hBMSCs and 
oral mucosa cells. Although the images look strange and there is not the usual blue colour 
this could be because of the thickness of the scaffold, DAPI images exhibited that cells co-
cultured on tri-layer PCL scaffolds can sustain separation on their specific regions; the 
dense dark layer in the middle region indicates that there was no cells migration in this 
region. However, some cell displacement into the trilayer PCL scaffolds was observed. 
This supports my hypothesis that the middle layer obstructs the crossover of cells in the 
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scaffolds because of its low porosity and is in agreement with Puwanun (2014) results on 
tri-layer membranes made from the same polymer and other polymers Bye et al. (2013). 
6.6 Conclusion 
This study provides preliminary evidence, that tri-layer PCL scaffolds could preserve and 
encourage the multi-culture of hBMSCs (on top) and both NOF with FNB6 cells (on 
bottom) and permits to the differentiation of osteogenic progenitor hBMSC cells. The 
scaffold does not permit the different cells to migrate to the opposite side during 24 days, 
probably because of the nanofibre structures of the middle layer of the tri-layer PCL 
scaffold, which has low porosity so is able to isolate different cells. The interest of this tri-
layer PCL scaffold could be in its ability to assist and isolate of hard and soft tissue until a 
newly healed tissue becomes mature. I suggest that the healing of the soft tissue would 
be faster and prevent movement to the bone tissue area that indicates slower healing. 
This could decrease the amount of wound tension created from the scar at the surgical 
area after the surgery of cleft palate, reduce the inhibition of the palate growth that occurs 
when a bone graft is implemented too early. The tri-layer PCL membrane may have a 
beneficial in reconstructive oral and craniofacial surgery that comprises multi-types of 
tissue such as GTR “guided tissue regeneration” in periodontology and alveolar ridge 
augmentation for a dental implant. 
6.7 Summary 
 PCL polymer fabricated trilayer electrospun fibre mat was revealed to sustain cell 
metabolic activity, attachment, and permit subsequent proliferation and cell 
differentiation compared to 24 days, in the meantime, it assisted segregation between 
bone formation and oral mucosa cells. 
 Trilayer PCL electrospun scaffold is considered as a suitable basement membrane for 
promoting the intrinsic repair of cleft palate. 
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CHAPTER SEVEN: CONCLUSIONS AND FUTURE DIRECTION 
The cleft palate therapy is one of the considerable challenges to face the orofacial surgeon 
and has several shortcomings such as numerous surgical interventions advance, the long 
time needed to complete the treatment, and donor site morbidity from the bone 
harvesting procedure. The perspective of using strategy of bone tissue engineering 
remains to increase the attention of the oral and craniofacial surgeon, may conquer the 
impediments to successful surgery through combination of biomaterial engineering 
scaffolds and other biochemical reagents with cells transplantation to emerge as new 
techniques for reconstructive and repairing of craniofacial bone and cleft palate. 
7.1 Primary human bone marrow mesenchymal stromal stem cells 
Human BMSCs are commonly applied in the engineering of bone. Chemical reagents 
scaffold topography and characteristics of surface coatings can stimulate hBMSCs 
differentiation. My results emphasized on hBMSCs and HJPs are able to osteogenesis 
through the ability of cells to differentiate into osteoblasts and deposit collagen and 
calcium on their ECM cultured in different xeno-free media and supplementations. 
Interestingly, all these cell types dramatically increased their proliferation, 
differentiation, and ECM deposition when they were cultured in human-derived 
formulations compared to 10% (v/v) FBS culture in both 2D monolayer and 3D scaffolds, 
although the size of the difference depended on donor and supplements used. HJPs have 
recently been used in bone tissue engineering because they can be straightforwardly 
harvested from the oral periosteum with minimum oral surgery compared to harvesting 
of bone marrow mesenchymal stem cells. 
Dexamethasone (Dex) is a glucocorticoid which clinically exerts an anti-inflammatory 
and immunosuppressant effect and is used for the treatment of different systemic 
diseases. Dex is widely used in vitro to induce early cell differentiation for a range of 
mesenchymal lineages. The mechanism of Dex is via its action on glucocorticoid 
receptors. Dex can have a paradoxical biphasic influence through increased proliferation 
after exposure to low-dose Dex and inhibition of growth after exposure to high-dose Dex 
on hBMSC and HJP cells. My results confirm that Dex influences the physiological function 
of hBMSC and HJP cells in vitro.  
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VEGF is a polypeptide substance derived from platelets and osteoblast cells to stimulate 
new blood vessels during wound healing. Insufficient vascularisation is a common feature 
of non-healing wounds and bone graft failure. Vascularisation is essential to the success 
of the engineered bone tissue at the site of an implant as it encourages the neighbouring 
endothelial cells to create new blood vessels to penetrate into the construct. My 
experiments on primary hBMSCs seeded in electrospun 3D PCL scaffolds on day 21 
indicated that osteogenic media in 10% (v/v) FBS significantly inhibited the secretion of 
VEGF although it did not completely diminish. Whereas osteogenic human-derived 
media, specifically, 5% (v/v) HPL significantly promoted angiogenesis indicating they 
would support creation of blood vessels inside the 3D electrospun PCL scaffolds. 
Mesenchymal stem cells are the best choice for bone tissue engineering because they can 
differentiate into different lineages. However, the best source of stem cells cannot easily 
recognise because the performance of extracted cells can differ based on several factors 
such as the site of the defect (either craniofacial or long bone), patient age, medical state, 
the cell collection approaches, and cell passages. The donor source from which cells were 
obtained affected cell proliferation, differentiation and in vitro-generated matrix 
mineralisation in 2D monolayer and 3D electrospun PCL scaffolds. In the cleft palate 
treatment, it requires further effort to elucidate what would be the best source of 
appropriate cells. 
Future investigation is required: 
 Evaluating the surface markers of osteogenic differentiation of cells such as  
cytokines, antigens, and genes expression of implicated in the early and late steps 
of cell differentiation. 
 Evaluating the of the osteoprogenitor cells differentiation osteogenically from many 
various anatomic harvesting regions. 
 Appraising the quality of mineralisation relative to a real bone by FT-IR, XRD, or EDX. 
7.2 Xeno-free media 
Xeno-free media defined in terms of cell culture is a media extracted from different 
sources, particularly human, which does not contain any animal-derived components. 
Xeno-free media has been shown to enhance cell proliferation, ECM, and calcium 
deposition in different cell types. My study used different commercial xeno-free media 
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for culture of two cells types, hBMSCs and HJPs, then compared this to 10% (v/v) foetal 
bovine serum (as a control) on both monolayer and 3D culture. My results showed that a 
type of media containing human serum commercially supplied as ‘human mesenchymal-
XF expansion medium’ (XF2) with supplementation could significantly enhance both cells 
type’s proliferation and osteogenic differentiation and support ECM construction by 
enriching calcium deposition and collagen formation compared to the animal-derived 
serum supplementation. XF2 augmented the metabolic activity, increased the ALP with 
mineralisation, and DNA quantity of hBMSCs to a greater extent compared to any other 
culture condition tested here. In addition, it was confirmed that a suitable Dex 
concentration for hBMSC is 10 nM, which induces the highest cell maintenance. While the 
100 nM of Dex concentration causes a reduction in cell number, this may be related to the 
physiological concentration of glucocorticoids, which has also been reported to be 
around is 10 nM. Hence, XF2 may be a useful xeno-free pre-clinical medium for 
proliferation and differentiation of hBMSCs towards therapeutic bone differentiation for 
tissue engineering applications.  
Osteogenic differentiation of hBMSCs was poor in ‘stem x vivoTM xeno-free human MSC 
expansion media’ (XF1), XF1 and these cells exhibited an insufficient proliferation and 
early osteogenic differentiation marker compared to the XF2 and 10% (v/v) FBS.  
Many factors will influence the cellular response to a media composition such as cell 
source (donor), and the biological and chemical supplements used to stimulate 
osteogenesis. Providing the appropriate balance of these factors could enable scale-up of 
clinical applications for bone graft substitutes during cleft palate repair and engineered 
bone tissue construction. Improvement of the methods to promote osteogenesis and 
vasculogenesis by the cells, would substantially improve integration between the 
construct acting as a bone graft substitute and the surrounding implanted region. 
Further investigation will be needed to: 
● Characterise of the biological activity present when cells are grown in human-derived 
medium to establish if this is sufficient to induce osteogenic differentiation. 
● Investigate fresh human-derived media collected from donors to support the cells and 
increase mineralisation 
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 HJPs indicated variability in growth rate and differentiation properties. Thus, it would 
be interesting to investigate the osteogenic potential of HJPs from more donors to 
compare the outcomes. 
7.3  Three-dimensional model platform for understanding the bone tissue 
engineering 
Several methodologies have been performed to fabricate the suitable scaffolds to restore 
the tissue damage by repairing the function. In the last decade, electrospinning has been 
used in the regeneration of different tissue because it is easy to fabricate a wide size of 
fibrous diameter and can be adjusted to modify a quantity of parameter. In my 
experiments, 3D electrospun PCL scaffolds were applied because their good 
processability and mechanical strength are preferred for bone reconstructions and they 
are well biocompatibility with neighbouring implanted structure. They can assist and 
maintain the hBMSC and HJP cells for propagation, expansion, and differentiation to the 
osteoblast-like cell with 10 nM Dex concentration. 
On the other hand, the limitations of PCL scaffolds are that they have neither 
osteoconductive nor osteoinductive characteristics. Based on a previous study, I choose 
the 10wt% PCL electrospun scaffold in my experiments, which was revealed to be an 
appropriate membrane for supporting cell, propagation, and improving osteogenesis. I 
found that HJPs and hBMSCs could form the bone matrix in electrospun PCL scaffolds. 
Moreover, HJPs and hBMSCs seeded on PCL scaffolds cultured in human-derived media 
induced a significantly higher mineralised matrix deposition than 10% (v/v) FBS.  
The SEM images showed a completed layer of bone covered the top surface of the 
electrospun PCL scaffolds with hBMSCs distributed throughout. Furthermore, the 
greatest matrix mineralisation was induced in the human-derived media supplemented 
with osteogenic substances and basal culture of human-derived formulations. Likewise, 
donor source affected in vitro-generated matrix mineralisation. The results indicated that 
total mineral deposition of hBMSCs within the PCL scaffolds in all donors was sustained 
and increased. VEGF secretion of hBMSCs by osteogenic supplementation was inhibited 
in 10% (v/v) FBS and enhanced in XF2 compared to basal culture media, while no effect 
could be seen in 5% (v/v) HPL. Therefore, the osteogenic media of human-derived media 
supported vasculogenesis in the scaffolds. Thus, this study could be open the gate to solve 
a significant obstacle of large-scale tissue-engineered grafts, which is a deficiency of new 
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vasculature inside the graft. Interestingly, the individual bioactive molecules contained 
in human-derived formulation media particular in XF2 were a therapeutically meaningful 
pre-clinic medium and a safe substitution for proliferation, expansion, and osteoblast-like 
cells differentiation with and without a requirement of exogenous drugs.  
Further investigation will be needed to:  
 Appraise the osteogenic differentiation of the cells seeded on PCL scaffolds culture in 
the human-derived medium by investigating osteogenic gene expression.  
 Evaluate the electrospun microfibers PCL scaffolds as a membrane for improving 
osteogenic differentiation in vivo 
 Assess different concentrations of human serum and HPL in 3D culture to verify 
whether I have indeed identified the best concentrations for osteogenesis. 
 Determine whether the higher mineralisation and VEGF secretion observed on 
scaffolds can be routinely produced in the absence of exogenous osteogenic inducers 
such as dexamethasone. 
 Compare the effect of PCL scaffolds on the mineralisation of cells with other scaffolds 
used in clinical applications. 
● Future work could be necessary to understand the effect of human-derived medium 
on hBMSCs biology in vivo. 
7.4  Trilayer PCL fibrous mat scaffolds 
Several kinds of research have addressed the formulation of tissue engineering strategies 
for oral and maxillofacial reconstruction and characterise what architectures of scaffold 
and materials would have the best function. In this respect, the scaffold's design should 
give a physiological condition and mimicking the natural maxillofacial construction. My 
proposal is to use a trilayer PCL electrospun membrane, attempting to imitate the 
functional construction of the orofacial region by possessing oral mucosa in one side and 
bone tissue on the other segregated by a membrane. The soft tissue (NOF and FNB6) cells 
were seeded on one side within a micro-fibre layer and hBMSCs on the other side also 
within a micro-fibre layer and these were separated by the nano-fibrous layer located at 
the middle of the scaffold. My study indicates that the tri-layer scaffold can preserve and 
encourage the coculture of cells between hBMSCs and soft tissue cells and permit 
differentiation of the osteogenic progenitor hBMSC cells. In addition, the scaffold 
maintained separation of both hard and soft tissue for long time culture (24 days).  
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Further inquiry is included: 
 Assess the ECM formation and confine the collagen production on the membranes for 
long time culture. 
 Investigate the different cell populations that comport with trilayer PCL membrane in 
both short and how they support the engineered tissue over the long term in vivo. 
 Compare the amount of VEGF secretion from the biomaterial scaffolds with the 
quantity of VEGF secretion in the implanted bone graft for inducing angiogenesis. 
7.5 Clinical implementation of craniofacial reconstruction 
Recently, the surgical treatment of cleft palate starts with management when the child is 
6 months to one-year-old. However, the disturbance of orofacial development is occurred 
in several dimension because of the formed fibrosis tissue may intrude into the alveolar 
defects. Wolford and Stevao, (2002) mentioned that the bone cleft palate repair occurs 
between 8 to 9 years (before the permanent canine teeth erupt on the defect area) using 
autologous bone graft which is recommended in the treatment of cleft palate. This 
procedure can also lead to inhibition of maxillary growth. The ideal time for cleft palate 
management is still controversial. The autologous graft is the gold standard to achieve 
bone regeneration. However, it has several drawbacks such as the insufficient quantity 
and quality of grafts, morbidity, threatening the donor site, creating bone resorption, and 
prolonged numbness or paraesthesia of the leg. While allografts could cause 
immunogenic reactions and the risk of contamination from pathogen could transmit to 
the patient. The functional reconstruction of cleft palate using tissue-engineering 
technology that may mitigate the concerns of the multiple surgical repairs. The 
advantages of tissue-engineering are grafting of the healthy tissue takes from the body, 
cells can be isolated, proliferated and expanded under an appropriate cell culture 
conditions then seeded on biocompatible scaffolds, and re-implanted back at the defect 
area. 
The suitable time of scaffolds for cleft palate engineering is so far controversial. It could 
be best before two years old to give the necessary time for developing speech with 
mitigate the concerns of hearing loss and decrease the multiple surgical repairs. On the 
other hand, it could be used at 8 to 9 years old to assist more bone growth before the 
adult cuspid teeth eruption. The tissue-engineering technique would be to minimise the 
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donor site morbidity, short operating time and stay in hospital compared with autologous 
iliac crest bone graft. In my viewpoint, the tissue-engineering of cleft palate is a talented 
strategy, whatever the selected time point is, better than the current treatment. My study 
demonstrated that both HJPs and hBMSCs cultured in human-derived media (XF2 and 5% 
(v/v) HPL) can differentiate to osteoblast-like cells and form ECM with deposition of 
calcium on monolayer and the biocompatible 3D electrospun PCL scaffolds. 
Human-derived formulation media was widely impactful at stimulating mineralisation on 
the surface of PCL electrospun membrane. These media could be clinically developed to 
evaluate bone augmentation on 3D PCL scaffolds and biocompatible of scaffolds with 
surrounding area after re-implanted at the defect site using clinical cone-beam computed 
tomography (CBCT) scan (it is a new type of dental radiograph which creates 3D images 
of the jaw and teeth).  The several hindrances need to be conquered before bone tissue 
engineering applies on routinely clinical protocols. Furthermore, short and long-time 
investigations of the implanted bone tissue engineering that demands to appraise the 
effectiveness results compared with the current treatment, where the essential 
consideration is whether the recent management progress enhances patient outcomes. 
7.6 Final conclusion 
 Primary osteoprogenitor cells (hBMSCs and HJPs) displayed the proliferation and 
osteogenic differentiation by deposition of calcium on 2D monolayers (chapter 3 and 
4) and 3D PCL electrospun scaffolds fabrication structure (chapter 5) under the 
culture conditions studied. 
 Human-derived media (XF2 and 5% (v/v) HPL) improved the deposition of calcium 
in all different types of cells on monolayers (chapter 4) and 3D structures (chapter 5) 
in osteogenic media supplemented with Dex 10 nM. 
 Cell metabolic activity was reduced when cells were supplemented with 100 nM Dex. 
 The human-derived media (XF2 and 5% (v/v) HPL) enabled the faster synthesis of 
DNA (cell proliferation) compared to 10% (v/v) FBS. 
 XF1 (human plasma) and chemically-defined media poorly supported cell 
proliferation in monolayer. 
 Donor variability was seen in the culture of monolayer (chapter 3 and 4) and 3D PCL 
electrospun scaffolds structures (chapter 5) under the culture conditions studied. 
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 There is lower metabolic activity with increased passage number. 
 PCL is a suitable carrier in bone tissue engineering to construct a reanimation ECM 
for successful of pre-clinical (chapter 5). 
 Amount of VEGF from hBMSCs was decreased by osteogenic supplemented with Dex 
10 nM in 10% (v/v) FBS and increased in XF2 compared to basal culture media in 3D 
culture, while there was no effect of 5% (v/v) HPL (chapter 5). 
 The tri-layer PCL mate membranes could assist and isolated three types of cell (NOFs, 
FNB6 and hBMSCs) to allow the bone and oral mucosa formation during 24 days 
(chapter 6). 
  




 the 96th General Session and Exhibition of the International Association for Dental 
Research (IADR) and IADR/PAN European Regional Congress “Appraisal of Xeno-
Free Media for Craniofacial Bone Tissue Engineering” 25-28 July 2018, London, 
England, UK. 
Poster presentation 
1. The 16th Annual Meeting of the Tissue and Cell Engineering Society: ‘The effect of 
xeno-free media on human MSC metabolic activity and differentiation for bone 
tissue engineering’, 4-6 July 2016, University College London, London, UK. 
2. The 16th MEIbioeng conference: ‘Xeno-Free Media can Accelerate Human MSC 
Expansion and Differentiation for Efficient Bone Tissue Engineering’, 5-6 
September 2016, Keble College, Oxford, UK. 
3. The 3rd International Conference on Dental and Craniofacial Stem Cells: 
‘Comparison of Xeno-Free Media for Human MSC Expansion, and 
Differentiation in Tissue Engineering for Cleft Palate’, 25-28 October 2016, 
Columbia Global Centers Europe, Paris, France. 
4. The 10th Annual Mesenchymal Stem Cell (MSC) Meeting: ‘Assessment of Xeno-free 
Media on Human MSC Metabolic activity and Osteogenic Differentiation 
Capacity in Cleft Palate’, 5th December, University of York, York, UK. 
5. The 95th General Session and Exhibition of the International Association for Dental 
Research (IADR), held in conjunction with the 46th Annual Meeting of the American 
Association for Dental Research and the 41st Annual Meeting of the Canadian 
Association for Dental Research: ‘Identifying Xeno-Free Media for Productive 
Craniofacial Bone Tissue Engineering’, 22–25 March 2017, in San Francisco, Calif., 
USA. 
6. European Chapter Meeting of the Tissue Engineering and Regenerative Medicine 
International Society (TERMIS-EU 2017): ‘Evaluation of the Effectiveness of Xeno-
free Media for Human MSC osteogenesis in 2D and Poly(ɛ-Caprolactone) 
Scaffolds’, 26-30 June 2017, Davos, Switzerland. 
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7. The 28th Annual Conference of the European Society for Biomaterials (ESB 2017): 
‘Assessment of Xeno-Free Efficacy for Human MSC Osteogenesis in 3D Poly(ɛ-
Caprolactone) Scaffolds’, 4-8 September 2017, Megaron Athens International 
Conference Centre, Athens, Greece. 
8. Biomaterials and Tissue Engineering Group 19th Annual White Rose Work in 
Progress Meeting: ‘Effect of Different Xeno-Free Media on Osteogenic 
Differentiation of Human MSC in 2D Monolayer and Poly(ɛ-Caprolactone) 
Scaffolds’ 18th December 2017, University of Leeds, UK. 
9. 8th World Congress of Biomechanics 'Osteoinductive Xeno-Free Culture of Human 
Bone-marrow MSCs on 3D Poly(ɛ-caprolactone) Scaffolds to Repair Cleft Palate' 
8-12 July 2018, Dublin, Ireland. 
10. Biomaterials and Tissue Engineering Group 20th Annual White Rose Work in Progress 
Meeting: “Feasibility of Human-derived Growth Supplements Formulations for 
Craniofacial Bone Tissue Engineering” 17th December 2018, University of Sheffield, 
UK. 
Publication 
1. [Abstract] ‘The effect of xeno-free media on human MSC metabolic activity and 
differentiation for bone tissue engineering’ in Journal European Cells and 
Materials, Vol.32, Suppl. 4, 2016 (page 66). 
2. [Abstract] ‘Evaluation of the effectiveness of xeno-free media for human MSC 
osteogenesis in 2D and poly(ɛ-Caprolactone) scaffolds’ in Journal European 
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Figures 














































































Metabolic activity of different donors of hBMSCs in different xeno-free media supplemented 
with Dex 10 nM on monolayer culture from day 4 to day 7. The scatter dot plots indicated 
individual wells and horizontal lines mean and standard deviation for each condition. (*) 
Higher than the other groups in the same donor. (#) Significantly lower. (P <0.05). n=3. Two-
way ANOVA, Tukey’s multiple comparison tests. 
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Metabolic activity of different passages of hBMSCs in different xeno-free media supplemented 
with Dex 100 nM on monolayer culture from day 4 to day 7. The symbols indicated individual 
wells and horizontal lines the mean and standard deviation for each condition. (*) Significantly 
higher than the other groups in the same medium. (#) Significantly lower. (Φ) Significantly 
higher than all the other conditions. (ns) There is no significant difference. (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests 













































































Metabolic activity of different passages of hBMSCs in different xeno-free media supplemented 
with ascorbic acid-2-phosphate (AA) 50 µM and β-glycerophosphate (βGP) 10 mM on 
monolayer culture from day 4 to day 7. The symbols indicated individual wells and the 
horizontal lines the mean and standard deviation for each condition. (*) Significantly higher 
than the other groups in the same medium. (#) Significantly lower. (Φ) Significantly higher 
than all the other conditions in the different media. (ns) There is no significant difference (P 
<0.05). n=3. Two-way ANOVA, Tukey’s multiple comparison tests. 
























































































Metabolic activity of different passages of hBMSCs on a different xeno-free medium 
supplemented with osteogenic-inductive ingredients {Dex 10 nM, ascorbic acid-2-phosphate 
(AA) 50 µM and β-glycerophosphate (βGP) 10 mM} on monolayer culture from day 4 to day 
7. The symbols represent an individual well and the horizontal lines mean and standard 
deviation for each condition. (*) Higher than the other donors in the same medium. (#) 
Significantly lower. (Φ) Significantly higher than all the other conditions. (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests. 
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Metabolic activity of different passages of hBMSCs on a different xeno-free medium 
supplemented with osteogenic-inductive ingredients {Dex 100 nM, ascorbic acid-2-phosphate 
(AA) 50 µM and β-glycerophosphate (βGP) 10 mM} on monolayer culture from day 4 to day 
7. The symbols represent an individual well and the horizontal lines mean and standard 
deviation for each condition. (*) Higher than the other donors in the same medium. (#) 
Significantly lower. (Φ) Significantly higher than all the other conditions. (P <0.05). n=3. 
Two-way ANOVA, Tukey’s multiple comparison tests. 
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